0001493152-18-011724.txt : 20180814 0001493152-18-011724.hdr.sgml : 20180814 20180814142341 ACCESSION NUMBER: 0001493152-18-011724 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180814 DATE AS OF CHANGE: 20180814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MARIMED INC. CENTRAL INDEX KEY: 0001522767 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 274672745 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54433 FILM NUMBER: 181016345 BUSINESS ADDRESS: STREET 1: 26 OSSIPEE RD STREET 2: SUITE 201 CITY: NEWTON STATE: MA ZIP: 02464 BUSINESS PHONE: 617-795-5140 MAIL ADDRESS: STREET 1: 26 OSSIPEE RD STREET 2: SUITE 201 CITY: NEWTON STATE: MA ZIP: 02464 FORMER COMPANY: FORMER CONFORMED NAME: WORLDS ONLINE INC. DATE OF NAME CHANGE: 20110608 10-Q 1 form10-q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period ended June 30, 2018

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________________ to __________________

 

Commission File number 0-54433

 

MARIMED INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware   27-4672745
(State or Other Jurisdiction of
Incorporation or Organization)		   (I.R.S. Employer
Identification No.)

 

26 Ossipee Road, Suite 201

Newton, MA 02464

(Address of Principal Executive Offices)

 

617-795-5140

(Registrant’s Telephone Number, Including Area Code)

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

(Check One):

 

Large Accelerated filer [  ] Accelerated filer [  ]
Non-accelerated filer [  ] Smaller reporting company [X]
(Do not check if a smaller reporting company)  
   
Emerging growth company [  ]  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [  ] No [X]

 

As of August 14, 2018, 195,228,998 shares of the Issuer’s Common Stock were outstanding.

 

 

 

 
 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

MariMed Inc.

Condensed Consolidated Financial Statements

Three and Six Months Ended June 30, 2018 and 2017

 

Table of Contents

 

  Page
Condensed Consolidated Balance Sheets as of June 30, 2018 (Unaudited) and December 31, 2017 3
   
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2018 and 2017 (Unaudited) 4
   
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2018 and 2017 (Unaudited) 5
   
Notes to Condensed Consolidated Financial Statements (Unaudited) 6

 

2
 

 

MariMed Inc.

Condensed Consolidated Balance Sheets

 

   June 30, 2018   December 31, 2017 
   (unaudited)     
Assets          
Current assets:          
Cash and cash equivalents  $5,077,126   $1,290,231 
Accounts receivable, net   3,120,070    1,453,484 
Deferred rents receivable   1,107,697    610,789 
Due from third parties   2,374,652    1,196,918 
Due from related parties   134,781    134,781 
Note receivable, current portion   48,359    45,444 
Other current assets   401,888    357,019 
Total current assets   

12,264,573

    5,088,666 
           
Property and equipment, net   31,364,803    25,954,931 
Note receivable, long-term portion   653,792    578,831 
Other assets   1,157,448    579,587 
Total assets  $45,440,616   $32,202,015 
           
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable  $2,833,687  $2,831,658 
Accrued expenses   1,602,834    1,405,336 
Due to related parties   204,996    400,996 
Mortgages payable, current portion   121,199    118,556 
Common stock subscriptions   2,584,433    - 
Notes payable   8,740,212    10,665,899 
Total current liabilities   16,087,361    15,422,445 
           
Mortgages payable, long-term portion   7,471,662    5,532,397 
Other liabilities   240,013    240,013 
Total liabilities   23,799,036    21,194,855 
           
Stockholders’ equity:          
Series A convertible preferred stock, $0.001 par value; 50,000,000 shares authorized at June 30, 2018 and December 31, 2017; no shares issued or outstanding at June 30, 2018 or December 31, 2017   -    - 
Series A preferred stock subscribed but not issued; zero and 500,000 shares at June 30, 2018 and December 31, 2017, respectively   -    500 

Common stock, $0.001 par value; 500,000,000 shares authorized at June 30, 2018 and December 31, 2017; 193,709,580 and 176,940,331 shares issued at June 30, 2018 and December 31, 2017, respectively; 193,462,052 and 176,850,331 shares outstanding at June 30, 2018 and December 31, 2017, respectively

   193,710    176,940 
Common stock subscribed but not issued; zero and 1,000,000 shares at June 30, 2018 and December 31, 2017   -    370,000 
Subscriptions receivable   (25,000)   (25,000)
Common stock warrants   8,546,405    2,176,379 
Treasury stock, at cost; 247,528 and 90,000 shares at June 30, 2018 and December 31, 2017, respectively   (545,000)   (45,000)
Additional paid-in capital   33,703,929    20,149,591 
Accumulated deficit   (20,214,651)   (11,971,740)
Noncontrolling interests   (17,813)   175,490 
Total stockholders’ equity   21,641,580    11,007,160 
Total liabilities and stockholders’ equity  $45,440,616   $32,202,015 

 

See accompanying notes to condensed consolidated financial statements.

 

3
 

 

MariMed Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

 

    Three Months Ended June 30,     Six Months Ended June 30,  
    2018     2017     2018     2017  
                         
Revenues   $ 2,937,325     $ 1,621,057     $ 5,020,275     $ 2,771,776  
                                 
Cost of revenues, including depreciation     913,357       469,294       1,802,226       940,361  
                                 
Gross profit     2,023,968       1,151,763       3,218,049       1,831,415  
                                 
Operating expenses:                                
Personnel     284,886       136,824       469,557       304,686  
Marketing and promotion     77,943       45,265       129,704       114,734  
General and administrative    

814,914

       368,557       1,521,397       582,326  
Total operating expenses    

1,177,743

       550,646       2,120,658       1,001,746  
                                 
Operating income    

846,225

       601,117       1,097,391       829,669  
                                 
Non-operating expenses:                                
Interest expense, net     267,186       96,312       563,613       177,905  
Equity compensation     6,290,802       -       6,863,609       19,295  
Loss on debt settlements     563,119       -       1,776,960       18,278  
Other     3,600       -       3,600       -  
Total non-operating expenses     7,124,707       96,312       9,207,782       215,478  
                                 
Net income (loss)     (6,278,482 )     504,805       (8,110,391 )     614,191  
                                 
Net income (loss) to noncontrolling interests     69,287       (42,195 )     132,520       99,431  
Net income (loss) attributable to MariMed Inc.   $ (6,347,769 )   $ 547,000     $ (8,242,911 )   $ 514,760  
                                 
Net income (loss) per share   $ (0.034 )   $ 0.008     $ (0.045 )   $ 0.008  
Weighted average common shares outstanding     186,645,833       65,593,751       182,746,858       64,912,354  

 

See accompanying notes to condensed consolidated financial statements.

 

4
 

 

MariMed Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

    Six Months Ended June 30,  
    2018     2017  
Cash flows from operating activities:                
Net income (loss) attributable to MariMed Inc.   $ (8,242,911 )   $ 514,760  
Net income (loss) attributable to noncontrolling interests     132,520       99,431  
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:                
Depreciation     253,713       163,410  
Equity compensation     6,863,609       19,295  
Acquisition of iRollie LLC     600,000       -  
Common stock issued for services     2,466,003       38,965  
Loss on preferred stock conversions     34,044       -  
Loss on debt settlements     818,204       -  
Loss on common stock issued for services     958,757       18,278  
Changes in operating assets and liabilities:                
Accounts receivable, net     (1,666,587 )     (448,183 )
Deferred rents receivable     (496,908 )     (67,437 )
Due from third parties     (1,177,734 )     (506,900 )
Due from related parties     -       (35,108 )
Other current assets     (44,870 )     (56,278 )
Other assets     (577,861 )     (109,520 )
Accounts payable     2,029       889,489  
Accrued expenses     246,810       (488,228 )
Due to related parties     (196,000 )     10,280  
Net cash provided by (used in) operating activities     (27,182 )     42,254  
                 
Cash flows from investing activities:                
Purchase of property and equipment     (5,663,585 )     (3,766,154 )
Investment in promissory note     (100,000 )     -  
Interest on notes receivable     22,125       25,097  
Net cash used in investing activities     (5,741,460 )     (3,741,057 )
                 
Cash flows from financing activities:                
Proceeds from subscribed preferred stock     -       200,000  
Proceeds from subscribed common stock     32,833       -  
Issuance of common stock     8,461,003       5,200,000  
Issuance of interest in subsidiary     -       150,000  
Issuance (repayments) of promissory notes     (700,000 )     400,000  
Proceeds from (payments of) mortgages payable, net     1,941,908       (4,728 )
Exercise of stock options     39,000       -  
Exercise of warrants     106,618       -  
Distributions     (325,825 )     -  
Net cash provided by financing activities     9,555,537       5,945,272  
                 
Net change to cash and cash equivalents     3,786,895       2,246,469  
Cash and cash equivalents at beginning of period     1,290,231       569,356  
Cash and cash equivalents at end of period   $ 5,077,126     $ 2,815,825  
                 
Supplemental disclosure of cash flow information:                
Cash paid for interest   $  553,206      $ 157,930  
Cash paid for taxes   $ 12,596      $ -  
                 
Non-cash activities:                
Equity issued to settle debt   $ $1,275,000     $ -  

 

See accompanying notes to condensed consolidated financial statements.

 

5
 

 

MariMed Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

 

MariMed Inc. (the “Company”), a Delaware corporation, develops and manages state-of-the-art, regulatory-compliant facilities for the cultivation, production, and dispensing of legal cannabis and cannabis-infused products. Such facilities, located in multiple states, are leased to the Company’s clients in the emerging cannabis industry. Along with operational oversight, the Company provides its clients with legal, accounting, human resources, business development, and other corporate and administrative services.

 

The Company also provides professional consultative services in all aspects of cannabis licensing procurement. To date, the Company has secured, on behalf of its clients, 11 cannabis licenses across five states—two in Delaware, two in Illinois, one in Nevada, three in Maryland and three in Massachusetts. Accordingly, the Company has developed seed-to-sale cannabis facilities across of these five states in excess of 300,000 square feet.

 

In addition, the Company licenses precision-dosed, cannabis-infused products to treat specific medical conditions or to achieve a certain result. These products are licensed under the brand names Kalm Fusion™ and Nature’s Heritage™, both of which were developed by the Company, and Betty’s Eddies™, acquired in October 2017. The Company also has exclusive sublicensing rights in certain states to distribute vaporizer pens developed by Lucid Mood™, as well as the clinically-tested medicinal cannabis strains developed in Israel by Tikun Olam™.

 

The Company’s stock is quoted on the OTCQB market under the ticker symbol MRMD.

 

The Company was originally incorporated in January 2011 under the name Worlds Online Inc., using the ticker symbol WORX. In early 2017, the Company name and ticker were changed to its current name and ticker. Since inception, the Company had operated an online portal that offers multi-user virtual environments to users. This segment of the business has had insignificant operations since early 2014.

 

In May 2014, the Company, through its subsidiary MariMed Advisors Inc., acquired Sigal Consulting LLC, a company operating in the cannabis industry. The purchase price consisted of Company common stock, options to purchase additional Company common stock, and a minority interest in MariMed Advisors Inc. This transaction, further disclosed in Note 3, was accounted for as a purchase acquisition where the Company was both the legal and accounting acquirer. In June 2017, the minority interest in MariMed Advisors Inc. was merged into the Company.

 

In May 2018, the Company acquired iRollie LLC, a manufacturer of branded cannabis products and accessories for consumers, and custom product and packaging for companies in the cannabis industry. This acquisition is further disclosed in Note 3.

 

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

 

In accordance with GAAP, these interim statements do not contain all of the disclosures normally required in annual statements. In addition, the results of operations of interim periods are not necessarily indicative of the results of operations to be expected for the full year. Accordingly, these interim financial statements should be read in conjunction with the Company’s audited annual financial statements and accompanying notes for the year ended December 31, 2017.

 

Certain reclassifications have been made to prior periods’ data to conform to the current period presentation. These reclassifications had no effect on reported income (losses) or cash flows.

 

Principles of Consolidation

 

The accompanying condensed consolidated financial statements include the accounts of MariMed Inc. and its subsidiaries, all of which are majority-owned. Intercompany accounts and transactions have been eliminated.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts within the financial statements and disclosures thereof. Actual results could differ from these estimates or assumptions.

 

Cash Equivalents

 

The Company considers all highly liquid investments with a maturity date of three months or less to be cash equivalents. The fair values of these investments approximate their carrying values.

 

Revenue Recognition

 

The Company’s main sources of revenue are comprised of: leasing of its developed cannabis cultivation, production, and dispensary facilities to its cannabis-licensed clients; agreements to provide comprehensive oversight and corporate support to its clients’ operations; consulting services to companies operating in the medical and legal recreational cannabis industries; arrangements for the procurement of cannabis materials and resources; and licensing of branded cannabis products.

 

The Company recognizes revenue when all of the following criteria are met: evidence of an arrangement exists such as a signed contract, delivery has occurred/services have been performed, the price is fixed or determinable, and collectability is reasonably assured.

 

6
 

 

Research and Development Costs

 

Research and development costs are charged to operations as incurred.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation, with depreciation recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term, if applicable. When assets are retired or disposed, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income. Repairs and maintenance are charged to expense in the period incurred.

 

The estimated useful lives of property and equipment are generally as follows: buildings and building improvements, seven to thirty-nine years; tenant improvements, the remaining duration of the related lease; furniture and fixtures, seven years; machinery and equipment, five to ten years. Land is not depreciated.

 

The Company’s property and equipment are individually reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of an asset exceeds the aggregate projected future cash flows over the anticipated holding period on an undiscounted basis. An impairment loss is measured based on the excess of the asset’s carrying amount over its estimated fair value.

 

Impairment analyses are based on management’s current plans, intended holding periods and available market information at the time the analyses are prepared. If these criteria change, the Company’s evaluation of impairment losses may be different and could have a material impact to the consolidated financial statements.

 

For the six months ended June 30, 2018 and 2017, based on its impairment analyses, the Company did not have any impairment losses.

 

Impairment of Long Lived Assets

 

The Company evaluates the recoverability of its fixed assets and other assets in accordance with the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) 360-10-15, Impairment or Disposal of Long-Lived Assets. Impairment of long-lived assets is recognized when the net book value of such assets exceeds their expected cash flows, in which case the assets are written down to fair value, which is determined based on discounted future cash flows or appraised values.

 

Fair Value of Financial Instruments

 

The Company follows the provisions of ASC 820, Fair Value Measurement, to measure the fair value of its financial instruments, and ASC 825, Financial Instruments, for disclosures on the fair value of its financial instruments. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value hierarchy defined by ASC 820 are:

 

Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
   
Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
   
Level 3 Pricing inputs that are generally observable inputs and not corroborated by market data.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable approximate their fair values due to the short maturity of these instruments. The fair value of option and warrant issuances are determined utilizing the binomial options pricing model and employing the following inputs: life of instrument, exercise price, value of the underlying security on issuance date, and 2-year volatility of underlying security.

 

Extinguishment of Liabilities

 

The Company accounts for extinguishment of liabilities in accordance with ASC 405-20, Extinguishments of Liabilities. When the conditions for extinguishment are met, the liabilities are written down to zero and a gain or loss is recognized.

 

Stock-Based Compensation

 

The Company accounts for stock-based compensation using the fair value method as set forth in ASC 718, Compensation—Stock Compensation, which requires a public entity to measure the cost of employee services received in exchange for an equity award based on the fair value of the award on the grant date, with limited exceptions. Such value will be incurred as compensation expense over the period an employee is required to provide service in exchange for the award, usually the vesting period. No compensation cost is recognized for equity awards for which employees do not render the requisite service.

 

7
 

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740, Income Taxes. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of operations in the period that includes the enactment date.

 

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. The Company did not take any uncertain tax positions and had no adjustments to unrecognized income tax liabilities or benefits for the six months ended June 30, 2018 and 2017.

 

Related Party Transactions

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

In accordance with ASC 850, the Company’s financial statements include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, as well as transactions that are eliminated in the preparation of financial statements.

 

Comprehensive Income

 

The Company reports comprehensive income and its components following guidance set forth by ASC 220, Comprehensive Income, which establishes standards for the reporting and display of comprehensive income and its components in the consolidated financial statements. There were no items of comprehensive income applicable to the Company during the period covered in the financial statements.

 

Earnings Per Share

 

Earnings per common share is computed pursuant to ASC 260, Earnings Per Share. Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income by the sum of the weighted average number of shares of common stock outstanding plus the weighted average number of potentially dilutive securities during the period.

 

As of June 30, 2018 and 2017, there were 12,508,932 and 10,475,000, respectively, of potentially dilutive securities in the form of options and warrants. Also as of June 30, 2018 and 2017, there were zero and 500,000 shares, respectively, of subscriptions on convertible preferred stock, and $250,000 and $3,125,000, respectively, of convertible promissory notes, that were potentially dilutive, whose conversion into common stock is based on a discount to the market value of common stock on or about the future conversion date. For the six months ended June 30, 2018, all potentially dilutive securities had an anti-dilutive effect on earnings per share, and in accordance with ASC 260, were excluded from the diluted net income per share calculation, resulting in calculations of basic and fully diluted net income per share that were identical for this period. These securities may dilute earnings per share in the future.

 

Commitments and Contingencies

 

The Company follows ASC 450, Contingencies, which requires the Company to assess the likelihood that a loss will be incurred from the occurrence or non-occurrence of one or more future events. Such assessment inherently involves an exercise of judgment. In assessing possible loss contingencies from legal proceedings or unasserted claims, the Company would evaluate the perceived merits of the proceedings or claims, and the perceived merits of the relief sought or expected to be sought.

 

If the assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can be estimated, then such estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

 

While not assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse effect on the Company’s financial position, results of operations or cash flows.

 

8
 

 

Risk and Uncertainties

 

The Company is subject to risks common to companies operating within the legal and medical marijuana industries, including, but not limited to, federal laws, government regulations and jurisdictional laws.

 

Noncontrolling Interests

 

Noncontrolling interests represent third-party minority ownership of the Company’s consolidated subsidiaries. Net income attributable to noncontrolling interests is shown in the consolidated statements of operations; and the value of net assets owned by noncontrolling interests are presented as a component of equity within the balance sheets.

 

Off Balance Sheet Arrangements

 

The Company does not have any off-balance sheet arrangements.

 

Recent Accounting Pronouncements

 

In November 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which enhances and clarifies the guidance on the classification and presentation of restricted cash in the statement of cash flows. This ASU will be effective in 2019 and its impact is dependent upon the level of restricted cash of the Company, which at this time is insignificant.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which modifies accounting for lessees by requiring the recording of lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. This ASU will be effective in 2020 and the Company is currently evaluating the impact of adoption, which will be determined by the Company’s lease portfolio at the time of implementation.

 

In 2014 and subsequently in 2016, the FASB issued new standards on the recognition of revenue. While the new standards amend the current standards, they are not expected to have a material impact on the amount and timing of revenue recognized in the Company’s consolidated financial statements when the new standards are adopted in 2019.

 

In addition to the above, the Company has reviewed all other recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption of any such pronouncements will have a material impact on its financial condition or the results of its operations.

 

NOTE 3 – ACQUISITIONS

 

In May 2014, the Company, through its subsidiary MariMed Advisors Inc., acquired Sigal Consulting LLC from its ownership group which included the current CEO and CFO of the Company (the “Sigal Ownership Group”). The purchase price received by the Sigal Ownership Group was comprised of (i) 31,954,236 shares of common stock valued at approximately $5,913.000, representing 50% of the Company’s outstanding shares on the closing date, (ii) options to purchase three million shares of the Company’s common stock, exercisable over five years with exercise prices ranging from $0.15 to $0.35, and valued at approximately $570,000, and (iii) a 49% ownership interest in MariMed Advisors Inc. The excess of purchase price over the book value of the acquired entity was recorded as goodwill, which was subsequently impaired in full and written down to zero.

 

In June 2017, the remaining 49% interest of MariMed Advisors Inc. was merged into the Company in exchange for an aggregate 75 million shares of common stock to the Sigal Ownership Group.

 

In October 2017, the Company acquired the intellectual property, formulations, recipes, proprietary equipment, know-how, and other certain assets of the Betty’s Eddies™ brand of cannabis-infused fruit chews. The purchase price was $140,000 plus subscriptions on 1,000,000 shares of the Company’s common stock. In addition, the selling company shall receive royalties based on a percentage of the Company’s sales of the Betty’s Eddies™ product line, commencing at 25% and decreasing to 2.5% as certain sales thresholds are met. For the six months ended June 30, 2018, such royalties approximated $14,000, of which $5,000 were paid and $9,000 accrued at June 30, 2018.

 

After applying the total purchase price, which consisted of the cash paid plus the fair value of the subscribed common stock on the date of the transaction, to the assessed fair values of the assets purchased, the transaction gave rise to goodwill of approximately $333,000. At June 30, 2018 and December 31, 2017, the Company reviewed the goodwill for impairment and determined that, based on the present value of future cash flows of the acquired assets, there was no impairment. The goodwill is included in Other Assets in the Company’s financial statements.

 

In May 2018, the Company issued $600,000 of subscriptions on common stock in exchange for 100% of the ownership interests of iRollie LLC. The Company acquired, among other assets and liabilities, iRollie’s entire product line, service offerings, clients, and intellectual property, and hired its two co-founders. After applying the purchase price to the fair value of the assets acquired and liabilities assumed, the Company recorded goodwill of approximately $119,000. At June 30, 2018, the Company determined that the goodwill had not been impaired, which is included in Other Assets in the Company’s financial statements.

 

NOTE 4 – PROPERTY AND EQUIPMENT

 

Property and equipment are shown net of accumulated depreciation and are primarily comprised of the following: land; buildings; building and tenant improvements; furniture and fixtures; and machinery and equipment.

 

During the six months ended June 30, 2018 and 2017, additions to property and equipment were approximately $5,664,000 million and $3,766,000 million, respectively.

 

Depreciation expense for the six months ended June 30, 2018 and 2017 was approximately $254,000 and $163,000, respectively. At June 30, 2018 and December 31, 2017, accumulated depreciation approximated $1,746,000 and $1,499,000, respectively.

 

9
 

 

NOTE 5 – DEBT

 

During the six months ended June 30, 2018, the Company received additional capital of approximately $1,998,000 from the existing mortgage on the cannabis cultivation and processing facility it is currently developing in the state of Massachusetts.

 

During the six months ended June 30, 2017, the Company raised $400,000 from the issuance of a promissory note with an interest rate of 10% and a term of 6 months. No promissory notes were issued during the six months ended June 30, 2018.

 

During the six months ended June 30, 2018, the Company repaid $700,000 of promissory notes, and converted $1,275,000 of promissory notes into 1,679,486 shares of common stock. The conversions resulted in the recording of non-cash losses totaling $818,000, based on the market value of the common stock on the conversion dates. No repayments or conversions of debt occurred during the same period in 2017.

 

NOTE 6 – EQUITY

 

Preferred Stock

 

In January 2017, the Company increased the number of authorized shares of preferred stock from 5 million to 50 million shares.

 

During the six months ended June 30, 2017, the Company issued subscriptions on 200,000 shares of Series A convertible preferred stock at $1.00 per share. No subscriptions were issued during the same period in 2018.

 

Series A convertible preferred stock accrues an annual dividend of six percent until conversion, and is convertible, along with any accrued dividends, into common stock at a twenty-five percent discount to the selling price of the common stock in a qualified offering, as defined in the subscription agreement. In addition, the Company shall have the ability to force the conversion of preferred stock at such time the Company has a market capitalization in excess of $50 million for ten consecutive trading days. In such event, the conversion price shall be a 25% discount to the average closing price of the Company’s common stock over the ten trading days prior to the Company’s notice of its intent to convert.

 

In January 2018, all 500,000 shares of subscribed Series A convertible preferred stock were converted into 970,989 shares of common stock at a conversion price of $0.55 per share. The Company recorded a non-cash loss on conversion of approximately $34,000 based on the market value of the common stock on the conversion date. No shares were converted during the same period in 2017.

 

Common Stock

 

In January 2017, the Company increased the number of authorized shares of common stock from 100 million to 500 million shares.

 

In June 2017, the Company issued 75 million shares of common stock to acquire the remaining 49% interest in its subsidiary MariMed Advisors Inc.

 

During the six months ended June 30, 2018, the Company sold 10,111,578 shares of common stock at prices ranging from $0.50 to $1.37 per share, resulting in total proceeds of $8,461,000. During the same period in 2017, the Company sold 22,178,888 shares of common stock at prices of $0.18 and $0.25 per share, resulting in total proceeds of $5,200,000.

 

During the six months ended June 30, 2018 and 2017, the Company issued 1,313,901 and 498,543 shares of common stock, respectively for services rendered by third parties. The Company recorded non-cash losses of approximately $959,000 in 2018 and $18,000 in 2017, based on the market value of the common stock on the issuance dates.

 

Common Stock Subscriptions

 

In October 2017, the Company issued subscriptions on 1,000,000 shares of common stock as part of the purchase price of the Betty’s Eddies™ acquired assets, as disclosed in Note 3. The common shares associated with these subscriptions were issued in June 2018.

 

During the six months ended June 30, 2018, the Company issued subscriptions on 264,317 shares of common stock to acquire iRollie LLC, as disclosed in Note 3. Also during this period, the Company issued (i) subscriptions on 32,083 shares of common stock for the exercise of a warrant, (ii) subscriptions on 2,001,641 shares of common stock to settle $1,951,600 of vendor invoices, where the number of subscriptions issued was determined using the fair value of the stock on the issuance date, and (iii) subscriptions on 9,281 shares of common stock, equivalent to an aggregate amount of $20,000, for the payment of rent for the months of May and June 2018 for a leased property in Massachusetts. No subscriptions on common stock were issued during the same period in 2017.

 

All of the subscriptions on common stock referred to above are reflected under the caption Common Stock Subscriptions within the current liabilities section of the Company’s balance sheet.

 

Membership Interests

 

During the six months ended June 30, 2017, the Company issued 1,667 Class A membership units of Mari Holdings MD LLC, a majority-owned subsidiary, for $150,000. These units represented 0.33% ownership of this subsidiary at June 30, 2017. No membership units were issued during the six months ended June 30, 2018.

 

NOTE 7 – STOCK OPTIONS

 

During the six months ended June 30, 2018, the Company granted options to purchase 1.45 million shares of common stock to the Company’s board members at exercise prices ranging from $0.14 to $0.77, vesting over a six-month period, and expiring between December 2020 and December 2022. The fair value of these options on grant date of approximately $458,000 was recorded as equity compensation during the six months ended June 30, 2018.

 

In May 2018, the Company granted options to purchase 200,000 shares of common stock to an employee at an exercise price of $0.90 per share, which expire in May 2023. As of June 30, 2018, the Company recorded approximately $36,000 of the total equity compensation on this grant of approximately $264,000 which shall be recorded over the six-month vesting period.

 

During the six months ended June 30, 2017, the Company granted options to purchase 100,000 shares of common stock to employees at exercise prices of $0.26 and $0.33, and expiring in March and April 2021. The fair value of these options on the grant date of approximately $19,000 was recorded as equity compensation over the respective vesting periods.

 

During the six months ended June 30, 2018, options to purchase 700,000 shares of common stock were exercised at exercise prices ranging from $0.08 to $0.63 per share. No options were exercised during the same period in 2017.

 

Options to purchase 300,000 shares of common stock were forfeited during the six-month period ended June 30, 2018. No options were forfeited during the same period in 2017.

 

10
 

 

Stock options outstanding and exercisable as of June 30, 2018 were:

 

Exercise Price   Shares Under Option   Remaining 
per Share   Outstanding   Exercisable   Life in Years 
$0.080    250,000    250,000    0.58 
$0.080    100,000    100,000    1.47 
$0.130    200,000    200,000    2.00 
$0.140    650,000    650,000    2.51 
$0.150    1,000,000    1,000,000    1.25 
$0.250    1,000,000    1,000,000    1.25 
$0.260    50,000    50,000    2.76 
$0.330    50,000    25,000    2.69 
$0.350    1,000,000    1,000,000    1.25 
$0.450    250,000    125,000    3.26 
$0.550    100,000    100,000    2.25 
$0.630    300,000    300,000    3.51 
$0.770    300,000    -    4.51 
$0.900    200,000    -    4.87 
      5,450,000    4,800,000      

 

NOTE 8 – WARRANTS

 

During the six months ended June 30, 2018 and 2017, the Company issued warrants to purchase 4,239,000 and 100,000 shares of common stock, respectively, expiring in February 2021 and March 2020, respectively, at exercise prices ranging from $0.30 to $2.25 per share. The Company recorded non-cash equity compensation of approximately $6,370,000 in 2018 and $19,000 in 2017 representing the estimated fair value of these instruments on the issuance dates.

 

During the six months ended June 30, 2018, warrants to purchase 1,425,379 shares of common stock were exercised, at exercise prices ranging from $0.10 and $0.50 per share. No warrants were exercised during the same period in 2017.

 

At June 30, 2018 and 2017, warrants to purchase 7,058,932 and 1,225,000 shares of common stock were outstanding, respectively, at exercise prices ranging between $0.10 and $2.25 per share.

 

NOTE 9 – RELATED PARTY TRANSACTIONS

 

As disclosed in Note 3 above, the current CEO and CFO of the Company are part in the Sigal Ownership Group from whom Sigal Consulting LLC was acquired in May 2014. The 49% ownership in the Company’s subsidiary, MariMed Advisors Inc., which the Sigal Ownership Group acquired as part of the purchase price, was acquired by the Company from the Sigal Ownership Group in June 2017 in exchange for 75 million shares of the Company’s common stock.

 

In September 2017, the former CEO of the Company, who is a currently a board member, exercised options to purchase 4.5 million shares of common stock at an exercise price of $0.01 per share. The aggregate exercise price of $45,000 was paid in a cashless transaction with 90,000 shares of common stock which were classified as treasury stock.

 

In October 2017, the Company acquired the intellectual property, formulations, recipes, proprietary equipment, and know-how of the Betty’s Eddies™ brand of cannabis-infused products, as disclosed in Note 3, from a company that is minority-owned by the Company’s chief operating officer.

 

In December 2017, options to purchase 200,000 shares of commons stock at an exercise price of $0.025 were forfeited by the CEO and by an independent board member (100,000 shares forfeited by each individual).

 

During the six months ended June 30, 2018, a current board member exercised options to purchase 400,000 shares of common stock, and the former CFO of the Company exercised options to purchase 300,000 shares of common stock. These options were exercised at exercise prices ranging from $0.08 to $0.63 per share. No options were exercised during the same period in 2017.

 

During the six months ended June 30, 2018 and 2017, the Company issued 170,000 and 169,487 shares, respectively, of common stock for services rendered by the former CFO of the Company. Based on the market value of the common stock on the dates of the two issuances, the Company recorded non-cash losses of approximately $112,000 in 2018 and $18,000 in 2017.

 

At June 30, 2018 and December 31, 2017, the Company owed approximately $19,000 and $14,000 to the CEO and CFO, respectively.

 

The caption Due from Related Parties in the Company’s financial statements is primarily comprised of short term loans to non-consolidated entities under common ownership.

 

11
 

 

The caption Due to Related Parties reflects short term loans from related parties and includes advances received from officers of the Company.

 

NOTE 10 – COMMITMENTS AND CONTINGENCIES

 

An employment agreement with the former CEO of the Company that provided this individual with salary, car allowances, stock options, life insurance, and other employee benefits was terminated in 2017.

 

The Company recorded an accrual of approximately $1,043,000 at June 30, 2018 and December 31, 2017 for any amounts that may be owed under this agreement. However, the Company is contesting the validity this agreement.

 

NOTE 11 – SEGMENT REPORTING

 

In accordance with ASC 280, the following is information regarding the Company’s operating segments:

 

    Six Months Ended June 30,  
    2018     2017  
Revenues:                
Online portal operations   $ —     $ 114  
Cannabis related operations     5,020,275       2,771,662  
Consolidated revenues   $ 5,020,275     $ 2,771,776  
                 
Depreciation:                
Online portal operations   $ —     $ —  
Cannabis related operations     253,713       163,410  
Depreciation   $ 253,713     $ 163,410  
                 
Net income (loss):                
Online portal operations   $ (181 )   $ (146,774 )
Cannabis related operations     (1,831,210 )     760,965  
Net income (loss)   $ (8,110,391 )   $ 614,191  
                 
Capital expenditures:                
Online portal operations   $ —     $ —  
Cannabis related operations     5,663,585       3,766,154  
Combined capital expenditures   $ 5,663,585     $ 3,766,154  
                 
Assets:                
Online portal operations   $ 1,217     $ 1,504  
Cannabis related operations     45,439,399       15,349,925  
Combined assets   $ 45,440,616     $ 15,351,429  

 

NOTE 12 – SUBSEQUENT EVENTS

 

Subsequent to June 30, 2018, the following events occurred:

 

-

The Company sold 1,200,780 shares of common stock, at prices ranging from $0.90 to $2.70 per share, for an aggregate amount of $2,200,000.

   
-

The Company issued warrants to purchase 544,500 shares of common stock at an exercise price of $4.20 per share.

   
-Warrant holders exercised warrants to purchase 232,083 shares of common stock at exercise prices of $0.10 and $0.40 per share.
   
 -

A board member was issued 302,000 shares of common stock from the exercise of stock options at exercise prices ranging from $0.08 to $0.63 per share. The aggregate number of shares exercised was 400,000, offset by 98,000 shares used to pay the aggregate exercise price of $98,000 in a cashless transaction.

   
 -

In August 2018, the Company made a payment of $250,000 pursuant to an exclusive worldwide licensing agreement for the production and distribution of precision-dosed, dissolvable cannabis products.

 

12
 

 

Item 2. Management’s Discussions and Analysis of Financial Condition and Results of Operations

 

Forward Looking Statements

 

When used in this form 10-Q and in future filings by the Company with the Commission, the words or phrases such as “anticipate,” “believe,” “could,” “should,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “will” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on any such forward looking statements, each of which speak only as of the date made. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical earnings and those presently anticipated or projected. The Company has no obligation to publicly release the result of any revisions which may be made to any forward-looking statements to reflect anticipated or unanticipated events or circumstances occurring after the date of such statements.

 

These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different. These factors include, but are not limited to, changes that may occur to general economic and business conditions; changes in current pricing levels that we can charge for our services or which we pay to our suppliers and business partners; changes in political, social and economic conditions in the jurisdictions in which we operate; changes to laws and regulations that pertain to our products and operations; and increased competition.

 

The following discussion should be read in conjunction with the unaudited financial statements and related notes which are included under Item 1.

 

We do not undertake to update our forward-looking statements or risk factors to reflect future events or circumstances.

 

Overview

 

General

 

We are industry experts in the development, operation, management and optimization of cannabis cultivation, production, and dispensing facilities. Such facilities, located in multiple states, are leased to the Company’s clients in the emerging cannabis industry. Our team acquires land and/or real estate for the purpose of developing state-of-the-art, regulatory-compliant legal cannabis facilities. These facilities are models of excellence in horticultural principals, cannabis production, product development, and dispensary operations. These facilities are leased to the Company’s clients who are entities that have been awarded legal and medical marijuana licenses from multiple states. Along with this operational oversight, the Company provides its clients with legal, accounting, human resources, and other corporate and administrative services.

 

The Company also provides industry leading expertise and consultative services in all aspects of cannabis licensing procurement. To date, the Company has secured, on behalf of its clients, 11 cannabis licenses across five states—two in Delaware, two in Illinois, one in Nevada, three in Maryland and three in Massachusetts. Accordingly, we have operating facilities located in the cities of Wilmington and Lewes in Delaware; the cities of Anna and Harrisburg in Illinois; Clark county in Nevada; Arundel county and the city of Hagerstown in Maryland; and the cities of New Bedford, Norwood and Middleborough in Massachusetts. In total, we have developed in excess of 300,000 square feet of seed-to-sale cannabis facilities.

 

In addition to our cannabis facilities, we are on the forefront of the development of precision-dosed, cannabis-infused products. Our proprietary branded products are comprised of Kalm Fusion™, designed for the treatment of specific medical conditions and related symptoms, Betty’s Eddies™, the recently acquired recreational-leaning brand of fruit chews, and Nature’s Heritage™, the newest member of the MariMed family of brands, consisting of organic products created from the finest seed lineages which we believe are “The best cannabis Mother Earth has to offer®”.

 

The Company also has exclusive sublicensing rights in certain states to distribute vaporizer pens developed by Lucid Mood™, as well as the clinically-tested medicinal cannabis strains developed in Israel by world-renowned Tikun Olam™. The Company continues to be committed to the licensing and distribution of branded cannabis products in states across the country and beyond.

 

As of this filing, we are contemplating a strategy to evolve the Company into a direct cultivator, producer, and dispenser of cannabis and cannabis-related products. Such a strategy would be executed via the securing of cannabis licenses for the benefit of the Company, acquiring or partnering with mature companies in the cannabis industry, and/or organic growth. While it is not certain at this time whether we will pursue such strategy, if implemented, we anticipate that it would occur by the end of fiscal 2019, and that the Company’s revenues and operations would increase significantly.

 

In May 2014, the Company, through its subsidiary MariMed Advisors Inc. (“MMA”), acquired Sigal Consulting LLC from its members, two of whom are now the CEO and CFO of the Company, in exchange for (i) an aggregate amount of the Company’s common stock equal to 50% of the Company’s outstanding shares on the closing date; (ii) options to purchase three million shares of the Company’s common stock, exercisable over five years with exercise prices ranging from $0.15 to $0.35, and (iii) a 49% ownership interest of MMA. In June 2017, the minority interest in MariMed Advisors Inc. was merged into the Company in exchange for 75 million shares of restricted common stock.

 

In May 2018, the Company acquired iRollie LLC, a manufacturer of branded cannabis products and accessories for consumers, and custom product and packaging for companies in the cannabis industry.

 

In August 2018, the Company entered into an exclusive global licensing agreement for the production and distribution rights in all existing and future legal cannabis markets of a proprietary technology that prints precision-dosed dissolvable cannabis products. This technology facilitates the production of multiple combinations of cannabinoids, terpenes, and nutrients , while avoiding fillers commonly found in cannabis and nutraceutical products, into a paper-thin, low-calorie, fast-absorbing product that is delivered sublingually, transdermally, or by drinking when dissolved in liquid. The process also allows for the printing of any graphic, such as a bar code or website address, on each product. These products transport easily and discreetly in purses, pockets, and wallets, and are produced at higher levels of efficiency than the current methods within the cannabis industry.

 

13
 

 

Revenues

 

Our revenues are comprised of the following primary categories:

 

Management – We receive fees for providing comprehensive oversight of our clients’ entire cannabis cultivation, production, and dispensary operations. Along with this oversight, we provide human resources, legal, accounting, sales, marketing, and reporting services.

 

Real Estate – Our state-of-the-art, regulatory-compliant legal cannabis facilities are leased to our cannabis-licensed clients over 20-year lease terms. We generate rental income from occupancy, tenant improvements, equipment rentals, and additional rental income based on the success of the cannabis licensees.

 

Licensing – We derive licensing revenue from the sale by the licensees of our branded precision-dosed cannabis-infused products, such as Kalm Fusion™ and Betty’s Eddies™, to legal dispensaries throughout the country.

 

Consulting – We assist third-parties in securing cannabis licenses, and provide advisory services in the areas of facility design and development, and cultivation and dispensing best practices

 

Supply Procurement – We have established large volume discounts with top national vendors of cultivation and production supplies and equipment, which we acquire and resell at competitive prices to our cannabis-licensed clients with a reasonable markup.

 

Expenses

 

We classify our expenses into three broad categories:

 

  ● cost of revenues, which includes the direct costs associated with the generation of our revenues, and depreciation expense on our properties and equipment;
     
  ● operating expenses, which include the sub-categories of personnel, marketing and promotion, and general and administrative; and
     
  ● non-operating expenses, which include the sub-categories of interest, non-cash equity compensation, and non-cash losses on debt settlements.

 

Liquidity and Capital Resources

 

During the six months ended June 30, 2018, we raised approximately $8.5 million from the issuance of common stock. In addition, capital of approximately $2.0 million was extended to us for building improvements on our New Bedford, MA property by the terms of the secured lender.

 

These funds will be used to fund Company operations, continue the development of our facilities, and expand our branded licensing business. We continue to pursue additional sources of capital in 2018, although there can be no assurance that any such capital will become available.

 

RESULTS OF OPERATIONS

 

Three months ended June 30, 2018 compared to three months ended June 30, 2017

 

Revenues for the three months ended June 30, 2017 increased 81.2% to approximately $2.9 million, compared with $1.6 million from the same period a year ago. This significant increase was primarily due to the growth of (i) rental income from our facilities in Maryland and Massachusetts which were fully developed and leased to tenants in late calendar 2017, (ii) supply procurement services provide to additional cannabis licensees in 2018, and (iii) management fees and additional rental revenue which we earn based on a percentage of revenue generated by our cannabis-licensed clients. For the three months ended June 30, 2018, the revenue generated by these clients increased 67.6% to approximately $4.6 million from approximately $2.7 million for the same period in 2017.

 

14
 

 

Cost of revenues increased from approximately $469,000 for the three months ended June 30, 2017 to approximately $913,000 for the three months ended June 30, 2018, and as a percentage of revenue, cost of revenues were 28.9% and 31.1%, respectively. The increase in this percentage is due to a higher level of cost associated with supply procurement and licensed products from year to year. Accordingly, gross profit as a percentage of revenue decreased from 71.1% for the three months ended June 30, 2017 to 68.9% for the three months ended June 30, 2018.

 

Personnel expense increased to approximately $285,000 for the three months ended June 30, 2018, which represented 9.7% of revenues, from approximately $137,000 for the same period a year ago, which represented and 8.4% of revenues. This increase was the result of increased staffing costs to support the higher level of revenues.

 

Marketing and promotion costs increased to approximately $77,000 for the three months ended June 30, 2018 from approximately $45,000 for the same period a year ago. This increase is due to our additional efforts to promote our services within the cannabis industry.

 

General and administrative costs increased to approximately to $815,000 for the three months ended June 30, 2018 from approximately $369,000 for the same period a year ago. This increase is primarily due to the operating costs and professional fees associated with our new active facilities in 2018.

 

Non-operating expenses for the three months ended June 30, 2018 primarily comprised of (i) interest expense on our mortgages and notes payable of approximately $286,000, offset by interest income on our note receivable of approximately $19,000, (ii) non-cash equity compensation of approximately $6.3 million arising from the issuance of stock options and warrants, and (iii) non-cash losses on the settlement of debt via the issuance of common stock and subscriptions on common stock of approximately $563,000. The two non-cash items, required by generally accepted accounting principles, had no effect on the operating earnings or liquidity of the Company. These non-cash items gave rise to the large year-over-year increase in non-operating costs. For the same period in 2017, net interest expense was approximately $96,000, and no options or warrants were issued.

 

As a result of the foregoing, we realized net income of approximately $505,000 for the three months ended June 30, 2017, compared with a net loss of approximately $6.3 million in 2018. The loss in the current period was due to the previously explained non-cash expenses which had no impact on the Company’s operating income or cash flow. Excluding these non-cash items, net income for the three months ended June 30, 2018 was approximately $575,000.

 

Six months ended June 30, 2018 compared to six months ended June 30, 2017

 

Revenues for the six months ended June 30, 2018 increased 81.1% to approximately $5.0 million, compared with $2.8 million from the same period a year ago. This significant increase was primarily due to the growth of (i) rental income from our facilities in Maryland and Massachusetts which were fully developed and leased to tenants in late calendar 2017, (ii) supply procurement services provide to additional cannabis licensees in 2018, and (iii) management fees and additional rental revenue which we earn based on a percentage of revenue generated by our cannabis-licensed clients. For the six months ended June 30, 2018, the revenue generated by these clients increased 62.6% to approximately $8.2 million from approximately $5.0 million for the same period in 2017.

 

Cost of revenues increased to approximately $1.8 million for the six months ended June 30, 2018 from approximately $940,000 for the six months ended June 30, 2017. As a percentage of revenue, cost of revenues for the six months ended June 30, 2018 increased to 35.9% from 33.9% for the same period in 2017. This increase was attributable to a higher level of cost associated with supply procurement and licensed products from year to year. Accordingly, gross profit as a percentage of revenue for the six months ended June 30, 2018 decreased to 64.13% from 66.1% for the same period in 2017.

 

Personnel expense increased to approximately $470,000 for the six months ended June 30, 2018 from $305,000 for the same period a year ago. Despite the increase in amount, which was the result of hiring additional staff to support the higher level of revenues, this expense decreased as a percentage of revenues to 9.4% in 2018 from 11.0% in 2017.

 

Marketing and promotion costs increased slightly to approximately $130,000 for the six months ended June 30, 2018 from approximately $115,000 for the same period a year ago. These costs decreased relative to the growth in revenues from year to year, representing 2.6% and 4.1% of revenues in 2018 and 2017, respectively.

 

15
 

 

General and administrative costs increased to approximately $1,521,000 for the six months ended June 30, 2018 from approximately $582,000 for the same period a year ago. This increase is predominantly due to the utilities, real estate taxes, security, and other cost associated with operating an increased number of active facilities, and is commensurate with the growth of revenues and the overall business.

 

Non-operating expenses comprised of (i) interest expense on our mortgages and notes payable of approximately $605,000, offset by interest income on our note receivable of approximately $39,000, (ii) non-cash equity compensation of approximately $6.9 million arising from the issuing of stock options and warrants, and (iii) non-cash losses on the settlement of debt via the issuance of common stock and subscriptions on common stock of approximately $1.8 million. The two non-cash items, required by generally accepted accounting principles, had no effect on the operating earnings or liquidity of the Company, and the cause for the large year-over-year variation in non-operating expenses. For the same period in 2017, net interest expense was approximately $178,000, and non-cash items approximated $38,000.

 

As a result of the foregoing, we incurred a net loss of approximately $8.1 million for the six months ended June 30, 2018, compared to net income of approximately $614,000 from the same period a year ago. The loss in the current period is due to the previously explained large non-cash expenses which had no impact on the Company’s operating income or cash flow. Excluding these non-cash items, net income for the six months ended June 30, 2017 was approximately $530,000.

 

16
 

 

Subsequent Events

 

Subsequent to June 30, 2018, the following events occurred:

 

-

The Company sold 1,200,780 shares of common stock, at prices ranging from $0.90 to $2.70 per share, for an aggregate amount of $2,200,000.

   
-

The Company issued warrants to purchase544,500 shares of common stock at an exercise price of $4.20 per share.

   
-Warrant holders exercised warrants to purchase 232,083 shares of common stock at exercise prices of $0.10 and $0.40 per share.
   
 - 

A board member was issued 302,000 shares of common stock from the exercise of stock options at exercise prices ranging from $0.08 to $0.63 per share. The aggregate number of shares exercised was 400,000, offset by 98,000 shares used to pay the aggregate exercise price of $98,000 in a cashless transaction.

   
 - In August 2018, the Company made a payment of $250,000 pursuant to an exclusive worldwide licensing agreement for the production and distribution of precision-dosed, dissolvable cannabis products.

 

Item 4. Controls and Procedures

 

As of June 30, 2018, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2018. The above statement notwithstanding, you are cautioned that no system is foolproof.

 

Changes in Internal Control Over Financial Reporting

 

During the quarter covered by this report there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

This quarterly report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the Securities and Exchange Commission that permit the Company to provide only management’s reports in this quarterly report.

 

17
 

 

PART II OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

Item 1A. Risk Factors

 

We are not obligated to disclose our risk factors in this report, however, limited information regarding our risk factors appears in Part I, Item 2. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” under the caption “Forward-Looking Statements” contained in this Quarterly Report on Form 10-Q. and in “Item 1A. RISK FACTORS” of our Annual Report on Form 10-K. There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

During the six months ended June 30, 2018, the Company sold 10,111,578 shares of restricted common stock at prices ranging from $0.50 to $1.37 per share, resulting in total proceeds of approximately $8.5 million. These funds will be used to fund Company operations, continue the development of our facilities, and expand our branded licensing business.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosure

 

Not applicable.

 

Item 5. Other Information

 

None.

 

Item 6. Exhibits

 

3.1   Certificate of Incorporation of the Registrant. Incorporated by reference from Registration Statement on Form 10-12G (File No. 000-54433) filed on June 9, 2011.
     
3.1.1   Amended Certificate of Incorporation of the Registrant. Incorporated by reference from Annual Report on Form 10-K filed on April 17, 2017.
     
3.2   Bylaws – Restated as Amended. Incorporated by reference from Registration Statement on Form 10-12G (File No. 000-54433) filed on June 9, 2011.
     
31.1   Certification of Chief Executive Officer
     
31.2   Certification of Chief Financial Officer
     
32.1   Statement required by 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2   Statement required by 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS* XBRL   Instance Document
     
101.SCH* XBRL   Taxonomy Extension Schema
     
101.CAL* XBRL   Taxonomy Extension Calculation Linkbase
     
101.DEF* XBRL   Taxonomy Extension Definition Linkbase
     
101.LAB* XBRL   Taxonomy Extension Label Linkbase
     
101.PRE* XBRL   Taxonomy Extension Presentation Linkbase

 

18
 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the Registrant caused this Report to be signed on its behalf by the undersigned thereto duly authorized.

 

Date: August 14, 2018

 

MARIMED INC.

 

By: /s/ Robert Fireman  
  Robert Fireman  
  President and Chief Executive Officer  
     
By: /s/ Jon R. Levine  
  Jon R. Levine  
  Chief Financial Officer  

 

19
 

 

INDEX TO EXHIBITS

 

Exhibit No.   Description
     
3.1   Certificate of Incorporation of the Registrant. Incorporated by reference from Registration Statement on Form 10-12G (File No. 000-54433) filed on June 9, 2011.
     
3.1.1   Amended Certificate of Incorporation of the Registrant. Incorporated by reference from Annual Report on Form 10-K filed on April 17, 2017.
     
3.2   Bylaws – Restated as Amended. Incorporated by reference from Registration Statement on Form 10-12G (File No. 000-54433) filed on June 9, 2011.
     
31.1   Certification of Chief Executive Officer
     
31.2   Certification of Chief Financial Officer
     
32.1   Statement required by 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
     
32.2   Statement required by 18 U.S.C. Section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002.
     
101.INS* XBRL   Instance Document
     
101.SCH* XBRL   Taxonomy Extension Schema
     
101.CAL* XBRL   Taxonomy Extension Calculation Linkbase
     
101.DEF* XBRL   Taxonomy Extension Definition Linkbase
     
101.LAB* XBRL   Taxonomy Extension Label Linkbase
     
101.PRE* XBRL   Taxonomy Extension Presentation Linkbase

 

20
 

 EX-31.1 2 ex31-1.htm

 

EXHIBIT 31.1

 

Certifications

 

I, Robert Fireman, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of MariMed Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

a) all significant deficiencies and material weaknesses in the design or operation of internal control which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 14, 2018  
   
/s/ Robert Fireman  
Robert Fireman  
Chief Executive Officer  

 

 
 

 

 

 EX-31.2 3 ex31-2.htm

 

EXHIBIT 31.2

 

Certifications

 

I, Jon R. Levine, certify that:

 

1. I have reviewed this quarterly report on Form 10-Q of MariMed Inc.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

 

a) all significant deficiencies and material weaknesses in the design or operation of internal control which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 14, 2018  
   
/s/ Jon R. Levine  
Jon R. Levine  
Chief Financial Officer  

 

 
 

 

 

 EX-32.1 4 ex32-1.htm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of MariMed Inc. (the “Company”) on Form 10-Q for the three and six months ended June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert Fireman, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Report fairly presents, in all material respects, our financial condition and result of operations.

 

  MARIMED INC.
  (Registrant)
     
Date: August 14, 2018 By: /s/ Robert Fireman
    Robert Fireman
    Chief Executive Officer

 

 
 

 

 

 EX-32.2 5 ex32-2.htm

 

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of MariMed Inc. (the “Company”) on Form 10-Q for the three and six months ended June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jon R. Levine, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, based on my knowledge:

 

  (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
     
  (2) The information contained in the Report fairly presents, in all material respects, our financial condition and result of operations.

 

  MARIMED INC.
  (Registrant)
     
Date: August 14, 2018 By: /s/ Jon R. Levine
    Jon R. Levine
    Chief Financial Officer

 

 
 

 

 

 

 

 

 

 EX-101.INS 6 mrmd-20180630.xml XBRL INSTANCE FILE 0001522767 2018-01-01 2018-06-30 0001522767 2017-12-31 0001522767 2018-06-30 0001522767 MRMD:MariMedAdvisorsIncMember 2014-05-31 0001522767 MRMD:RangeOneMember 2018-01-01 2018-06-30 0001522767 MRMD:RangeOneMember 2018-06-30 0001522767 MRMD:RangeTwoMember 2018-01-01 2018-06-30 0001522767 MRMD:RangeTwoMember 2018-06-30 0001522767 MRMD:RangeThreeMember 2018-01-01 2018-06-30 0001522767 MRMD:RangeThreeMember 2018-06-30 0001522767 MRMD:RangeFourMember 2018-01-01 2018-06-30 0001522767 MRMD:RangeFourMember 2018-06-30 0001522767 MRMD:RangeFiveMember 2018-01-01 2018-06-30 0001522767 MRMD:RangeFiveMember 2018-06-30 0001522767 MRMD:RangeSixMember 2018-01-01 2018-06-30 0001522767 MRMD:RangeSixMember 2018-06-30 0001522767 MRMD:RangeSevenMember 2018-01-01 2018-06-30 0001522767 MRMD:RangeSevenMember 2018-06-30 0001522767 MRMD:RangeEightMember 2018-01-01 2018-06-30 0001522767 MRMD:RangeEightMember 2018-06-30 0001522767 MRMD:OnlinePortalOperationsMember 2018-01-01 2018-06-30 0001522767 MRMD:OnlinePortalOperationsMember 2018-06-30 0001522767 MRMD:CannabisRelatedOperationsMember 2018-01-01 2018-06-30 0001522767 MRMD:CannabisRelatedOperationsMember 2018-06-30 0001522767 MRMD:RangeNineMember 2018-06-30 0001522767 MRMD:RangeNineMember 2018-01-01 2018-06-30 0001522767 MRMD:MariMedAdvisorsIncMember 2017-06-30 0001522767 MRMD:MariMedAdvisorsIncMember 2017-06-01 2017-06-30 0001522767 2017-06-30 0001522767 us-gaap:BuildingAndBuildingImprovementsMember srt:MinimumMember 2018-01-01 2018-06-30 0001522767 MRMD:BuildingsandBuildingImprovementsMember srt:MaximumMember 2018-01-01 2018-06-30 0001522767 2018-08-14 0001522767 us-gaap:FurnitureAndFixturesMember 2018-01-01 2018-06-30 0001522767 srt:MinimumMember 2017-01-31 0001522767 srt:MaximumMember 2017-01-31 0001522767 srt:MinimumMember 2018-06-30 0001522767 srt:MaximumMember 2018-06-30 0001522767 us-gaap:StockOptionMember 2018-01-01 2018-06-30 0001522767 us-gaap:StockOptionMember MRMD:OverSixMonthPeriodMember 2018-06-29 2018-06-30 0001522767 us-gaap:MachineryAndEquipmentMember srt:MaximumMember 2018-01-01 2018-06-30 0001522767 us-gaap:MachineryAndEquipmentMember srt:MinimumMember 2018-01-01 2018-06-30 0001522767 MRMD:MariHoldingsMDLLCMember MRMD:ClassAMembershipUnitsMember 2017-01-01 2017-06-30 0001522767 us-gaap:ChiefExecutiveOfficerMember 2017-09-01 2017-09-30 0001522767 us-gaap:ChiefExecutiveOfficerMember 2017-09-30 0001522767 2017-10-01 2017-10-31 0001522767 MRMD:SeriesAConvertiblePreferredStockMember 2018-06-30 0001522767 MRMD:EmploymentAgreementMember 2018-06-30 0001522767 MRMD:EmploymentAgreementMember 2017-12-31 0001522767 us-gaap:ChiefExecutiveOfficerMember 2017-12-31 0001522767 us-gaap:ConvertiblePreferredStockMember 2017-01-01 2017-06-30 0001522767 MRMD:ConvertiblePromissoryNotesMember 2017-01-01 2017-06-30 0001522767 2017-01-01 2017-06-30 0001522767 2016-12-31 0001522767 us-gaap:ConvertiblePreferredStockMember 2018-01-01 2018-06-30 0001522767 MRMD:ConvertiblePromissoryNotesMember 2018-01-01 2018-06-30 0001522767 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001522767 us-gaap:CommonStockMember 2017-01-01 2017-06-30 0001522767 MRMD:SeriesAConvertiblePreferredStockMember 2018-01-31 0001522767 us-gaap:WarrantMember 2017-01-01 2017-06-30 0001522767 us-gaap:WarrantMember 2017-06-30 0001522767 us-gaap:WarrantMember 2018-01-01 2018-06-30 0001522767 us-gaap:WarrantMember 2018-06-30 0001522767 MRMD:SigalConsultingLLCMember 2014-05-01 2014-05-31 0001522767 MRMD:SigalConsultingLLCMember 2014-05-31 0001522767 MRMD:OnlinePortalOperationsMember 2017-01-01 2017-06-30 0001522767 MRMD:CannabisRelatedOperationsMember 2017-01-01 2017-06-30 0001522767 MRMD:OnlinePortalOperationsMember 2017-06-30 0001522767 MRMD:CannabisRelatedOperationsMember 2017-06-30 0001522767 MRMD:OptionsAndWarrantsMember 2018-01-01 2018-06-30 0001522767 MRMD:OptionsAndWarrantsMember 2017-01-01 2017-06-30 0001522767 us-gaap:CommonStockMember 2018-01-31 0001522767 MRMD:WarrantOneMember 2018-06-30 0001522767 MRMD:WarrantOneMember 2017-06-30 0001522767 MRMD:WarrantOneMember srt:MinimumMember 2018-06-30 0001522767 MRMD:WarrantOneMember srt:MaximumMember 2018-06-30 0001522767 MRMD:RangeTenMember 2018-01-01 2018-06-30 0001522767 MRMD:RangeTenMember 2018-06-30 0001522767 MRMD:RangeElevenMember 2018-01-01 2018-06-30 0001522767 MRMD:RangeElevenMember 2018-06-30 0001522767 MRMD:RangeTwelveMember 2018-01-01 2018-06-30 0001522767 MRMD:RangeTwelveMember 2018-06-30 0001522767 MRMD:RangeThirteenMember 2018-01-01 2018-06-30 0001522767 MRMD:RangeThirteenMember 2018-06-30 0001522767 us-gaap:CommonStockMember srt:MinimumMember 2018-06-30 0001522767 us-gaap:CommonStockMember srt:MaximumMember 2018-06-30 0001522767 us-gaap:CommonStockMember srt:MinimumMember 2017-06-30 0001522767 us-gaap:CommonStockMember srt:MaximumMember 2017-06-30 0001522767 MRMD:WarrantTwoMember 2018-06-30 0001522767 MRMD:WarrantTwoMember 2017-06-30 0001522767 MRMD:CommonStockSubscriptionsMember 2018-01-01 2018-06-30 0001522767 MRMD:MariHoldingsMDLLCMember MRMD:ClassAMembershipUnitsMember 2017-06-30 0001522767 2018-04-01 2018-06-30 0001522767 2017-04-01 2017-06-30 0001522767 MRMD:SeriesAConvertiblePreferredStockMember 2017-01-01 2017-06-30 0001522767 MRMD:SeriesAConvertiblePreferredStockMember 2017-06-30 0001522767 us-gaap:StockOptionMember 2018-06-29 2018-06-30 0001522767 us-gaap:StockOptionMember MRMD:EmployeesMember 2017-01-01 2017-06-30 0001522767 us-gaap:StockOptionMember MRMD:EmployeesMember srt:MinimumMember 2017-01-01 2017-06-30 0001522767 us-gaap:StockOptionMember MRMD:EmployeesMember srt:MaximumMember 2017-01-01 2017-06-30 0001522767 MRMD:BoardMember 2018-01-01 2018-06-30 0001522767 us-gaap:StockOptionMember MRMD:EmployeesMember 2018-05-01 2018-05-31 0001522767 us-gaap:ChiefFinancialOfficerMember 2018-01-01 2018-06-30 0001522767 MRMD:RangeFourteenMember 2018-06-30 0001522767 MRMD:RangeFourteenMember 2018-01-01 2018-06-30 0001522767 us-gaap:CommonStockMember 2017-01-31 0001522767 MRMD:CommonStockSubscriptionsMember 2017-01-01 2017-06-30 0001522767 MRMD:CommonStockSubscriptionsMember 2017-10-01 2017-10-31 0001522767 MRMD:CommonStockSubscriptionsMember MRMD:IRollieLLCMember 2018-01-01 2018-06-30 0001522767 MRMD:WarrantsMember 2018-06-30 0001522767 MRMD:WarrantsOneMember 2018-06-30 0001522767 MRMD:WarrantsOneMember srt:MinimumMember 2018-06-30 0001522767 MRMD:WarrantsOneMember srt:MaximumMember 2018-06-30 0001522767 us-gaap:ChiefExecutiveOfficerMember 2017-12-01 2017-12-31 0001522767 MRMD:IndividualsMember 2017-12-01 2017-12-31 0001522767 MRMD:CEOMember 2018-06-30 0001522767 MRMD:CFOMember 2017-12-31 0001522767 MRMD:SigalConsultingLLCMember srt:MinimumMember 2014-05-31 0001522767 MRMD:SigalConsultingLLCMember srt:MaximumMember 2014-05-31 0001522767 MRMD:CommonStockSubscriptionsMember MRMD:IRollieLLCMember 2018-05-01 2018-05-31 0001522767 MRMD:IRollieLLCMember 2018-05-31 0001522767 us-gaap:CommonStockMember MRMD:ThirdPartyMember 2018-01-01 2018-06-30 0001522767 us-gaap:CommonStockMember MRMD:ThirdPartyMember 2017-01-01 2017-06-30 0001522767 us-gaap:CommonStockMember MRMD:FormerChiefFinancialOfficerMember 2018-01-01 2018-06-30 0001522767 us-gaap:CommonStockMember MRMD:FormerChiefFinancialOfficerMember 2017-01-01 2017-06-30 0001522767 MRMD:SeriesAConvertiblePreferredStockMember 2018-01-01 2018-01-30 0001522767 MRMD:CommonStockSubscriptionsMember 2018-05-01 2018-05-31 0001522767 MRMD:CommonStockSubscriptionsMember 2018-06-01 2018-06-30 0001522767 MRMD:WorldwideLicensingAgreementMember 2018-01-01 2018-06-30 0001522767 MRMD:CommonStockSubscriptionsMember MRMD:VendorMember 2018-01-01 2018-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure MARIMED INC. 0001522767 10-Q 2018-06-30 false --12-31 Smaller Reporting Company Q2 195228998 1290231 5077126 2815825 569356 1453484 3120070 610789 1107697 134781 134781 45444 48359 357019 401888 5088666 12264573 25954931 31364803 578831 653792 579587 1157448 32202015 45440616 400996 204996 10665899 8740212 15422445 16087361 240013 240013 21194855 23799036 176940 193710 25000 25000 2176379 8546405 20149591 33703929 -11971740 -20214651 175490 -17813 11007160 21641580 32202015 45440616 0.001 0.001 50000000 50000000 5000000 50000000 500000 0 0.001 0.001 500000000 500000000 100000000 500000000 176940331 193709580 176850331 193462052 1000000 0 5020275 5020275 2771776 114 2771662 2937325 1621057 3218049 1831415 2023968 1151763 1521397 582326 814914 368557 129704 114734 77943 45265 469557 304686 284886 136824 2120658 1001746 1177743 550646 1097391 829669 846225 601117 9207782 215478 7124707 96312 -8110391 614191 -6278482 504805 132520 99431 69287 -42195 -8242911 514760 -6347769 547000 -0.045 0.008 -0.034 0.008 182746858 64912354 186645833 65593751 1666587 448183 35108 44870 56278 577861 109520 -196000 10280 -27182 42254 -5741460 -3741057 8461003 5200000 8461000 5200000 22125 25097 9555537 5945272 3786895 2246469 118556 121199 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 &#8211; ORGANIZATION AND DESCRIPTION OF BUSINESS</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">MariMed Inc. (the &#8220;Company&#8221;), a Delaware corporation, develops and manages state-of-the-art, regulatory-compliant facilities for the cultivation, production, and dispensing of legal cannabis and cannabis-infused products. Such facilities, located in multiple states, are leased to the Company&#8217;s clients in the emerging cannabis industry. Along with operational oversight, the Company provides its clients with legal, accounting, human resources, business development, and other corporate and administrative services.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company also provides professional consultative services in all aspects of cannabis licensing procurement. To date, the Company has secured, on behalf of its clients, 11 cannabis licenses across five states&#8212;two in Delaware, two in Illinois, one in Nevada, three in Maryland and three in Massachusetts. Accordingly, the Company has developed seed-to-sale cannabis facilities across of these five states in excess of 300,000 square feet.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the Company licenses precision-dosed, cannabis-infused products to treat specific medical conditions or to achieve a certain result. These products are licensed under the brand names Kalm Fusion&#8482; and Nature&#8217;s Heritage&#8482;, both of which were developed by the Company, and Betty&#8217;s Eddies&#8482;, acquired in October 2017. The Company also has exclusive sublicensing rights in certain states to distribute vaporizer pens developed by Lucid Mood&#8482;, as well as the clinically-tested medicinal cannabis strains developed in Israel by Tikun Olam&#8482;.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s stock is quoted on the OTCQB market under the ticker symbol MRMD.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company was originally incorporated in January 2011 under the name Worlds Online Inc., using the ticker symbol WORX. In early 2017, the Company name and ticker were changed to its current name and ticker. Since inception, the Company had operated an online portal that offers multi-user virtual environments to users. This segment of the business has had insignificant operations since early 2014.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the Company, through its subsidiary MariMed Advisors Inc., acquired Sigal Consulting LLC, a company operating in the cannabis industry. The purchase price consisted of Company common stock, options to purchase additional Company common stock, and a minority interest in MariMed Advisors Inc. This transaction, further disclosed in Note 3, was accounted for as a purchase acquisition where the Company was both the legal and accounting acquirer. In June 2017, the minority interest in MariMed Advisors Inc. was merged into the Company.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2018, the Company acquired iRollie LLC, a manufacturer of branded cannabis products and accessories for consumers, and custom product and packaging for companies in the cannabis industry. This acquisition is further disclosed in Note 3.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Basis of Presentation</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with GAAP, these interim statements do not contain all of the disclosures normally required in annual statements. In addition, the results of operations of interim periods are not necessarily indicative of the results of operations to be expected for the full year. Accordingly, these interim financial statements should be read in conjunction with the Company&#8217;s audited annual financial statements and accompanying notes for the year ended December 31, 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain reclassifications have been made to prior periods&#8217; data to conform to the current period presentation. These reclassifications had no effect on reported income (losses) or cash flows.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Principles of Consolidation</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying condensed consolidated financial statements include the accounts of MariMed Inc. and its subsidiaries, all of which are majority-owned. Intercompany accounts and transactions have been eliminated.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Use of Estimates</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts within the financial statements and disclosures thereof. Actual results could differ from these estimates or assumptions.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Cash Equivalents</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid investments with a maturity date of three months or less to be cash equivalents. The fair values of these investments approximate their carrying values.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Revenue Recognition</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s main sources of revenue are comprised of: leasing of its developed cannabis cultivation, production, and dispensary facilities to its cannabis-licensed clients; agreements to provide comprehensive oversight and corporate support to its clients&#8217; operations; consulting services to companies operating in the medical and legal recreational cannabis industries; arrangements for the procurement of cannabis materials and resources; and licensing of branded cannabis products.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue when all of the following criteria are met: evidence of an arrangement exists such as a signed contract, delivery has occurred/services have been performed, the price is fixed or determinable, and collectability is reasonably assured.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Research and Development Costs</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are charged to operations as incurred.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Property and Equipment</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost less accumulated depreciation, with depreciation recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term, if applicable. When assets are retired or disposed, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income. Repairs and maintenance are charged to expense in the period incurred.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated useful lives of property and equipment are generally as follows: buildings and building improvements, seven to thirty-nine years; tenant improvements, the remaining duration of the related lease; furniture and fixtures, seven years; machinery and equipment, five to ten years. Land is not depreciated.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s property and equipment are individually reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of an asset exceeds the aggregate projected future cash flows over the anticipated holding period on an undiscounted basis. An impairment loss is measured based on the excess of the asset&#8217;s carrying amount over its estimated fair value.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Impairment analyses are based on management&#8217;s current plans, intended holding periods and available market information at the time the analyses are prepared. If these criteria change, the Company&#8217;s evaluation of impairment losses may be different and could have a material impact to the consolidated financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the six months ended June 30, 2018 and 2017, based on its impairment analyses, the Company did not have any impairment losses.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Impairment of Long Lived Assets</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates the recoverability of its fixed assets and other assets in accordance with the Financial Accounting Standards Board&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;) 360-10-15, <i>Impairment or Disposal of Long-Lived Assets</i>. Impairment of long-lived assets is recognized when the net book value of such assets exceeds their expected cash flows, in which case the assets are written down to fair value, which is determined based on discounted future cash flows or appraised values.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Fair Value of Financial Instruments</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 820, <i>Fair Value Measurement</i>, to measure the fair value of its financial instruments, and ASC 825, <i>Financial Instruments, </i>for disclosures on the fair value of its financial instruments. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value hierarchy defined by ASC 820 are:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 1</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 2</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 3</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Pricing inputs that are generally observable inputs and not corroborated by market data.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts of the Company&#8217;s financial assets and liabilities, such as cash and accounts payable approximate their fair values due to the short maturity of these instruments. The fair value of option and warrant issuances are determined utilizing the binomial options pricing model and employing the following inputs: life of instrument, exercise price, value of the underlying security on issuance date, and 2-year volatility of underlying security.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Extinguishment of Liabilities</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for extinguishment of liabilities in accordance with ASC 405-20, <i>Extinguishments of Liabilities. </i>When the conditions for extinguishment are met, the liabilities are written down to zero and a gain or loss is recognized.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Stock-Based Compensation</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for stock-based compensation using the fair value method as set forth in ASC 718, <i>Compensation&#8212;Stock Compensation, </i>which requires a public entity to measure the cost of employee services received in exchange for an equity award based on the fair value of the award on the grant date, with limited exceptions. Such value will be incurred as compensation expense over the period an employee is required to provide service in exchange for the award, usually the vesting period. No compensation cost is recognized for equity awards for which employees do not render the requisite service.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Income Taxes</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes in accordance with ASC 740, <i>Income Taxes</i>. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of operations in the period that includes the enactment date.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. The Company did not take any uncertain tax positions and had no adjustments to unrecognized income tax liabilities or benefits for the six months ended June 30, 2018 and 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Related Party Transactions</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows ASC 850, <i>Related Party Disclosures</i>, for the identification of related parties and disclosure of related party transactions.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 850, the Company&#8217;s financial statements include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, as well as transactions that are eliminated in the preparation of financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Comprehensive Income</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reports comprehensive income and its components following guidance set forth by ASC 220, <i>Comprehensive Income</i>, which establishes standards for the reporting and display of comprehensive income and its components in the consolidated financial statements. There were no items of comprehensive income applicable to the Company during the period covered in the financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Earnings Per Share</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Earnings per common share is computed pursuant to ASC 260, <i>Earnings Per Share</i>. Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income by the sum of the weighted average number of shares of common stock outstanding plus the weighted average number of potentially dilutive securities during the period.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2018 and 2017, there were 12,508,932 and 10,475,000, respectively, of potentially dilutive securities in the form of options and warrants. Also as of June 30, 2018 and 2017, there were zero and 500,000 shares, respectively, of subscriptions on convertible preferred stock, and $250,000 and $3,125,000, respectively, of convertible promissory notes, that were potentially dilutive, whose conversion into common stock is based on a discount to the market value of common stock on or about the future conversion date. For the six months ended June 30, 2018, all potentially dilutive securities had an anti-dilutive effect on earnings per share, and in accordance with ASC 260, were excluded from the diluted net income per share calculation, resulting in calculations of basic and fully diluted net income per share that were identical for this period. These securities may dilute earnings per share in the future.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Commitments and Contingencies</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows ASC 450, <i>Contingencies</i>, which requires the Company to assess the likelihood that a loss will be incurred from the occurrence or non-occurrence of one or more future events. Such assessment inherently involves an exercise of judgment. In assessing possible loss contingencies from legal proceedings or unasserted claims, the Company would evaluate the perceived merits of the proceedings or claims, and the perceived merits of the relief sought or expected to be sought.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If the assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can be estimated, then such estimated liability would be accrued in the Company&#8217;s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">While not assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse effect on the Company&#8217;s financial position, results of operations or cash flows.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Risk and Uncertainties</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to risks common to companies operating within the legal and medical marijuana industries, including, but not limited to, federal laws, government regulations and jurisdictional laws.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Noncontrolling Interests</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Noncontrolling interests represent third-party minority ownership of the Company&#8217;s consolidated subsidiaries. Net income attributable to noncontrolling interests is shown in the consolidated statements of operations; and the value of net assets owned by noncontrolling interests are presented as a component of equity within the balance sheets.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Off Balance Sheet Arrangements</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company does not have any off-balance sheet arrangements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Recent Accounting Pronouncements</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU No. 2016-18, <i>Statement of Cash Flows (Topic 230): Restricted Cash</i>, which enhances and clarifies the guidance on the classification and presentation of restricted cash in the statement of cash flows. This ASU will be effective in 2019 and its impact is dependent upon the level of restricted cash of the Company, which at this time is insignificant.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU No. 2016-02, <i>Leases (Topic 842)</i>, which modifies accounting for lessees by requiring the recording of lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. This ASU will be effective in 2020 and the Company is currently evaluating the impact of adoption, which will be determined by the Company&#8217;s lease portfolio at the time of implementation.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2014 and subsequently in 2016, the FASB issued new standards on the recognition of revenue. While the new standards amend the current standards, they are not expected to have a material impact on the amount and timing of revenue recognized in the Company&#8217;s consolidated financial statements when the new standards are adopted in 2019.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the above, the Company has reviewed all other recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption of any such pronouncements will have a material impact on its financial condition or the results of its operations.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 &#8211; PROPERTY AND EQUIPMENT</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are shown net of accumulated depreciation and are primarily comprised of the following: land; buildings; building and tenant improvements; furniture and fixtures; and machinery and equipment.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2018 and 2017, additions to property and equipment were approximately $5,664,000 million and $3,766,000 million, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense for the six months ended June 30, 2018 and 2017 was approximately $254,000 and $163,000, respectively. At June 30, 2018 and December 31, 2017, accumulated depreciation approximated $1,746,000 and $1,499,000, respectively.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 9 &#8211; RELATED PARTY TRANSACTIONS</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As disclosed in Note 3 above, the current CEO and CFO of the Company are part in the Sigal Ownership Group from whom Sigal Consulting LLC was acquired in May 2014. The 49% ownership in the Company&#8217;s subsidiary, MariMed Advisors Inc., which the Sigal Ownership Group acquired as part of the purchase price, was acquired by the Company from the Sigal Ownership Group in June 2017 in exchange for 75 million shares of the Company&#8217;s common stock.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In September 2017, the former CEO of the Company, who is a currently a board member, exercised options to purchase 4.5 million shares of common stock at an exercise price of $0.01 per share. The aggregate exercise price of $45,000 was paid in a cashless transaction with 90,000 shares of common stock which were classified as treasury stock.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2017, the Company acquired the intellectual property, formulations, recipes, proprietary equipment, and know-how of the Betty&#8217;s Eddies&#8482; brand of cannabis-infused products, as disclosed in Note 3, from a company that is minority-owned by the Company&#8217;s chief operating officer.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2017, options to purchase 200,000 shares of commons stock at an exercise price of $0.025 were forfeited by the CEO and by an independent board member (100,000 shares forfeited by each individual).</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2018, a current board member exercised options to purchase 400,000 shares of common stock, and the former CFO of the Company exercised options to purchase 300,000 shares of common stock. These options were exercised at exercise prices ranging from $0.08 to $0.63 per share. No options were exercised during the same period in 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2018 and 2017, the Company issued 170,000 and 169,487 shares, respectively, of common stock for services rendered by the former CFO of the Company. Based on the market value of the common stock on the dates of the two issuances, the Company recorded non-cash losses of approximately $112,000 in 2018 and $18,000 in 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2018 and December 31, 2017, the Company owed approximately $19,000 and $14,000 to the CEO and CFO, respectively.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The caption <i>Due from Related Parties</i> in the Company&#8217;s financial statements is primarily comprised of short term loans to non-consolidated entities under common ownership.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The caption <i>Due to Related Parties </i>reflects short term loans from related parties and includes advances received from officers of the Company.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 10 &#8211; <font style="text-transform: uppercase">COMMITMENTS AND CONTINGENCIES</font></b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">An employment agreement with the former CEO of the Company that provided this individual with salary, car allowances, stock options, life insurance, and other employee benefits was terminated in 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded an accrual of approximately $1,043,000 at June 30, 2018 and December 31, 2017 for any amounts that may be owed under this agreement. However, the Company is contesting the validity this agreement.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 11 &#8211; SEGMENT REPORTING </b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 280, the following is information regarding the Company&#8217;s operating segments:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Six Months Ended June 30,</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Revenues:</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 64%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Online portal operations</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">114</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cannabis related operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,020,275</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,771,662</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Consolidated revenues</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,020,275</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,771,776</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Depreciation:</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Online portal operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cannabis related operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">253,713</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">163,410</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">253,713</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">163,410</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Net income (loss):</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Online portal operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(181</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(146,774</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cannabis related operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,831,210</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">760,965</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Net income (loss)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(8,110,391</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">614,191</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Capital expenditures:</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Online portal operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cannabis related operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,663,585</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,766,154</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Combined capital expenditures</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,663,585</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,766,154</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Assets:</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Online portal operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,217</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,504</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cannabis related operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">45,439,399</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,349,925</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Combined assets</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">45,440,616</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,351,429</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 280, the following is information regarding the Company&#8217;s operating segments:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Six Months Ended June 30,</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>2017</b></font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Revenues:</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 64%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Online portal operations</font></td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 15%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 14%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">114</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cannabis&#160;related&#160;operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,020,275</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,771,662</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Consolidated revenues</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,020,275</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2,771,776</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Depreciation:</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Online portal operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cannabis&#160;related&#160;operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">253,713</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">163,410</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Depreciation</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">253,713</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">163,410</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Net income (loss):</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Online portal operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(181</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(146,774</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cannabis&#160;related&#160;operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(1,831,210</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">760,965</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Net income (loss)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">(8,110,391</font></td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">)</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">614,191</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Capital expenditures:</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Online portal operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">&#8212;</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cannabis&#160;related&#160;operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,663,585</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,766,154</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Combined capital expenditures</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,663,585</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3,766,154</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif"><b>Assets:</b></font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Online portal operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,217</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,504</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Cannabis&#160;related&#160;operations</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">45,439,399</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,349,925</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Combined assets</font></td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">45,440,616</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">15,351,429</font></td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock options outstanding and exercisable as of June 30, 2018 were:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise Price</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Shares Under Option</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">per Share</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Life in Years</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 21%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.080</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 2%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 26%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">250,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 21%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">250,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 107%">&#160;</td> <td style="width: 20%; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.58</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.080</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.47</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.130</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.00</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.140</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">650,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">650,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.51</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.150</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.25</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.250</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.25</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.260</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.76</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.330</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.69</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.350</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.25</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.450</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">250,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">125,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.26</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.550</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.25</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.630</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">300,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">300,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.51</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.770</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">300,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.51</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.900</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.87</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,450,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,800,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 0.50 570000 302000 P5Y 0.01 0.025 0.15 0.35 0.49 0.49 0.0033 1.00 500000 3125000 0 250000 12508932 10475000 1667 10111578 22178888 264317 200000 1000000 32083 600000 2001641 150000 1951600 100000 4239000 1425379 7058932 1225000 544500 232083 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 12 &#8211; SUBSEQUENT EVENTS</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Subsequent to June 30, 2018, the following events occurred:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px">&#160;</td> <td style="width: 24px; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">The Company sold 1,200,780 shares of common stock, at prices ranging from $0.90 to $2.70 per share, for an aggregate amount of $2,200,000.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">The Company issued warrants to purchase 544,500 shares of common stock at an exercise price of $4.20 per share.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Warrant holders exercised warrants to purchase 232,083 shares of common stock at exercise prices of $0.10 and $0.40 per share.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 12pt Times New Roman, Times, Serif">-</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">A board member was issued 302,000 shares of common stock from the exercise of stock options at exercise prices ranging from $0.08 to $0.63 per share. The aggregate number of shares exercised was 400,000, offset by 98,000 shares used to pay the aggregate exercise price of $98,000 in a cashless transaction.</font></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="text-align: justify; line-height: 107%">&#160;</td> <td style="line-height: 107%"><font style="font: 12pt Times New Roman, Times, Serif">-</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">In August 2018, the Company made a payment of $250,000 pursuant to an exclusive worldwide licensing agreement for the production and distribution of precision-dosed, dissolvable cannabis products.</font></td></tr> </table> <p style="margin: 0pt"></p> 1196918 2374652 400000 0.080 0.080 0.130 0.140 0.150 0.250 0.260 0.330 0.350 0.450 0.550 0.630 0.770 0.900 90000 247528 39000 553206 157930 75000000 31954236 1450000 100000 200000 45440616 1217 45439399 15351429 1504 15349925 -8110391 -181 -1831210 614191 -146774 760965 5663585 5663585 3766154 3766154 5450000 250000 100000 200000 650000 1000000 1000000 50000 50000 1000000 250000 100000 300000 300000 200000 4800000 250000 100000 200000 650000 1000000 1000000 50000 25000 1000000 125000 100000 300000 0.50 1.37 0.18 0.25 1.00 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Use of Estimates</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts within the financial statements and disclosures thereof. Actual results could differ from these estimates or assumptions.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Cash Equivalents</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid investments with a maturity date of three months or less to be cash equivalents. The fair values of these investments approximate their carrying values.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Revenue Recognition</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s main sources of revenue are comprised of: leasing of its developed cannabis cultivation, production, and dispensary facilities to its cannabis-licensed clients; agreements to provide comprehensive oversight and corporate support to its clients&#8217; operations; consulting services to companies operating in the medical and legal recreational cannabis industries; arrangements for the procurement of cannabis materials and resources; and licensing of branded cannabis products.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes revenue when all of the following criteria are met: evidence of an arrangement exists such as a signed contract, delivery has occurred/services have been performed, the price is fixed or determinable, and collectability is reasonably assured.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Research and Development Costs</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development costs are charged to operations as incurred.</p> 496908 67437 1275000 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Property and Equipment</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost less accumulated depreciation, with depreciation recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term, if applicable. When assets are retired or disposed, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income. Repairs and maintenance are charged to expense in the period incurred.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The estimated useful lives of property and equipment are generally as follows: buildings and building improvements, seven to thirty-nine years; tenant improvements, the remaining duration of the related lease; furniture and fixtures, seven years; machinery and equipment, five to ten years. Land is not depreciated.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s property and equipment are individually reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of an asset exceeds the aggregate projected future cash flows over the anticipated holding period on an undiscounted basis. An impairment loss is measured based on the excess of the asset&#8217;s carrying amount over its estimated fair value.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Impairment analyses are based on management&#8217;s current plans, intended holding periods and available market information at the time the analyses are prepared. If these criteria change, the Company&#8217;s evaluation of impairment losses may be different and could have a material impact to the consolidated financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">For the six months ended June 30, 2018 and 2017, based on its impairment analyses, the Company did not have any impairment losses.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Impairment of Long Lived Assets</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company evaluates the recoverability of its fixed assets and other assets in accordance with the Financial Accounting Standards Board&#8217;s Accounting Standards Codification (&#8220;ASC&#8221;) 360-10-15,&#160;<i>Impairment or Disposal of Long-Lived Assets</i>. Impairment of long-lived assets is recognized when the net book value of such assets exceeds their expected cash flows, in which case the assets are written down to fair value, which is determined based on discounted future cash flows or appraised values.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Fair Value of Financial Instruments</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of ASC 820,&#160;<i>Fair Value Measurement</i>, to measure the fair value of its financial instruments, and ASC 825,&#160;<i>Financial Instruments,&#160;</i>for disclosures on the fair value of its financial instruments. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value hierarchy defined by ASC 820 are:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 72px; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 1</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 2</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.</font></td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%">&#160;</td> <td style="text-align: justify; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Level 3</font></td> <td style="text-align: justify; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Pricing inputs that are generally observable inputs and not corroborated by market data.</font></td></tr> </table> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The carrying amounts of the Company&#8217;s financial assets and liabilities, such as cash and accounts payable approximate their fair values due to the short maturity of these instruments. The fair value of option and warrant issuances are determined utilizing the binomial options pricing model and employing the following inputs: life of instrument, exercise price, value of the underlying security on issuance date, and 2-year volatility of underlying security.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Extinguishment of Liabilities</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for extinguishment of liabilities in accordance with ASC 405-20,&#160;<i>Extinguishments of Liabilities.&#160;</i>When the conditions for extinguishment are met, the liabilities are written down to zero and a gain or loss is recognized.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Stock-Based Compensation</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for stock-based compensation using the fair value method as set forth in ASC 718,&#160;<i>Compensation&#8212;Stock Compensation,&#160;</i>which requires a public entity to measure the cost of employee services received in exchange for an equity award based on the fair value of the award on the grant date, with limited exceptions. Such value will be incurred as compensation expense over the period an employee is required to provide service in exchange for the award, usually the vesting period. No compensation cost is recognized for equity awards for which employees do not render the requisite service.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Income Taxes</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes in accordance with ASC 740,&#160;<i>Income Taxes</i>. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of operations in the period that includes the enactment date.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. The Company did not take any uncertain tax positions and had no adjustments to unrecognized income tax liabilities or benefits for the six months ended June 30, 2018 and 2017.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Related Party Transactions</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows ASC 850,&#160;<i>Related Party Disclosures</i>, for the identification of related parties and disclosure of related party transactions.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 850, the Company&#8217;s financial statements include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, as well as transactions that are eliminated in the preparation of financial statements.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Comprehensive Income</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company reports comprehensive income and its components following guidance set forth by ASC 220,&#160;<i>Comprehensive Income</i>, which establishes standards for the reporting and display of comprehensive income and its components in the consolidated financial statements. There were no items of comprehensive income applicable to the Company during the period covered in the financial statements.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Earnings Per Share</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Earnings per common share is computed pursuant to ASC 260, <i>Earnings Per Share</i>. Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income by the sum of the weighted average number of shares of common stock outstanding plus the weighted average number of potentially dilutive securities during the period.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2018 and 2017, there were 12,508,932 and 10,475,000, respectively, of potentially dilutive securities in the form of options and warrants. Also as of June 30, 2018 and 2017, there were zero and 500,000 shares, respectively, of subscriptions on convertible preferred stock, and $250,000 and $3,125,000, respectively, of convertible promissory notes, that were potentially dilutive, whose conversion into common stock is based on a discount to the market value of common stock on or about the future conversion date. For the six months ended June 30, 2018, all potentially dilutive securities had an anti-dilutive effect on earnings per share, and in accordance with ASC 260, were excluded from the diluted net income per share calculation, resulting in calculations of basic and fully diluted net income per share that were identical for this period. These securities may dilute earnings per share in the future.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Commitments and Contingencies</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows ASC 450,&#160;<i>Contingencies</i>, which requires the Company to assess the likelihood that a loss will be incurred from the occurrence or non-occurrence of one or more future events. Such assessment inherently involves an exercise of judgment. In assessing possible loss contingencies from legal proceedings or unasserted claims, the Company would evaluate the perceived merits of the proceedings or claims, and the perceived merits of the relief sought or expected to be sought.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">If the assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can be estimated, then such estimated liability would be accrued in the Company&#8217;s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">While not assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse effect on the Company&#8217;s financial position, results of operations or cash flows.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Risk and Uncertainties</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company is subject to risks common to companies operating within the legal and medical marijuana industries, including, but not limited to, federal laws, government regulations and jurisdictional laws.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Off Balance Sheet Arrangements</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company does not have any off-balance sheet arrangements.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Recent Accounting Pronouncements</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2016, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued ASU No. 2016-18,&#160;<i>Statement of Cash Flows (Topic 230): Restricted Cash</i>, which enhances and clarifies the guidance on the classification and presentation of restricted cash in the statement of cash flows. This ASU will be effective in 2019 and its impact is dependent upon the level of restricted cash of the Company, which at this time is insignificant.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU No. 2016-02,&#160;<i>Leases (Topic 842)</i>, which modifies accounting for lessees by requiring the recording of lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. This ASU will be effective in 2020 and the Company is currently evaluating the impact of adoption, which will be determined by the Company&#8217;s lease portfolio at the time of implementation.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In 2014 and subsequently in 2016, the FASB issued new standards on the recognition of revenue. While the new standards amend the current standards, they are not expected to have a material impact on the amount and timing of revenue recognized in the Company&#8217;s consolidated financial statements when the new standards are adopted in 2019.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to the above, the Company has reviewed all other recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption of any such pronouncements will have a material impact on its financial condition or the results of its operations.</p> 563613 177905 267186 96312 6863609 458000 264000 19295 19000 6370000 6290802 36000 19000 2831658 2833687 1405336 1602834 1043000 1043000 2029 889489 246810 -488228 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 &#8211; DEBT</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2018, the Company received additional capital of approximately $1,998,000 from the existing mortgage on the cannabis cultivation and processing facility it is currently developing in the state of Massachusetts.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2017, the Company raised $400,000 from the issuance of a promissory note with an interest rate of 10% and a term of 6 months. No promissory notes were issued during the six months ended June 30, 2018.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2018, the Company repaid $700,000 of promissory notes, and converted $1,275,000 of promissory notes into 1,679,486 shares of common stock. The conversions resulted in the recording of non-cash losses totaling $818,000, based on the market value of the common stock on the conversion dates. No repayments or conversions of debt occurred during the same period in 2017.</p> P7Y P39Y P7Y P10Y P5Y 2.25 0.30 0.10 0.50 0.10 2.25 4.20 0.10 0.40 expiring in March 2020 expiring in February 2021 45000 545000 1177734 506900 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 6 &#8211; EQUITY</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Preferred Stock</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2017, the Company increased the number of authorized shares of preferred stock from 5 million to 50 million shares.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2017, the Company issued subscriptions on 200,000 shares of Series A convertible preferred stock at $1.00 per share. No subscriptions were issued during the same period in 2018.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Series A convertible preferred stock accrues an annual dividend of six percent until conversion, and is convertible, along with any accrued dividends, into common stock at a twenty-five percent discount to the selling price of the common stock in a qualified offering, as defined in the subscription agreement. In addition, the Company shall have the ability to force the conversion of preferred stock at such time the Company has a market capitalization in excess of $50 million for ten consecutive trading days. In such event, the conversion price shall be a 25% discount to the average closing price of the Company&#8217;s common stock over the ten trading days prior to the Company&#8217;s notice of its intent to convert.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2018, all 500,000 shares of subscribed Series A convertible preferred stock were converted into 970,989 shares of common stock at a conversion price of $0.55 per share. The Company recorded a non-cash loss on conversion of approximately $34,000 based on the market value of the common stock on the conversion date. No shares were converted during the same period in 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Common Stock</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2017, the Company increased the number of authorized shares of common stock from 100 million to 500 million shares.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2017, the Company issued 75 million shares of common stock to acquire the remaining 49% interest in its subsidiary MariMed Advisors Inc.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2018, the Company sold 10,111,578 shares of common stock at prices ranging from $0.50 to $1.37 per share, resulting in total proceeds of $8,461,000. During the same period in 2017, the Company sold 22,178,888 shares of common stock at prices of $0.18 and $0.25 per share, resulting in total proceeds of $5,200,000.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2018 and 2017, the Company issued 1,313,901 and 498,543 shares of common stock, respectively for services rendered by third parties. The Company recorded non-cash losses of approximately $959,000 in 2018 and $18,000 in 2017, based on the market value of the common stock on the issuance dates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Common Stock Subscriptions</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2017, the Company issued subscriptions on 1,000,000 shares of common stock as part of the purchase price of the Betty&#8217;s Eddies&#8482; acquired assets, as disclosed in Note 3. The common shares associated with these subscriptions were issued in June 2018.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2018, the Company issued subscriptions on 264,317 shares of common stock to acquire iRollie LLC, as disclosed in Note 3. Also during this period, the Company issued (i) subscriptions on 32,083 shares of common stock for the exercise of a warrant, (ii) subscriptions on 2,001,641 shares of common stock to settle $1,951,600 of vendor invoices, where the number of subscriptions issued was determined using the fair value of the stock on the issuance date, and (iii) subscriptions on 9,281 shares of common stock, equivalent to an aggregate amount of $20,000, for the payment of rent for the months of May and June 2018 for a leased property in Massachusetts. No subscriptions on common stock were issued during the same period in 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">All of the subscriptions on common stock referred to above are reflected under the caption <i>Common Stock Subscriptions </i>within the current liabilities section of the Company&#8217;s balance sheet.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Membership Interests</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2017, the Company issued 1,667 Class A membership units of Mari Holdings MD LLC, a majority-owned subsidiary, for $150,000. These units represented 0.33% ownership of this subsidiary at June 30, 2017. No membership units were issued during the six months ended June 30, 2018.</p> <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Principles of Consolidation</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying condensed consolidated financial statements include the accounts of MariMed Inc. and its subsidiaries, all of which are majority-owned. Intercompany accounts and transactions have been eliminated.</p> 1679486 1275000 50000000 1313901 498543 170000 169487 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Noncontrolling Interests</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Noncontrolling interests represent third-party minority ownership of the Company&#8217;s consolidated subsidiaries. Net income attributable to noncontrolling interests is shown in the consolidated statements of operations; and the value of net assets owned by noncontrolling interests are presented as a component of equity within the balance sheets.</p> 0.55 253713 253713 163410 163410 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Basis of Presentation</u></i></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;).</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with GAAP, these interim statements do not contain all of the disclosures normally required in annual statements. In addition, the results of operations of interim periods are not necessarily indicative of the results of operations to be expected for the full year. Accordingly, these interim financial statements should be read in conjunction with the Company&#8217;s audited annual financial statements and accompanying notes for the year ended December 31, 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain reclassifications have been made to prior periods&#8217; data to conform to the current period presentation. These reclassifications had no effect on reported income (losses) or cash flows.</p> P6M expiring between December 2020 and December 2022 Expiring in March and April 2021 5913000 5532397 7471662 150000 1941908 -4728 325825 12596 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7 &#8211; STOCK OPTIONS </b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2018, the Company granted options to purchase 1.45 million shares of common stock to the Company&#8217;s board members at exercise prices ranging from $0.14 to $0.77, vesting over a six-month period, and expiring between December 2020 and December 2022. The fair value of these options on grant date of approximately $458,000 was recorded as equity compensation during the six months ended June 30, 2018.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2018, the Company granted options to purchase 200,000 shares of common stock to an employee at an exercise price of $0.90 per share, which expire in May 2023. As of June 30, 2018, the Company recorded approximately $36,000 of the total equity compensation on this grant of approximately $264,000 which shall be recorded over the six-month vesting period.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2017, the Company granted options to purchase 100,000 shares of common stock to employees at exercise prices of $0.26 and $0.33, and expiring in March and April 2021. The fair value of these options on the grant date of approximately $19,000 was recorded as equity compensation over the respective vesting periods.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2018, options to purchase 700,000 shares of common stock were exercised at exercise prices ranging from $0.08 to $0.63 per share. No options were exercised during the same period in 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Options to purchase 300,000 shares of common stock were forfeited during the six-month period ended June 30, 2018. No options were forfeited during the same period in 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Stock options outstanding and exercisable as of June 30, 2018 were:</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercise Price</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Shares Under Option</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Remaining</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">per Share</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Outstanding</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Exercisable</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">Life in Years</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="width: 21%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.080</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 25%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">250,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 22%; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">250,000</font></td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; line-height: 107%">&#160;</td> <td style="width: 1%; text-align: center; line-height: 107%">&#160;</td> <td style="width: 21%; text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.58</font></td> <td style="width: 1%; line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.080</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.47</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.130</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.00</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.140</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">650,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">650,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.51</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.150</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.25</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.250</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.25</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.260</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.76</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.330</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">50,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">25,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.69</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.350</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1,000,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">1.25</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.450</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">250,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">125,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.26</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.550</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">100,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">2.25</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.630</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">300,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">300,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">3.51</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.770</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">300,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.51</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">$</font></td> <td style="text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">0.900</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">200,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; line-height: 107%">&#160;</td> <td style="border-bottom: black 1.5pt solid; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">-</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4.87</font></td> <td style="line-height: 107%">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="line-height: 107%">&#160;</td> <td style="text-align: right; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">5,450,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; line-height: 107%">&#160;</td> <td style="border-bottom: black 2.25pt double; text-align: right; line-height: 107%"><font style="font: 10pt Times New Roman, Times, Serif">4,800,000</font></td> <td style="line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="text-align: center; line-height: 107%">&#160;</td> <td style="line-height: 107%">&#160;</td></tr> </table> <p style="margin: 0pt"></p> 0.25 500000 970989 959000 18000 112000 18000 34000 P6M29D P1Y5M20D P2Y P2Y6M3D P1Y2M30D P1Y2M30D P2Y9M3D P2Y8M9D P1Y2M30D P3Y3M4D P2Y2M30D P3Y6M3D P4Y6M3D P4Y10M14D 4500000 3000000 200000 100000 32833 106618 1499000 1746000 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 8 &#8211; WARRANTS</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2018 and 2017, the Company issued warrants to purchase 4,239,000 and 100,000 shares of common stock, respectively, expiring in February 2021 and March 2020, respectively, at exercise prices ranging from $0.30 to $2.25 per share. The Company recorded non-cash equity compensation of approximately $6,370,000 in 2018 and $19,000 in 2017 representing the estimated fair value of these instruments on the issuance dates.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">During the six months ended June 30, 2018, warrants to purchase 1,425,379 shares of common stock were exercised, at exercise prices ranging from $0.10 and $0.50 per share. No warrants were exercised during the same period in 2017.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2018 and 2017, warrants to purchase 7,058,932 and 1,225,000 shares of common stock were outstanding, respectively, at exercise prices ranging between $0.10 and $2.25 per share.</p> 1998000 700000 400000 300000 2584433 1776960 18278 563119 1802226 940361 913357 469294 MRMD 0.10 An employment agreement with the former CEO of the Company that provided this individual with salary, car allowances, stock options, life insurance, and other employee benefits was terminated in 2017. 500 370000 -700000 400000 3600 3600 300000 789474 0.90 2.70 700000 0.63 0.77 0.63 0.90 0.08 0.14 0.26 0.33 0.08 P6M P6M 2023-05-31 5663585 140000 3766154 200000 34044 958757 18278 -100000 <p style="margin: 0pt"></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 &#8211; ACQUISITIONS</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2014, the Company, through its subsidiary MariMed Advisors Inc., acquired Sigal Consulting LLC from its ownership group which included the current CEO and CFO of the Company (the &#8220;Sigal Ownership Group&#8221;). The purchase price received by the Sigal Ownership Group was comprised of (i) 31,954,236 shares of common stock valued at approximately $5,913.000, representing 50% of the Company&#8217;s outstanding shares on the closing date, (ii) options to purchase three million shares of the Company&#8217;s common stock, exercisable over five years with exercise prices ranging from $0.15 to $0.35, and valued at approximately $570,000, and (iii) a 49% ownership interest in MariMed Advisors Inc. The excess of purchase price over the book value of the acquired entity was recorded as goodwill, which was subsequently impaired in full and written down to zero.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2017, the remaining 49% interest of MariMed Advisors Inc. was merged into the Company in exchange for an aggregate 75 million shares of common stock to the Sigal Ownership Group.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2017, the Company acquired the intellectual property, formulations, recipes, proprietary equipment, know-how, and other certain assets of the Betty&#8217;s Eddies&#8482; brand of cannabis-infused fruit chews. The purchase price was $140,000 plus subscriptions on 1,000,000 shares of the Company&#8217;s common stock. In addition, the selling company shall receive royalties based on a percentage of the Company&#8217;s sales of the Betty&#8217;s Eddies&#8482; product line, commencing at 25% and decreasing to 2.5% as certain sales thresholds are met. For the six months ended June 30, 2018, such royalties approximated $14,000, of which $5,000 were paid and $9,000 accrued at June 30, 2018.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">After applying the total purchase price, which consisted of the cash paid plus the fair value of the subscribed common stock on the date of the transaction, to the assessed fair values of the assets purchased, the transaction gave rise to goodwill of approximately $333,000. At June 30, 2018 and December 31, 2017, the Company reviewed the goodwill for impairment and determined that, based on the present value of future cash flows of the acquired assets, there was no impairment.&#160;The goodwill is included in <i>Other Assets</i> in the Company&#8217;s financial statements.</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2018, the Company issued $600,000 of subscriptions on common stock in exchange for 100% of the ownership interests of iRollie LLC. The Company acquired, among other assets and liabilities, iRollie&#8217;s entire product line, service offerings, clients, and intellectual property, and hired its two co-founders. After applying the purchase price to the fair value of the assets acquired and liabilities assumed, the Company recorded goodwill of approximately <font style="background-color: white">$119,000</font>. At June 30, 2018, the Company determined that the goodwill had not been impaired, which is included in <i>Other Assets</i> in the Company&#8217;s financial statements.</p> 818000 19000 14000 14000 5000 9000 333000 119000 In addition, the selling company shall receive royalties based on a percentage of the Company's sales of the Betty's Eddies product line, commencing at 25% and decreasing to 2.5% as certain sales thresholds are met.In addition, the selling company shall receive royalties based on a percentage of the Company's sales of the Betty's Eddies product line, commencing at 25% and decreasing to 2.5% as certain sales thresholds are met. 45000 90000 2466003 38965 600000 2200000 98000 98000 9281 9281 20000 20000 250000 2018 EX-101.SCH 7 mrmd-20180630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Acquisition link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stock Options link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Acquisition (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Stock Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Warrants (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Commitments and Contingencies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Segment Reporting - Schedule of Operating Segments (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 mrmd-20180630_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 mrmd-20180630_def.xml XBRL DEFINITION FILE EX-101.LAB 10 mrmd-20180630_lab.xml XBRL LABEL FILE Legal Entity [Axis] MariMed Advisors Inc. [Member] Exercise Price Range [Axis] Range One [Member] Range Two [Member] Range Three [Member] Range Four [Member] Range Five [Member] Range Six [Member] Range Seven [Member] Range Eight [Member] Segments [Axis] Online Portal Operations [Member] Cannabis Related Operations [Member] Range Nine [Member] Property, Plant and Equipment, Type [Axis] Buildings and Building Improvements [Member] Range [Axis] Minimum [Member] Buildings and Building Improvements [Member] Maximum [Member] Furniture and Fixtures [Member] Derivative Instrument [Axis] Stock Options [Member] Award Date [Axis] Over Six-Month Period [Member] Machinery and Equipment [Member] Mari Holdings MD LLC [Member] Equity Components [Axis] Class A Membership Units [Member] Title of Individual [Axis] CEO [Member] Class of Stock [Axis] Series A Convertible Preferred Stock [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Employment Agreement [Member] Convertible Preferred Stock [Member] Debt Instrument [Axis] Convertible Promissory Notes [Member] Common Stock [Member] Warrant [Member] Sigal Consulting LLC [Member] Options and Warrants [Member] Warrant One [Member] Range Ten [Member] Range Eleven [Member] Range Twelve [Member] Range Thirteen [Member] Warrant Two [Member] Common Stock Subscriptions [Member] Employees [Member] Board Member [Member] Chief Financial Officer [Member] Range Fourteen [Member] iRollie LLC [Member] Warrant [Member] Warrant One [Member] Individual's [Member] CEO [Member] CFO [Member] Related Party [Axis] Third Party [Member] Former Chief Financial Officer [Member] Worldwide Licensing Agreement [Member] Vendor [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Trading Symbol Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets: Cash and cash equivalents Accounts receivable, net Deferred rents receivable Due from third parties Due from related parties Note receivable, current portion Other current assets Total current assets Property and equipment, net Note receivable, long-term portion Other assets Total assets Liabilities and stockholders' equity Current liabilities: Accounts payable Accrued expenses Due to related parties Mortgages payable, current portion Common stock subscriptions Notes payable Total current liabilities Mortgages payable, long-term portion Other liabilities Total liabilities Stockholders' equity: Series A convertible preferred stock, $0.001 par value; 50,000,000 shares authorized at June 30, 2018 and December 31, 2017; no shares issued or outstanding at June 30, 2018 or December 31, 2017 Series A preferred stock subscribed but not issued; zero and 500,000 shares at June 30, 2018 and December 31, 2017, respectively Common stock, $0.001 par value; 500,000,000 shares authorized at June 30, 2018 and December 31, 2017; 193,709,580 and 176,940,331 shares issued at June 30, 2018 and December 31, 2017, respectively; 193,462,052 and 176,850,331 shares outstanding at June 30, 2018 and December 31, 2017, respectively Common stock subscribed but not issued; zero and 1,000,000 shares at June 30, 2018 and December 31, 2017 Subscriptions receivable Common stock warrants Treasury stock, at cost; 247,528 and 90,000 shares at June 30, 2018 and December 31, 2017, respectively Additional paid-in capital Accumulated deficit Noncontrolling interests Total stockholders' equity Total liabilities and stockholders' equity Series A convertible preferred stock, par value Series A convertible preferred stock, shares authorized Series A convertible preferred stock, shares issued Series A convertible preferred stock, shares outstanding Series A preferred stock, shares subscribed but unissued Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Common stock, shares subscribed but unissued Treasury stock, shares Income Statement [Abstract] Revenues Cost of revenues, including depreciation Gross profit Operating expenses: Personnel Marketing and promotion General and administrative Total operating expenses Operating income Non-operating expenses: Interest expense, net Equity compensation Loss on debt settlements Other Total non-operating expenses Net income (loss) Net income (loss) to noncontrolling interests Net income (loss) attributable to MariMed Inc. Net income (loss) per share Weighted average common shares outstanding Statement of Cash Flows [Abstract] Cash flows from operating activities: Net income (loss) attributable to MariMed Inc. Net income (loss) attributable to noncontrolling interests Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Depreciation Acquisition of iRollie LLC Common stock issued for services Loss on preferred stock conversions Loss on debt settlements Loss on common stock issued for services Changes in operating assets and liabilities: Accounts receivable, net Deferred rents receivable Due from third parties Due from related parties Other current assets Other assets Accounts payable Accrued expenses Due to related parties Net cash provided by (used in) operating activities Cash flows from investing activities: Purchase of property and equipment Investment in promissory note Interest on notes receivable Net cash used in investing activities Cash flows from financing activities: Proceeds from subscribed preferred stock Proceeds from subscribed common stock Issuance of common stock Issuance of interest in subsidiary Issuance (repayments) of promissory notes Proceeds from (payments of) mortgages payable, net Exercise of stock options Exercise of warrants Distributions Net cash provided by financing activities Net change to cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information: Cash paid for interest Cash paid for taxes Non-cash activities: Equity issued to settle debt Accounting Policies [Abstract] Organization and Description of Business Summary of Significant Accounting Policies Business Combinations [Abstract] Acquisition Property, Plant and Equipment [Abstract] Property and Equipment Debt Disclosure [Abstract] Debt Equity [Abstract] Equity Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock Options Warrants Related Party Transactions [Abstract] Related Party Transactions Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Segment Reporting [Abstract] Segment Reporting Subsequent Events [Abstract] Subsequent Events Basis of Presentation Principles of Consolidation Use of Estimates Cash Equivalents Revenue Recognition Research and Development Costs Property and Equipment Impairment of Long Lived Assets Fair Value of Financial Instruments Extinguishment of Liabilities Stock-Based Compensation Income Taxes Related Party Transactions Comprehensive Income Earnings Per Share Commitments and Contingencies Risk and Uncertainties Noncontrolling Interests Off Balance Sheet Arrangements Recent Accounting Pronouncements Schedule of Stock Options Outstanding and Exercisable Schedule of Operating Segments Statement [Table] Statement [Line Items] Useful lives of property plant and equipment Impairment losses Unrecognized tax liabilities or benefits Potentially dilutive securities Stock issued during period acquisitions, shares Stock issued during period acquisitions, value Common stock outstanding shares percentage Options to purchase shares of common stock Exercisable contractual term Exercise price per share Options to purchase shares of common stock, value Ownership percentage Purchase price of property Number of shares issued during period Royalty description Royalty expense Royalties paid Accrued royalties Goodwill Additions to property and equipment Accumulated depreciation Proceeds from mortgage debt Issuance of promissory notes Interest rate Debt term Repayments of promissory notes Debt conversion of convertible amount Debt conversion of convertible shares Loss on conversion of common stock Preferred stock, shares authorized Share issued price Market capitalization Preferred stock conversion price percentage Conversion of stock shares converted Conversion price per share Non-cash loss on conversion Number of shares issued to acquisition Ownership interest Proceeds from issuance of common stock Shares in exchange for services Number of shares issued during period, value Number of shares issued for payment of rent, shares Number of shares issued for payment of rent, value Options to purchase shares of common stock Exercise price of common stock, lower limit Exercise price of common stock, upper limit Stock options vesting period Stock options expiration period, description Non-cash equity compensation Options expiration date Share exercised option Number of options forfeited Outstanding and exercisable exercise price per share Outstanding shares under option Exercisable shares under option Remaining life in years Number of warrants issued to purchase common stock Warrant expiration description Warrants exercise price Number of common stock classified as treasury stock, value Number of common stock classified as treasury stock Principal amount Agreement term description Net income (loss) Capital expenditures Assets Number of shares sold Sale of stock price per share Number of shares sold, value Stock option, granted Number of shares used to pay aggregate exercise price, shares Number of shares used to pay aggregate exercise price, value Payments to acquire intangible asset Agreement term description. Anna, Illinois [Member] Betty's Eddies [Member] Buildings and Building Improvements [Member] Cannabis Cultivation Facility [Member] Cannabis Operations [Member] Class A Membership Units [Member] Class A Units [Member] Class A Units One [Member] Class A Units Two [Member] Common stock outstanding shares percentage. Common Stock Subscribed But Not Issued [Member] Common Stock Subscriptions [Member] Common Stock Warrants [Member] Convertible Promissory Notes [Member] Convertible Promissory Notes One [Member] Directors [Member] Employment Agreement [Member] Extinguishment of liabilities [Policy Text Block] First State Compassion Center, Inc. [Member] Five Accredited Investors [Member] Global Links Corp [Member] Hagerstown, Maryland [Member] Harrisburg, Illinois [Member] iRollie LLC [Member] Individual's [Member] Lewes, Delaware [Member] Mortgages payable, long-term portion. Mari Holding MD [Member] Mari Holdings MD LLC [Member] MariMed Advisors Inc. [Member] Market capitalization. Mia Development Inc [Member] Mia Development LLC [Member] Middleborough, Massachusetts [Member] Mortgage Agreement [Member ] Mortgage payable, current portion. Net income loss from operating segments. New Bedford, Massachusetts [Member] New Bedford [Member] Newton, Massachusetts [Member] Non-cash loss on conversion. Noncontrolling interests [Policy Text Block] Online Portal Operations [Member] Options and Warrants [Member] Options [Member] Options Three [Member] Options Two [Member] Over Six-Month Period [Member] Paid Inc [Member] Personnel. Preferred stock conversion price percentage. Proceeds from subscribed common stock. Range Eight [Member] Range Eleven [Member] Range Five [Member] Range Four [Member] Range Eight [Member] Range One [Member] Range Seven [Member] Range Six [Member] Range Ten [Member] Range Thirteen [Member] Range Three [Member] Range Twelve [Member] Range Two [Member] Related party transactions [Policy Text Block] Rental Equipment [Member] Rental Properties [Member] Royalties [Member] Series A Convertible Preferred Stock [Member] Series A Convertible Preferred Stock Subscribed But Not Issued [Member] Series A convertible Preferred [Member] Outstanding and exercisable exercise price per share. Sigal Consulting LLC [Member] Six Accredited Investors [Member] Stock options expiration period, description. Subscriptions Receivable [Member] Tenant Improvements [Member] Third Parties [Member] Thom Kidrin [Member] Two Accredited Investors [Member] 2.99 Times [Member] Two Promissory Notes [Member] Warrant expiration description. Warrant One [Member] Warrant Two [Member] Warrants [Text Block] Wilmington, Delaware [Member] Worlds Inct [Member] Employees [Member] Board Member [Member] Range Fourteen [Member] Former Chief Financial Officer [Member] Loss on preferred stock conversions. Loss on common stock issued for services. Investment in promissory note. Loss on conversion of common stock. Warrant [Member] Warrant One [Member] Royalty description. Third Party [Member] CEO [Member] CFO [Member] Number of common stock classified as treasury stock, value. Number of common stock classified as treasury stock. Cannabis Related Operations [Member] Acquisition of business. Number of shares used to pay aggregate exercise price. Number of shares used to pay aggregate exercise price, value. Number of shares issued for payment of rent. Number of shares issued for payment of rent, value. Worldwide Licensing Agreement [Member] Vendor [Member] BuildingsandBuildingImprovementsMember WarrantsMember WarrantsOneMember CEOMember Assets, Current Assets [Default Label] Liabilities, Current Liabilities Stockholders' Equity Note, Subscriptions Receivable Treasury Stock, Value Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Nonoperating Income (Expense) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Increase (Decrease) in Accounts Receivable Increase (Decrease) in Other Receivables Increase (Decrease) Due from Officers and Stockholders Increase (Decrease) in Due from Related Parties Increase (Decrease) in Other Current Assets Increase (Decrease) in Other Noncurrent Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Due to Related Parties Net Cash Provided by (Used in) Operating Activities Net Cash Provided by (Used in) Investing Activities Payments of Capital Distribution Net Cash Provided by (Used in) Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Property, Plant and Equipment, Policy [Policy Text Block] RelatedPartyTransactionsPolicyTextBlock Commitments and Contingencies, Policy [Policy Text Block] Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award Net Assets EX-101.PRE 11 mrmd-20180630_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2018
Aug. 14, 2018
Document And Entity Information    
Entity Registrant Name MARIMED INC.  
Entity Central Index Key 0001522767  
Document Type 10-Q  
Document Period End Date Jun. 30, 2018  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   195,228,998
Trading Symbol MRMD  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2018  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets - USD ($)
Jun. 30, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 5,077,126 $ 1,290,231
Accounts receivable, net 3,120,070 1,453,484
Deferred rents receivable 1,107,697 610,789
Due from third parties 2,374,652 1,196,918
Due from related parties 134,781 134,781
Note receivable, current portion 48,359 45,444
Other current assets 401,888 357,019
Total current assets 12,264,573 5,088,666
Property and equipment, net 31,364,803 25,954,931
Note receivable, long-term portion 653,792 578,831
Other assets 1,157,448 579,587
Total assets 45,440,616 32,202,015
Current liabilities:    
Accounts payable 2,833,687 2,831,658
Accrued expenses 1,602,834 1,405,336
Due to related parties 204,996 400,996
Mortgages payable, current portion 121,199 118,556
Common stock subscriptions 2,584,433
Notes payable 8,740,212 10,665,899
Total current liabilities 16,087,361 15,422,445
Mortgages payable, long-term portion 7,471,662 5,532,397
Other liabilities 240,013 240,013
Total liabilities 23,799,036 21,194,855
Stockholders' equity:    
Series A convertible preferred stock, $0.001 par value; 50,000,000 shares authorized at June 30, 2018 and December 31, 2017; no shares issued or outstanding at June 30, 2018 or December 31, 2017
Series A preferred stock subscribed but not issued; zero and 500,000 shares at June 30, 2018 and December 31, 2017, respectively 500
Common stock, $0.001 par value; 500,000,000 shares authorized at June 30, 2018 and December 31, 2017; 193,709,580 and 176,940,331 shares issued at June 30, 2018 and December 31, 2017, respectively; 193,462,052 and 176,850,331 shares outstanding at June 30, 2018 and December 31, 2017, respectively 193,710 176,940
Common stock subscribed but not issued; zero and 1,000,000 shares at June 30, 2018 and December 31, 2017 370,000
Subscriptions receivable (25,000) (25,000)
Common stock warrants 8,546,405 2,176,379
Treasury stock, at cost; 247,528 and 90,000 shares at June 30, 2018 and December 31, 2017, respectively (545,000) (45,000)
Additional paid-in capital 33,703,929 20,149,591
Accumulated deficit (20,214,651) (11,971,740)
Noncontrolling interests (17,813) 175,490
Total stockholders' equity 21,641,580 11,007,160
Total liabilities and stockholders' equity $ 45,440,616 $ 32,202,015
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Jun. 30, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Series A convertible preferred stock, par value $ 0.001 $ 0.001
Series A convertible preferred stock, shares authorized 50,000,000 50,000,000
Series A convertible preferred stock, shares issued
Series A convertible preferred stock, shares outstanding
Series A preferred stock, shares subscribed but unissued 0 500,000
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 193,709,580 176,940,331
Common stock, shares outstanding 193,462,052 176,850,331
Common stock, shares subscribed but unissued 0 1,000,000
Treasury stock, shares 247,528 90,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Income Statement [Abstract]        
Revenues $ 2,937,325 $ 1,621,057 $ 5,020,275 $ 2,771,776
Cost of revenues, including depreciation 913,357 469,294 1,802,226 940,361
Gross profit 2,023,968 1,151,763 3,218,049 1,831,415
Operating expenses:        
Personnel 284,886 136,824 469,557 304,686
Marketing and promotion 77,943 45,265 129,704 114,734
General and administrative 814,914 368,557 1,521,397 582,326
Total operating expenses 1,177,743 550,646 2,120,658 1,001,746
Operating income 846,225 601,117 1,097,391 829,669
Non-operating expenses:        
Interest expense, net 267,186 96,312 563,613 177,905
Equity compensation 6,290,802 6,863,609 19,295
Loss on debt settlements 563,119 1,776,960 18,278
Other 3,600 3,600
Total non-operating expenses 7,124,707 96,312 9,207,782 215,478
Net income (loss) (6,278,482) 504,805 (8,110,391) 614,191
Net income (loss) to noncontrolling interests 69,287 (42,195) 132,520 99,431
Net income (loss) attributable to MariMed Inc. $ (6,347,769) $ 547,000 $ (8,242,911) $ 514,760
Net income (loss) per share $ (0.034) $ 0.008 $ (0.045) $ 0.008
Weighted average common shares outstanding 186,645,833 65,593,751 182,746,858 64,912,354
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Cash flows from operating activities:    
Net income (loss) attributable to MariMed Inc. $ (8,242,911) $ 514,760
Net income (loss) attributable to noncontrolling interests 132,520 99,431
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
Depreciation 253,713 163,410
Equity compensation 6,863,609 19,295
Acquisition of iRollie LLC 600,000
Common stock issued for services 2,466,003 38,965
Loss on preferred stock conversions 34,044
Loss on debt settlements (1,776,960) (18,278)
Loss on common stock issued for services 958,757 18,278
Changes in operating assets and liabilities:    
Accounts receivable, net (1,666,587) (448,183)
Deferred rents receivable (496,908) (67,437)
Due from third parties (1,177,734) (506,900)
Due from related parties (35,108)
Other current assets (44,870) (56,278)
Other assets (577,861) (109,520)
Accounts payable 2,029 889,489
Accrued expenses 246,810 (488,228)
Due to related parties (196,000) 10,280
Net cash provided by (used in) operating activities (27,182) 42,254
Cash flows from investing activities:    
Purchase of property and equipment (5,663,585) (3,766,154)
Investment in promissory note (100,000)
Interest on notes receivable 22,125 25,097
Net cash used in investing activities (5,741,460) (3,741,057)
Cash flows from financing activities:    
Proceeds from subscribed preferred stock 200,000
Proceeds from subscribed common stock 32,833  
Issuance of common stock 8,461,003 5,200,000
Issuance of interest in subsidiary 150,000
Issuance (repayments) of promissory notes (700,000) 400,000
Proceeds from (payments of) mortgages payable, net 1,941,908 (4,728)
Exercise of stock options 39,000
Exercise of warrants 106,618
Distributions (325,825)  
Net cash provided by financing activities 9,555,537 5,945,272
Net change to cash and cash equivalents 3,786,895 2,246,469
Cash and cash equivalents at beginning of period 1,290,231 569,356
Cash and cash equivalents at end of period 5,077,126 2,815,825
Supplemental disclosure of cash flow information:    
Cash paid for interest 553,206 157,930
Cash paid for taxes 12,596
Non-cash activities:    
Equity issued to settle debt $ 1,275,000
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Organization and Description of Business
 6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
Organization and Description of Business

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

 

MariMed Inc. (the “Company”), a Delaware corporation, develops and manages state-of-the-art, regulatory-compliant facilities for the cultivation, production, and dispensing of legal cannabis and cannabis-infused products. Such facilities, located in multiple states, are leased to the Company’s clients in the emerging cannabis industry. Along with operational oversight, the Company provides its clients with legal, accounting, human resources, business development, and other corporate and administrative services.

 

The Company also provides professional consultative services in all aspects of cannabis licensing procurement. To date, the Company has secured, on behalf of its clients, 11 cannabis licenses across five states—two in Delaware, two in Illinois, one in Nevada, three in Maryland and three in Massachusetts. Accordingly, the Company has developed seed-to-sale cannabis facilities across of these five states in excess of 300,000 square feet.

 

In addition, the Company licenses precision-dosed, cannabis-infused products to treat specific medical conditions or to achieve a certain result. These products are licensed under the brand names Kalm Fusion™ and Nature’s Heritage™, both of which were developed by the Company, and Betty’s Eddies™, acquired in October 2017. The Company also has exclusive sublicensing rights in certain states to distribute vaporizer pens developed by Lucid Mood™, as well as the clinically-tested medicinal cannabis strains developed in Israel by Tikun Olam™.

 

The Company’s stock is quoted on the OTCQB market under the ticker symbol MRMD.

 

The Company was originally incorporated in January 2011 under the name Worlds Online Inc., using the ticker symbol WORX. In early 2017, the Company name and ticker were changed to its current name and ticker. Since inception, the Company had operated an online portal that offers multi-user virtual environments to users. This segment of the business has had insignificant operations since early 2014.

 

In May 2014, the Company, through its subsidiary MariMed Advisors Inc., acquired Sigal Consulting LLC, a company operating in the cannabis industry. The purchase price consisted of Company common stock, options to purchase additional Company common stock, and a minority interest in MariMed Advisors Inc. This transaction, further disclosed in Note 3, was accounted for as a purchase acquisition where the Company was both the legal and accounting acquirer. In June 2017, the minority interest in MariMed Advisors Inc. was merged into the Company.

 

In May 2018, the Company acquired iRollie LLC, a manufacturer of branded cannabis products and accessories for consumers, and custom product and packaging for companies in the cannabis industry. This acquisition is further disclosed in Note 3.
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies
 6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

 

In accordance with GAAP, these interim statements do not contain all of the disclosures normally required in annual statements. In addition, the results of operations of interim periods are not necessarily indicative of the results of operations to be expected for the full year. Accordingly, these interim financial statements should be read in conjunction with the Company’s audited annual financial statements and accompanying notes for the year ended December 31, 2017.

 

Certain reclassifications have been made to prior periods’ data to conform to the current period presentation. These reclassifications had no effect on reported income (losses) or cash flows.

 

Principles of Consolidation

 

The accompanying condensed consolidated financial statements include the accounts of MariMed Inc. and its subsidiaries, all of which are majority-owned. Intercompany accounts and transactions have been eliminated.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts within the financial statements and disclosures thereof. Actual results could differ from these estimates or assumptions.

 

Cash Equivalents

 

The Company considers all highly liquid investments with a maturity date of three months or less to be cash equivalents. The fair values of these investments approximate their carrying values.

 

Revenue Recognition

 

The Company’s main sources of revenue are comprised of: leasing of its developed cannabis cultivation, production, and dispensary facilities to its cannabis-licensed clients; agreements to provide comprehensive oversight and corporate support to its clients’ operations; consulting services to companies operating in the medical and legal recreational cannabis industries; arrangements for the procurement of cannabis materials and resources; and licensing of branded cannabis products.

 

The Company recognizes revenue when all of the following criteria are met: evidence of an arrangement exists such as a signed contract, delivery has occurred/services have been performed, the price is fixed or determinable, and collectability is reasonably assured.

 

Research and Development Costs

 

Research and development costs are charged to operations as incurred.

 

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation, with depreciation recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term, if applicable. When assets are retired or disposed, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income. Repairs and maintenance are charged to expense in the period incurred.

 

The estimated useful lives of property and equipment are generally as follows: buildings and building improvements, seven to thirty-nine years; tenant improvements, the remaining duration of the related lease; furniture and fixtures, seven years; machinery and equipment, five to ten years. Land is not depreciated.

 

The Company’s property and equipment are individually reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of an asset exceeds the aggregate projected future cash flows over the anticipated holding period on an undiscounted basis. An impairment loss is measured based on the excess of the asset’s carrying amount over its estimated fair value.

 

Impairment analyses are based on management’s current plans, intended holding periods and available market information at the time the analyses are prepared. If these criteria change, the Company’s evaluation of impairment losses may be different and could have a material impact to the consolidated financial statements.

 

For the six months ended June 30, 2018 and 2017, based on its impairment analyses, the Company did not have any impairment losses.

 

Impairment of Long Lived Assets

 

The Company evaluates the recoverability of its fixed assets and other assets in accordance with the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) 360-10-15, Impairment or Disposal of Long-Lived Assets. Impairment of long-lived assets is recognized when the net book value of such assets exceeds their expected cash flows, in which case the assets are written down to fair value, which is determined based on discounted future cash flows or appraised values.

 

Fair Value of Financial Instruments

 

The Company follows the provisions of ASC 820, Fair Value Measurement, to measure the fair value of its financial instruments, and ASC 825, Financial Instruments, for disclosures on the fair value of its financial instruments. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value hierarchy defined by ASC 820 are:

 

Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
   
Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
   
Level 3 Pricing inputs that are generally observable inputs and not corroborated by market data.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable approximate their fair values due to the short maturity of these instruments. The fair value of option and warrant issuances are determined utilizing the binomial options pricing model and employing the following inputs: life of instrument, exercise price, value of the underlying security on issuance date, and 2-year volatility of underlying security.

 

Extinguishment of Liabilities

 

The Company accounts for extinguishment of liabilities in accordance with ASC 405-20, Extinguishments of Liabilities. When the conditions for extinguishment are met, the liabilities are written down to zero and a gain or loss is recognized.

 

Stock-Based Compensation

 

The Company accounts for stock-based compensation using the fair value method as set forth in ASC 718, Compensation—Stock Compensation, which requires a public entity to measure the cost of employee services received in exchange for an equity award based on the fair value of the award on the grant date, with limited exceptions. Such value will be incurred as compensation expense over the period an employee is required to provide service in exchange for the award, usually the vesting period. No compensation cost is recognized for equity awards for which employees do not render the requisite service.

 

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740, Income Taxes. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of operations in the period that includes the enactment date.

 

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. The Company did not take any uncertain tax positions and had no adjustments to unrecognized income tax liabilities or benefits for the six months ended June 30, 2018 and 2017.

 

Related Party Transactions

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

In accordance with ASC 850, the Company’s financial statements include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, as well as transactions that are eliminated in the preparation of financial statements.

 

Comprehensive Income

 

The Company reports comprehensive income and its components following guidance set forth by ASC 220, Comprehensive Income, which establishes standards for the reporting and display of comprehensive income and its components in the consolidated financial statements. There were no items of comprehensive income applicable to the Company during the period covered in the financial statements.

 

Earnings Per Share

 

Earnings per common share is computed pursuant to ASC 260, Earnings Per Share. Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income by the sum of the weighted average number of shares of common stock outstanding plus the weighted average number of potentially dilutive securities during the period.

 

As of June 30, 2018 and 2017, there were 12,508,932 and 10,475,000, respectively, of potentially dilutive securities in the form of options and warrants. Also as of June 30, 2018 and 2017, there were zero and 500,000 shares, respectively, of subscriptions on convertible preferred stock, and $250,000 and $3,125,000, respectively, of convertible promissory notes, that were potentially dilutive, whose conversion into common stock is based on a discount to the market value of common stock on or about the future conversion date. For the six months ended June 30, 2018, all potentially dilutive securities had an anti-dilutive effect on earnings per share, and in accordance with ASC 260, were excluded from the diluted net income per share calculation, resulting in calculations of basic and fully diluted net income per share that were identical for this period. These securities may dilute earnings per share in the future.

 

Commitments and Contingencies

 

The Company follows ASC 450, Contingencies, which requires the Company to assess the likelihood that a loss will be incurred from the occurrence or non-occurrence of one or more future events. Such assessment inherently involves an exercise of judgment. In assessing possible loss contingencies from legal proceedings or unasserted claims, the Company would evaluate the perceived merits of the proceedings or claims, and the perceived merits of the relief sought or expected to be sought.

 

If the assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can be estimated, then such estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

 

While not assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse effect on the Company’s financial position, results of operations or cash flows.

 

Risk and Uncertainties

 

The Company is subject to risks common to companies operating within the legal and medical marijuana industries, including, but not limited to, federal laws, government regulations and jurisdictional laws.

 

Noncontrolling Interests

 

Noncontrolling interests represent third-party minority ownership of the Company’s consolidated subsidiaries. Net income attributable to noncontrolling interests is shown in the consolidated statements of operations; and the value of net assets owned by noncontrolling interests are presented as a component of equity within the balance sheets.

 

Off Balance Sheet Arrangements

 

The Company does not have any off-balance sheet arrangements.

 

Recent Accounting Pronouncements

 

In November 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which enhances and clarifies the guidance on the classification and presentation of restricted cash in the statement of cash flows. This ASU will be effective in 2019 and its impact is dependent upon the level of restricted cash of the Company, which at this time is insignificant.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which modifies accounting for lessees by requiring the recording of lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. This ASU will be effective in 2020 and the Company is currently evaluating the impact of adoption, which will be determined by the Company’s lease portfolio at the time of implementation.

 

In 2014 and subsequently in 2016, the FASB issued new standards on the recognition of revenue. While the new standards amend the current standards, they are not expected to have a material impact on the amount and timing of revenue recognized in the Company’s consolidated financial statements when the new standards are adopted in 2019.

 

In addition to the above, the Company has reviewed all other recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption of any such pronouncements will have a material impact on its financial condition or the results of its operations.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisition
 6 Months Ended
Jun. 30, 2018
Business Combinations [Abstract]  
Acquisition

NOTE 3 – ACQUISITIONS

 

In May 2014, the Company, through its subsidiary MariMed Advisors Inc., acquired Sigal Consulting LLC from its ownership group which included the current CEO and CFO of the Company (the “Sigal Ownership Group”). The purchase price received by the Sigal Ownership Group was comprised of (i) 31,954,236 shares of common stock valued at approximately $5,913.000, representing 50% of the Company’s outstanding shares on the closing date, (ii) options to purchase three million shares of the Company’s common stock, exercisable over five years with exercise prices ranging from $0.15 to $0.35, and valued at approximately $570,000, and (iii) a 49% ownership interest in MariMed Advisors Inc. The excess of purchase price over the book value of the acquired entity was recorded as goodwill, which was subsequently impaired in full and written down to zero.

 

In June 2017, the remaining 49% interest of MariMed Advisors Inc. was merged into the Company in exchange for an aggregate 75 million shares of common stock to the Sigal Ownership Group.

 

In October 2017, the Company acquired the intellectual property, formulations, recipes, proprietary equipment, know-how, and other certain assets of the Betty’s Eddies™ brand of cannabis-infused fruit chews. The purchase price was $140,000 plus subscriptions on 1,000,000 shares of the Company’s common stock. In addition, the selling company shall receive royalties based on a percentage of the Company’s sales of the Betty’s Eddies™ product line, commencing at 25% and decreasing to 2.5% as certain sales thresholds are met. For the six months ended June 30, 2018, such royalties approximated $14,000, of which $5,000 were paid and $9,000 accrued at June 30, 2018.

 

After applying the total purchase price, which consisted of the cash paid plus the fair value of the subscribed common stock on the date of the transaction, to the assessed fair values of the assets purchased, the transaction gave rise to goodwill of approximately $333,000. At June 30, 2018 and December 31, 2017, the Company reviewed the goodwill for impairment and determined that, based on the present value of future cash flows of the acquired assets, there was no impairment. The goodwill is included in Other Assets in the Company’s financial statements.

 

In May 2018, the Company issued $600,000 of subscriptions on common stock in exchange for 100% of the ownership interests of iRollie LLC. The Company acquired, among other assets and liabilities, iRollie’s entire product line, service offerings, clients, and intellectual property, and hired its two co-founders. After applying the purchase price to the fair value of the assets acquired and liabilities assumed, the Company recorded goodwill of approximately $119,000. At June 30, 2018, the Company determined that the goodwill had not been impaired, which is included in Other Assets in the Company’s financial statements.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Property and Equipment
 6 Months Ended
Jun. 30, 2018
Property, Plant and Equipment [Abstract]  
Property and Equipment

NOTE 4 – PROPERTY AND EQUIPMENT

 

Property and equipment are shown net of accumulated depreciation and are primarily comprised of the following: land; buildings; building and tenant improvements; furniture and fixtures; and machinery and equipment.

 

During the six months ended June 30, 2018 and 2017, additions to property and equipment were approximately $5,664,000 million and $3,766,000 million, respectively.

 

Depreciation expense for the six months ended June 30, 2018 and 2017 was approximately $254,000 and $163,000, respectively. At June 30, 2018 and December 31, 2017, accumulated depreciation approximated $1,746,000 and $1,499,000, respectively.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt
 6 Months Ended
Jun. 30, 2018
Debt Disclosure [Abstract]  
Debt

NOTE 5 – DEBT

 

During the six months ended June 30, 2018, the Company received additional capital of approximately $1,998,000 from the existing mortgage on the cannabis cultivation and processing facility it is currently developing in the state of Massachusetts.

 

During the six months ended June 30, 2017, the Company raised $400,000 from the issuance of a promissory note with an interest rate of 10% and a term of 6 months. No promissory notes were issued during the six months ended June 30, 2018.

 

During the six months ended June 30, 2018, the Company repaid $700,000 of promissory notes, and converted $1,275,000 of promissory notes into 1,679,486 shares of common stock. The conversions resulted in the recording of non-cash losses totaling $818,000, based on the market value of the common stock on the conversion dates. No repayments or conversions of debt occurred during the same period in 2017.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Equity
 6 Months Ended
Jun. 30, 2018
Equity [Abstract]  
Equity

NOTE 6 – EQUITY

 

Preferred Stock

 

In January 2017, the Company increased the number of authorized shares of preferred stock from 5 million to 50 million shares.

 

During the six months ended June 30, 2017, the Company issued subscriptions on 200,000 shares of Series A convertible preferred stock at $1.00 per share. No subscriptions were issued during the same period in 2018.

 

Series A convertible preferred stock accrues an annual dividend of six percent until conversion, and is convertible, along with any accrued dividends, into common stock at a twenty-five percent discount to the selling price of the common stock in a qualified offering, as defined in the subscription agreement. In addition, the Company shall have the ability to force the conversion of preferred stock at such time the Company has a market capitalization in excess of $50 million for ten consecutive trading days. In such event, the conversion price shall be a 25% discount to the average closing price of the Company’s common stock over the ten trading days prior to the Company’s notice of its intent to convert.

 

In January 2018, all 500,000 shares of subscribed Series A convertible preferred stock were converted into 970,989 shares of common stock at a conversion price of $0.55 per share. The Company recorded a non-cash loss on conversion of approximately $34,000 based on the market value of the common stock on the conversion date. No shares were converted during the same period in 2017.

 

Common Stock

 

In January 2017, the Company increased the number of authorized shares of common stock from 100 million to 500 million shares.

 

In June 2017, the Company issued 75 million shares of common stock to acquire the remaining 49% interest in its subsidiary MariMed Advisors Inc.

 

During the six months ended June 30, 2018, the Company sold 10,111,578 shares of common stock at prices ranging from $0.50 to $1.37 per share, resulting in total proceeds of $8,461,000. During the same period in 2017, the Company sold 22,178,888 shares of common stock at prices of $0.18 and $0.25 per share, resulting in total proceeds of $5,200,000.

 

During the six months ended June 30, 2018 and 2017, the Company issued 1,313,901 and 498,543 shares of common stock, respectively for services rendered by third parties. The Company recorded non-cash losses of approximately $959,000 in 2018 and $18,000 in 2017, based on the market value of the common stock on the issuance dates.

 

Common Stock Subscriptions

 

In October 2017, the Company issued subscriptions on 1,000,000 shares of common stock as part of the purchase price of the Betty’s Eddies™ acquired assets, as disclosed in Note 3. The common shares associated with these subscriptions were issued in June 2018.

 

During the six months ended June 30, 2018, the Company issued subscriptions on 264,317 shares of common stock to acquire iRollie LLC, as disclosed in Note 3. Also during this period, the Company issued (i) subscriptions on 32,083 shares of common stock for the exercise of a warrant, (ii) subscriptions on 2,001,641 shares of common stock to settle $1,951,600 of vendor invoices, where the number of subscriptions issued was determined using the fair value of the stock on the issuance date, and (iii) subscriptions on 9,281 shares of common stock, equivalent to an aggregate amount of $20,000, for the payment of rent for the months of May and June 2018 for a leased property in Massachusetts. No subscriptions on common stock were issued during the same period in 2017.

 

All of the subscriptions on common stock referred to above are reflected under the caption Common Stock Subscriptions within the current liabilities section of the Company’s balance sheet.

 

Membership Interests

 

During the six months ended June 30, 2017, the Company issued 1,667 Class A membership units of Mari Holdings MD LLC, a majority-owned subsidiary, for $150,000. These units represented 0.33% ownership of this subsidiary at June 30, 2017. No membership units were issued during the six months ended June 30, 2018.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Options
 6 Months Ended
Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock Options

NOTE 7 – STOCK OPTIONS

 

During the six months ended June 30, 2018, the Company granted options to purchase 1.45 million shares of common stock to the Company’s board members at exercise prices ranging from $0.14 to $0.77, vesting over a six-month period, and expiring between December 2020 and December 2022. The fair value of these options on grant date of approximately $458,000 was recorded as equity compensation during the six months ended June 30, 2018.

 

In May 2018, the Company granted options to purchase 200,000 shares of common stock to an employee at an exercise price of $0.90 per share, which expire in May 2023. As of June 30, 2018, the Company recorded approximately $36,000 of the total equity compensation on this grant of approximately $264,000 which shall be recorded over the six-month vesting period.

 

During the six months ended June 30, 2017, the Company granted options to purchase 100,000 shares of common stock to employees at exercise prices of $0.26 and $0.33, and expiring in March and April 2021. The fair value of these options on the grant date of approximately $19,000 was recorded as equity compensation over the respective vesting periods.

 

During the six months ended June 30, 2018, options to purchase 700,000 shares of common stock were exercised at exercise prices ranging from $0.08 to $0.63 per share. No options were exercised during the same period in 2017.

 

Options to purchase 300,000 shares of common stock were forfeited during the six-month period ended June 30, 2018. No options were forfeited during the same period in 2017.

 

Stock options outstanding and exercisable as of June 30, 2018 were:

 

Exercise Price     Shares Under Option     Remaining  
per Share     Outstanding     Exercisable     Life in Years  
$ 0.080       250,000       250,000       0.58  
$ 0.080       100,000       100,000       1.47  
$ 0.130       200,000       200,000       2.00  
$ 0.140       650,000       650,000       2.51  
$ 0.150       1,000,000       1,000,000       1.25  
$ 0.250       1,000,000       1,000,000       1.25  
$ 0.260       50,000       50,000       2.76  
$ 0.330       50,000       25,000       2.69  
$ 0.350       1,000,000       1,000,000       1.25  
$ 0.450       250,000       125,000       3.26  
$ 0.550       100,000       100,000       2.25  
$ 0.630       300,000       300,000       3.51  
$ 0.770       300,000       -       4.51  
$ 0.900       200,000       -       4.87  
          5,450,000       4,800,000          
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Warrants
 6 Months Ended
Jun. 30, 2018
Equity [Abstract]  
Warrants

NOTE 8 – WARRANTS

 

During the six months ended June 30, 2018 and 2017, the Company issued warrants to purchase 4,239,000 and 100,000 shares of common stock, respectively, expiring in February 2021 and March 2020, respectively, at exercise prices ranging from $0.30 to $2.25 per share. The Company recorded non-cash equity compensation of approximately $6,370,000 in 2018 and $19,000 in 2017 representing the estimated fair value of these instruments on the issuance dates.

 

During the six months ended June 30, 2018, warrants to purchase 1,425,379 shares of common stock were exercised, at exercise prices ranging from $0.10 and $0.50 per share. No warrants were exercised during the same period in 2017.

 

At June 30, 2018 and 2017, warrants to purchase 7,058,932 and 1,225,000 shares of common stock were outstanding, respectively, at exercise prices ranging between $0.10 and $2.25 per share.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions
 6 Months Ended
Jun. 30, 2018
Related Party Transactions [Abstract]  
Related Party Transactions

NOTE 9 – RELATED PARTY TRANSACTIONS

 

As disclosed in Note 3 above, the current CEO and CFO of the Company are part in the Sigal Ownership Group from whom Sigal Consulting LLC was acquired in May 2014. The 49% ownership in the Company’s subsidiary, MariMed Advisors Inc., which the Sigal Ownership Group acquired as part of the purchase price, was acquired by the Company from the Sigal Ownership Group in June 2017 in exchange for 75 million shares of the Company’s common stock.

 

In September 2017, the former CEO of the Company, who is a currently a board member, exercised options to purchase 4.5 million shares of common stock at an exercise price of $0.01 per share. The aggregate exercise price of $45,000 was paid in a cashless transaction with 90,000 shares of common stock which were classified as treasury stock.

 

In October 2017, the Company acquired the intellectual property, formulations, recipes, proprietary equipment, and know-how of the Betty’s Eddies™ brand of cannabis-infused products, as disclosed in Note 3, from a company that is minority-owned by the Company’s chief operating officer.

 

In December 2017, options to purchase 200,000 shares of commons stock at an exercise price of $0.025 were forfeited by the CEO and by an independent board member (100,000 shares forfeited by each individual).

 

During the six months ended June 30, 2018, a current board member exercised options to purchase 400,000 shares of common stock, and the former CFO of the Company exercised options to purchase 300,000 shares of common stock. These options were exercised at exercise prices ranging from $0.08 to $0.63 per share. No options were exercised during the same period in 2017.

 

During the six months ended June 30, 2018 and 2017, the Company issued 170,000 and 169,487 shares, respectively, of common stock for services rendered by the former CFO of the Company. Based on the market value of the common stock on the dates of the two issuances, the Company recorded non-cash losses of approximately $112,000 in 2018 and $18,000 in 2017.

 

At June 30, 2018 and December 31, 2017, the Company owed approximately $19,000 and $14,000 to the CEO and CFO, respectively.

 

The caption Due from Related Parties in the Company’s financial statements is primarily comprised of short term loans to non-consolidated entities under common ownership.

 

The caption Due to Related Parties reflects short term loans from related parties and includes advances received from officers of the Company.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

NOTE 10 – COMMITMENTS AND CONTINGENCIES

 

An employment agreement with the former CEO of the Company that provided this individual with salary, car allowances, stock options, life insurance, and other employee benefits was terminated in 2017.

 

The Company recorded an accrual of approximately $1,043,000 at June 30, 2018 and December 31, 2017 for any amounts that may be owed under this agreement. However, the Company is contesting the validity this agreement.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Reporting
 6 Months Ended
Jun. 30, 2018
Segment Reporting [Abstract]  
Segment Reporting

NOTE 11 – SEGMENT REPORTING

 

In accordance with ASC 280, the following is information regarding the Company’s operating segments:

 

    Six Months Ended June 30,  
    2018     2017  
Revenues:                
Online portal operations   $ —     $ 114  
Cannabis related operations     5,020,275       2,771,662  
Consolidated revenues   $ 5,020,275     $ 2,771,776  
                 
Depreciation:                
Online portal operations   $ —     $ —  
Cannabis related operations     253,713       163,410  
Depreciation   $ 253,713     $ 163,410  
                 
Net income (loss):                
Online portal operations   $ (181 )   $ (146,774 )
Cannabis related operations     (1,831,210 )     760,965  
Net income (loss)   $ (8,110,391 )   $ 614,191  
                 
Capital expenditures:                
Online portal operations   $ —     $ —  
Cannabis related operations     5,663,585       3,766,154  
Combined capital expenditures   $ 5,663,585     $ 3,766,154  
                 
Assets:                
Online portal operations   $ 1,217     $ 1,504  
Cannabis related operations     45,439,399       15,349,925  
Combined assets   $ 45,440,616     $ 15,351,429  
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events
 6 Months Ended
Jun. 30, 2018
Subsequent Events [Abstract]  
Subsequent Events

NOTE 12 – SUBSEQUENT EVENTS

 

Subsequent to June 30, 2018, the following events occurred:

 

  - The Company sold 1,200,780 shares of common stock, at prices ranging from $0.90 to $2.70 per share, for an aggregate amount of $2,200,000.
     
  - The Company issued warrants to purchase 544,500 shares of common stock at an exercise price of $4.20 per share.
     
  - Warrant holders exercised warrants to purchase 232,083 shares of common stock at exercise prices of $0.10 and $0.40 per share.
     
  - A board member was issued 302,000 shares of common stock from the exercise of stock options at exercise prices ranging from $0.08 to $0.63 per share. The aggregate number of shares exercised was 400,000, offset by 98,000 shares used to pay the aggregate exercise price of $98,000 in a cashless transaction.
     
  - In August 2018, the Company made a payment of $250,000 pursuant to an exclusive worldwide licensing agreement for the production and distribution of precision-dosed, dissolvable cannabis products.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2018
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

 

In accordance with GAAP, these interim statements do not contain all of the disclosures normally required in annual statements. In addition, the results of operations of interim periods are not necessarily indicative of the results of operations to be expected for the full year. Accordingly, these interim financial statements should be read in conjunction with the Company’s audited annual financial statements and accompanying notes for the year ended December 31, 2017.

 

Certain reclassifications have been made to prior periods’ data to conform to the current period presentation. These reclassifications had no effect on reported income (losses) or cash flows.
Principles of Consolidation

Principles of Consolidation

 

The accompanying condensed consolidated financial statements include the accounts of MariMed Inc. and its subsidiaries, all of which are majority-owned. Intercompany accounts and transactions have been eliminated.
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts within the financial statements and disclosures thereof. Actual results could differ from these estimates or assumptions.
Cash Equivalents

Cash Equivalents

 

The Company considers all highly liquid investments with a maturity date of three months or less to be cash equivalents. The fair values of these investments approximate their carrying values.
Revenue Recognition

Revenue Recognition

 

The Company’s main sources of revenue are comprised of: leasing of its developed cannabis cultivation, production, and dispensary facilities to its cannabis-licensed clients; agreements to provide comprehensive oversight and corporate support to its clients’ operations; consulting services to companies operating in the medical and legal recreational cannabis industries; arrangements for the procurement of cannabis materials and resources; and licensing of branded cannabis products.

 

The Company recognizes revenue when all of the following criteria are met: evidence of an arrangement exists such as a signed contract, delivery has occurred/services have been performed, the price is fixed or determinable, and collectability is reasonably assured.
Research and Development Costs

Research and Development Costs

 

Research and development costs are charged to operations as incurred.
Property and Equipment

Property and Equipment

 

Property and equipment are stated at cost less accumulated depreciation, with depreciation recognized on a straight-line basis over the shorter of the estimated useful life of the asset or the lease term, if applicable. When assets are retired or disposed, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income. Repairs and maintenance are charged to expense in the period incurred.

 

The estimated useful lives of property and equipment are generally as follows: buildings and building improvements, seven to thirty-nine years; tenant improvements, the remaining duration of the related lease; furniture and fixtures, seven years; machinery and equipment, five to ten years. Land is not depreciated.

 

The Company’s property and equipment are individually reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of an asset exceeds the aggregate projected future cash flows over the anticipated holding period on an undiscounted basis. An impairment loss is measured based on the excess of the asset’s carrying amount over its estimated fair value.

 

Impairment analyses are based on management’s current plans, intended holding periods and available market information at the time the analyses are prepared. If these criteria change, the Company’s evaluation of impairment losses may be different and could have a material impact to the consolidated financial statements.

 

For the six months ended June 30, 2018 and 2017, based on its impairment analyses, the Company did not have any impairment losses.
Impairment of Long Lived Assets

Impairment of Long Lived Assets

 

The Company evaluates the recoverability of its fixed assets and other assets in accordance with the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) 360-10-15, Impairment or Disposal of Long-Lived Assets. Impairment of long-lived assets is recognized when the net book value of such assets exceeds their expected cash flows, in which case the assets are written down to fair value, which is determined based on discounted future cash flows or appraised values.
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company follows the provisions of ASC 820, Fair Value Measurement, to measure the fair value of its financial instruments, and ASC 825, Financial Instruments, for disclosures on the fair value of its financial instruments. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three levels of fair value hierarchy defined by ASC 820 are:

 

Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date.
   
Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date.
   
Level 3 Pricing inputs that are generally observable inputs and not corroborated by market data.

 

The carrying amounts of the Company’s financial assets and liabilities, such as cash and accounts payable approximate their fair values due to the short maturity of these instruments. The fair value of option and warrant issuances are determined utilizing the binomial options pricing model and employing the following inputs: life of instrument, exercise price, value of the underlying security on issuance date, and 2-year volatility of underlying security.
Extinguishment of Liabilities

Extinguishment of Liabilities

 

The Company accounts for extinguishment of liabilities in accordance with ASC 405-20, Extinguishments of Liabilities. When the conditions for extinguishment are met, the liabilities are written down to zero and a gain or loss is recognized.
Stock-Based Compensation

Stock-Based Compensation

 

The Company accounts for stock-based compensation using the fair value method as set forth in ASC 718, Compensation—Stock Compensation, which requires a public entity to measure the cost of employee services received in exchange for an equity award based on the fair value of the award on the grant date, with limited exceptions. Such value will be incurred as compensation expense over the period an employee is required to provide service in exchange for the award, usually the vesting period. No compensation cost is recognized for equity awards for which employees do not render the requisite service.
Income Taxes

Income Taxes

 

The Company accounts for income taxes in accordance with ASC 740, Income Taxes. Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities, and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the consolidated statements of operations in the period that includes the enactment date.

 

ASC 740 prescribes a comprehensive model for how companies should recognize, measure, present, and disclose in their financial statements uncertain tax positions taken or expected to be taken on a tax return. The Company did not take any uncertain tax positions and had no adjustments to unrecognized income tax liabilities or benefits for the six months ended June 30, 2018 and 2017.
Related Party Transactions

Related Party Transactions

 

The Company follows ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.

 

In accordance with ASC 850, the Company’s financial statements include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business, as well as transactions that are eliminated in the preparation of financial statements.
Comprehensive Income

Comprehensive Income

 

The Company reports comprehensive income and its components following guidance set forth by ASC 220, Comprehensive Income, which establishes standards for the reporting and display of comprehensive income and its components in the consolidated financial statements. There were no items of comprehensive income applicable to the Company during the period covered in the financial statements.
Earnings Per Share

Earnings Per Share

 

Earnings per common share is computed pursuant to ASC 260, Earnings Per Share. Basic earnings per share is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share is computed by dividing net income by the sum of the weighted average number of shares of common stock outstanding plus the weighted average number of potentially dilutive securities during the period.

 

As of June 30, 2018 and 2017, there were 12,508,932 and 10,475,000, respectively, of potentially dilutive securities in the form of options and warrants. Also as of June 30, 2018 and 2017, there were zero and 500,000 shares, respectively, of subscriptions on convertible preferred stock, and $250,000 and $3,125,000, respectively, of convertible promissory notes, that were potentially dilutive, whose conversion into common stock is based on a discount to the market value of common stock on or about the future conversion date. For the six months ended June 30, 2018, all potentially dilutive securities had an anti-dilutive effect on earnings per share, and in accordance with ASC 260, were excluded from the diluted net income per share calculation, resulting in calculations of basic and fully diluted net income per share that were identical for this period. These securities may dilute earnings per share in the future.
Commitments and Contingencies

Commitments and Contingencies

 

The Company follows ASC 450, Contingencies, which requires the Company to assess the likelihood that a loss will be incurred from the occurrence or non-occurrence of one or more future events. Such assessment inherently involves an exercise of judgment. In assessing possible loss contingencies from legal proceedings or unasserted claims, the Company would evaluate the perceived merits of the proceedings or claims, and the perceived merits of the relief sought or expected to be sought.

 

If the assessment of a contingency indicates that it is probable that a material loss will be incurred and the amount of the liability can be estimated, then such estimated liability would be accrued in the Company’s financial statements. If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed. Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.

 

While not assured, management does not believe, based upon information available at this time, that a loss contingency will have material adverse effect on the Company’s financial position, results of operations or cash flows.
Risk and Uncertainties

Risk and Uncertainties

 

The Company is subject to risks common to companies operating within the legal and medical marijuana industries, including, but not limited to, federal laws, government regulations and jurisdictional laws.
Noncontrolling Interests

Noncontrolling Interests

 

Noncontrolling interests represent third-party minority ownership of the Company’s consolidated subsidiaries. Net income attributable to noncontrolling interests is shown in the consolidated statements of operations; and the value of net assets owned by noncontrolling interests are presented as a component of equity within the balance sheets.
Off Balance Sheet Arrangements

Off Balance Sheet Arrangements

 

The Company does not have any off-balance sheet arrangements.
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In November 2016, the Financial Accounting Standards Board (the “FASB”) issued ASU No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash, which enhances and clarifies the guidance on the classification and presentation of restricted cash in the statement of cash flows. This ASU will be effective in 2019 and its impact is dependent upon the level of restricted cash of the Company, which at this time is insignificant.

 

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), which modifies accounting for lessees by requiring the recording of lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. This ASU will be effective in 2020 and the Company is currently evaluating the impact of adoption, which will be determined by the Company’s lease portfolio at the time of implementation.

 

In 2014 and subsequently in 2016, the FASB issued new standards on the recognition of revenue. While the new standards amend the current standards, they are not expected to have a material impact on the amount and timing of revenue recognized in the Company’s consolidated financial statements when the new standards are adopted in 2019.

 

In addition to the above, the Company has reviewed all other recently issued, but not yet effective, accounting pronouncements, and does not believe the future adoption of any such pronouncements will have a material impact on its financial condition or the results of its operations.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Options (Tables)
 6 Months Ended
Jun. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Stock Options Outstanding and Exercisable

Stock options outstanding and exercisable as of June 30, 2018 were:

 

Exercise Price     Shares Under Option     Remaining  
per Share     Outstanding     Exercisable     Life in Years  
$ 0.080       250,000       250,000       0.58  
$ 0.080       100,000       100,000       1.47  
$ 0.130       200,000       200,000       2.00  
$ 0.140       650,000       650,000       2.51  
$ 0.150       1,000,000       1,000,000       1.25  
$ 0.250       1,000,000       1,000,000       1.25  
$ 0.260       50,000       50,000       2.76  
$ 0.330       50,000       25,000       2.69  
$ 0.350       1,000,000       1,000,000       1.25  
$ 0.450       250,000       125,000       3.26  
$ 0.550       100,000       100,000       2.25  
$ 0.630       300,000       300,000       3.51  
$ 0.770       300,000       -       4.51  
$ 0.900       200,000       -       4.87  
          5,450,000       4,800,000          
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2018
Segment Reporting [Abstract]  
Schedule of Operating Segments

In accordance with ASC 280, the following is information regarding the Company’s operating segments:

 

    Six Months Ended June 30,  
    2018     2017  
Revenues:                
Online portal operations   $ —     $ 114  
Cannabis related operations     5,020,275       2,771,662  
Consolidated revenues   $ 5,020,275     $ 2,771,776  
                 
Depreciation:                
Online portal operations   $ —     $ —  
Cannabis related operations     253,713       163,410  
Depreciation   $ 253,713     $ 163,410  
                 
Net income (loss):                
Online portal operations   $ (181 )   $ (146,774 )
Cannabis related operations     (1,831,210 )     760,965  
Net income (loss)   $ (8,110,391 )   $ 614,191  
                 
Capital expenditures:                
Online portal operations   $ —     $ —  
Cannabis related operations     5,663,585       3,766,154  
Combined capital expenditures   $ 5,663,585     $ 3,766,154  
                 
Assets:                
Online portal operations   $ 1,217     $ 1,504  
Cannabis related operations     45,439,399       15,349,925  
Combined assets   $ 45,440,616     $ 15,351,429  
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Impairment losses
Unrecognized tax liabilities or benefits
Convertible Promissory Notes [Member]    
Potentially dilutive securities 250,000 3,125,000
Options and Warrants [Member]    
Potentially dilutive securities 12,508,932 10,475,000
Convertible Preferred Stock [Member]    
Potentially dilutive securities 0 500,000
Buildings and Building Improvements [Member] | Minimum [Member]    
Useful lives of property plant and equipment 7 years  
Buildings and Building Improvements [Member] | Maximum [Member]    
Useful lives of property plant and equipment 39 years  
Furniture and Fixtures [Member]    
Useful lives of property plant and equipment 7 years  
Machinery and Equipment [Member] | Minimum [Member]    
Useful lives of property plant and equipment 5 years  
Machinery and Equipment [Member] | Maximum [Member]    
Useful lives of property plant and equipment 10 years  
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisition (Details Narrative) - USD ($)
 1 Months Ended 6 Months Ended
May 31, 2018
Oct. 31, 2017
Jun. 30, 2017
May 31, 2014
Jun. 30, 2018
Jun. 30, 2017
Purchase price of property   $ 140,000     $ 5,663,585 $ 3,766,154
Royalty description   In addition, the selling company shall receive royalties based on a percentage of the Company's sales of the Betty's Eddies product line, commencing at 25% and decreasing to 2.5% as certain sales thresholds are met.In addition, the selling company shall receive royalties based on a percentage of the Company's sales of the Betty's Eddies product line, commencing at 25% and decreasing to 2.5% as certain sales thresholds are met.        
Royalty expense         14,000  
Royalties paid         5,000  
Accrued royalties         9,000  
Goodwill         $ 333,000  
Common Stock Subscriptions [Member]            
Number of shares issued during period   1,000,000     264,317
Sigal Consulting LLC [Member]            
Stock issued during period acquisitions, shares       31,954,236    
Stock issued during period acquisitions, value       $ 5,913,000    
Common stock outstanding shares percentage       50.00%    
Options to purchase shares of common stock       $ 3,000,000    
Exercisable contractual term       5 years    
Options to purchase shares of common stock, value       570,000    
Sigal Consulting LLC [Member] | Minimum [Member]            
Exercise price per share       $ 0.15    
Sigal Consulting LLC [Member] | Maximum [Member]            
Exercise price per share       $ 0.35    
MariMed Advisors Inc. [Member]            
Stock issued during period acquisitions, shares     75,000,000      
Ownership percentage     49.00% 49.00%   49.00%
iRollie LLC [Member]            
Ownership percentage 100.00%          
Goodwill $ 119,000          
iRollie LLC [Member] | Common Stock Subscriptions [Member]            
Number of shares issued during period 600,000       32,083  
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Property and Equipment (Details Narrative) - USD ($)
 1 Months Ended 6 Months Ended
Oct. 31, 2017
Jun. 30, 2018
Jun. 30, 2017
Dec. 31, 2017
Property, Plant and Equipment [Abstract]        
Additions to property and equipment $ 140,000 $ 5,663,585 $ 3,766,154  
Depreciation   253,713 $ 163,410  
Accumulated depreciation   $ 1,746,000   $ 1,499,000
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Debt (Details Narrative) - USD ($)
 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Debt Disclosure [Abstract]    
Proceeds from mortgage debt $ 1,998,000  
Issuance of promissory notes   $ 400,000
Interest rate   10.00%
Debt term   6 months
Repayments of promissory notes 700,000
Debt conversion of convertible amount $ 1,275,000
Debt conversion of convertible shares 1,679,486  
Loss on conversion of common stock $ 818,000  
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Equity (Details Narrative) - USD ($)
 1 Months Ended 6 Months Ended
Jun. 30, 2018
May 31, 2018
Jan. 30, 2018
Oct. 31, 2017
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Jan. 31, 2018
Dec. 31, 2017
Jan. 31, 2017
May 31, 2014
Preferred stock, shares authorized 50,000,000         50,000,000     50,000,000    
Non-cash loss on conversion           $ 959,000 $ 18,000        
Common stock, shares authorized 500,000,000         500,000,000     500,000,000    
Proceeds from issuance of common stock           $ 8,461,003 $ 5,200,000        
MariMed Advisors Inc. [Member]                      
Number of shares issued to acquisition         75,000,000            
Ownership interest         49.00%   49.00%       49.00%
iRollie LLC [Member]                      
Ownership interest   100.00%                  
Common Stock [Member]                      
Number of shares issued during period           10,111,578 22,178,888        
Conversion of stock shares converted               970,989    
Proceeds from issuance of common stock           $ 8,461,000 $ 5,200,000        
Common Stock [Member] | Third Party [Member]                      
Shares in exchange for services           1,313,901 498,543        
Common Stock Subscriptions [Member]                      
Number of shares issued during period       1,000,000   264,317        
Number of shares issued for payment of rent, shares 9,281 9,281                  
Number of shares issued for payment of rent, value $ 20,000 $ 20,000                  
Common Stock Subscriptions [Member] | Vendor [Member]                      
Number of shares issued during period           2,001,641          
Number of shares issued during period, value           $ 1,951,600          
Common Stock Subscriptions [Member] | iRollie LLC [Member]                      
Number of shares issued during period   600,000       32,083          
Class A Membership Units [Member] | Mari Holdings MD LLC [Member]                      
Number of shares issued during period             1,667        
Ownership interest         0.33%   0.33%        
Number of shares issued during period, value             $ 150,000        
Series A Convertible Preferred Stock [Member]                      
Number of shares issued during period             200,000        
Share issued price       $ 1.00 $ 1.00        
Market capitalization $ 50,000,000         $ 50,000,000          
Preferred stock conversion price percentage 25.00%         25.00%          
Conversion of stock shares converted               500,000      
Conversion price per share               $ 0.55      
Non-cash loss on conversion     $ 34,000                
Minimum [Member]                      
Preferred stock, shares authorized                   5,000,000  
Common stock, shares authorized                   100,000,000  
Minimum [Member] | Common Stock [Member]                      
Share issued price $ 0.50       0.18 $ 0.50 0.18        
Maximum [Member]                      
Preferred stock, shares authorized                   50,000,000  
Common stock, shares authorized                   500,000,000  
Maximum [Member] | Common Stock [Member]                      
Share issued price $ 1.37       $ 0.25 $ 1.37 $ 0.25        
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Options (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended
Jun. 30, 2018
May 31, 2018
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Exercise price of common stock, lower limit         $ 0.08  
Exercise price of common stock, upper limit         $ 0.63  
Non-cash equity compensation     $ 6,290,802 $ 6,863,609 $ 19,295
Share exercised option         700,000
Stock Options [Member]            
Options to purchase shares of common stock         1,450,000  
Exercise price of common stock, lower limit         $ 0.14  
Exercise price of common stock, upper limit         $ 0.77  
Stock options vesting period 6 months       6 months  
Stock options expiration period, description         expiring between December 2020 and December 2022  
Non-cash equity compensation $ 36,000       $ 458,000  
Number of options forfeited         300,000  
Stock Options [Member] | Employees [Member]            
Options to purchase shares of common stock   200,000       100,000
Exercise price of common stock, upper limit   $ 0.90        
Stock options expiration period, description           Expiring in March and April 2021
Non-cash equity compensation           $ 19,000
Options expiration date   May 31, 2023        
Stock Options [Member] | Over Six-Month Period [Member]            
Non-cash equity compensation $ 264,000          
Stock Options [Member] | Minimum [Member] | Employees [Member]            
Exercise price of common stock, lower limit           $ 0.26
Stock Options [Member] | Maximum [Member] | Employees [Member]            
Exercise price of common stock, lower limit           $ 0.33
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details)
 6 Months Ended
Jun. 30, 2018
$ / shares
shares
Outstanding shares under option 5,450,000
Exercisable shares under option 4,800,000
Range One [Member]  
Outstanding and exercisable exercise price per share | $ / shares $ 0.080
Outstanding shares under option 250,000
Exercisable shares under option 250,000
Remaining life in years 6 months 29 days
Range Two [Member]  
Outstanding and exercisable exercise price per share | $ / shares $ 0.080
Outstanding shares under option 100,000
Exercisable shares under option 100,000
Remaining life in years 1 year 5 months 20 days
Range Three [Member]  
Outstanding and exercisable exercise price per share | $ / shares $ 0.130
Outstanding shares under option 200,000
Exercisable shares under option 200,000
Remaining life in years 2 years
Range Four [Member]  
Outstanding and exercisable exercise price per share | $ / shares $ 0.140
Outstanding shares under option 650,000
Exercisable shares under option 650,000
Remaining life in years 2 years 6 months 3 days
Range Five [Member]  
Outstanding and exercisable exercise price per share | $ / shares $ 0.150
Outstanding shares under option 1,000,000
Exercisable shares under option 1,000,000
Remaining life in years 1 year 2 months 30 days
Range Six [Member]  
Outstanding and exercisable exercise price per share | $ / shares $ 0.250
Outstanding shares under option 1,000,000
Exercisable shares under option 1,000,000
Remaining life in years 1 year 2 months 30 days
Range Seven [Member]  
Outstanding and exercisable exercise price per share | $ / shares $ 0.260
Outstanding shares under option 50,000
Exercisable shares under option 50,000
Remaining life in years 2 years 9 months 3 days
Range Eight [Member]  
Outstanding and exercisable exercise price per share | $ / shares $ 0.330
Outstanding shares under option 50,000
Exercisable shares under option 25,000
Remaining life in years 2 years 8 months 9 days
Range Nine [Member]  
Outstanding and exercisable exercise price per share | $ / shares $ 0.350
Outstanding shares under option 1,000,000
Exercisable shares under option 1,000,000
Remaining life in years 1 year 2 months 30 days
Range Ten [Member]  
Outstanding and exercisable exercise price per share | $ / shares $ 0.450
Outstanding shares under option 250,000
Exercisable shares under option 125,000
Remaining life in years 3 years 3 months 4 days
Range Eleven [Member]  
Outstanding and exercisable exercise price per share | $ / shares $ 0.550
Outstanding shares under option 100,000
Exercisable shares under option 100,000
Remaining life in years 2 years 2 months 30 days
Range Twelve [Member]  
Outstanding and exercisable exercise price per share | $ / shares $ 0.630
Outstanding shares under option 300,000
Exercisable shares under option 300,000
Remaining life in years 3 years 6 months 3 days
Range Thirteen [Member]  
Outstanding and exercisable exercise price per share | $ / shares $ 0.770
Outstanding shares under option 300,000
Exercisable shares under option
Remaining life in years 4 years 6 months 3 days
Range Fourteen [Member]  
Outstanding and exercisable exercise price per share | $ / shares $ 0.900
Outstanding shares under option 200,000
Exercisable shares under option
Remaining life in years 4 years 10 months 14 days
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Warrants (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Non-cash equity compensation $ 6,290,802 $ 6,863,609 $ 19,295
Warrant [Member]        
Number of warrants issued to purchase common stock 4,239,000 100,000 4,239,000 100,000
Warrant expiration description     expiring in February 2021 expiring in March 2020
Warrants exercise price $ 0.30 $ 2.25 $ 0.30 $ 2.25
Non-cash equity compensation     $ 6,370,000 $ 19,000
Warrant One [Member]        
Number of warrants issued to purchase common stock 1,425,379 1,425,379
Warrant One [Member] | Minimum [Member]        
Warrants exercise price $ 0.10   $ 0.10  
Warrant One [Member] | Maximum [Member]        
Warrants exercise price $ 0.50   $ 0.50  
Warrant Two [Member]        
Number of warrants issued to purchase common stock 7,058,932 1,225,000 7,058,932 1,225,000
Warrants exercise price $ 0.10 $ 2.25 $ 0.10 $ 2.25
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions (Details Narrative) - USD ($)
 1 Months Ended 6 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
May 31, 2014
Share exercised option       700,000  
Exercise price of common stock, lower limit       $ 0.08    
Exercise price of common stock, upper limit       $ 0.63    
Non-cash loss on conversion       $ 959,000 $ 18,000  
CEO [Member]            
Options to purchase shares of common stock $ 200,000 $ 4,500,000        
Exercise price per share $ 0.025 $ 0.01        
Number of common stock classified as treasury stock, value   $ 45,000        
Number of common stock classified as treasury stock   90,000        
Board Member [Member]            
Share exercised option       400,000    
Exercise price of common stock, lower limit       $ 0.08    
Exercise price of common stock, upper limit       $ 0.63    
Chief Financial Officer [Member]            
Share exercised option       300,000    
Individual's [Member]            
Options to purchase shares of common stock $ 100,000          
Former Chief Financial Officer [Member] | Common Stock [Member]            
Shares in exchange for services       170,000 169,487  
Non-cash loss on conversion       $ 112,000 $ 18,000  
CEO [Member]            
Principal amount       $ 19,000    
CFO [Member]            
Principal amount $ 14,000          
MariMed Advisors Inc. [Member]            
Ownership percentage     49.00%   49.00% 49.00%
Stock issued during period acquisitions, shares     75,000,000      
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies (Details Narrative) - USD ($)
 6 Months Ended
Jun. 30, 2018
Dec. 31, 2017
Agreement term description An employment agreement with the former CEO of the Company that provided this individual with salary, car allowances, stock options, life insurance, and other employee benefits was terminated in 2017.  
Accrued expenses $ 1,602,834 $ 1,405,336
Employment Agreement [Member]    
Accrued expenses $ 1,043,000 $ 1,043,000
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment Reporting - Schedule of Operating Segments (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Revenues $ 2,937,325 $ 1,621,057 $ 5,020,275 $ 2,771,776
Depreciation     253,713 163,410
Net income (loss)     (8,110,391) 614,191
Capital expenditures     5,663,585 3,766,154
Assets 45,440,616 15,351,429 45,440,616 15,351,429
Online Portal Operations [Member]        
Revenues     114
Depreciation    
Net income (loss)     (181) (146,774)
Capital expenditures    
Assets 1,217 1,504 1,217 1,504
Cannabis Related Operations [Member]        
Revenues     5,020,275 2,771,662
Depreciation     253,713 163,410
Net income (loss)     (1,831,210) 760,965
Capital expenditures     5,663,585 3,766,154
Assets $ 45,439,399 $ 15,349,925 $ 45,439,399 $ 15,349,925
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events (Details Narrative) - USD ($)
 6 Months Ended
Jun. 30, 2018
Jun. 30, 2017
Exercise price of common stock, lower limit $ 0.08  
Exercise price of common stock, upper limit $ 0.63  
Share exercised option 700,000
Worldwide Licensing Agreement [Member]    
Payments to acquire intangible asset $ 250,000  
Board Member [Member]    
Stock option, granted 302,000  
Exercise price of common stock, lower limit $ 0.08  
Exercise price of common stock, upper limit $ 0.63  
Share exercised option 400,000  
Number of shares used to pay aggregate exercise price, shares 98,000  
Number of shares used to pay aggregate exercise price, value $ 98,000  
Minimum [Member]    
Sale of stock price per share $ 0.90  
Maximum [Member]    
Sale of stock price per share $ 2.70  
Common Stock [Member]    
Number of shares sold 789,474  
Number of shares sold, value $ 2,200,000  
Warrant [Member]    
Number of warrants issued to purchase common stock 544,500  
Warrants exercise price $ 4.20  
Warrant One [Member]    
Number of warrants issued to purchase common stock 232,083  
Warrant One [Member] | Minimum [Member]    
Warrants exercise price $ 0.10  
Warrant One [Member] | Maximum [Member]    
Warrants exercise price $ 0.40  
EXCEL 44 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( !=S#DT?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ %W,.36;S"V"" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGB06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " 7&ULS9+/3L,P#(=?!>7>NFD'&E'7"X@32$A, G&+$F^+:/XH,6KW]K1A MZX3@ 3C&_N7S9\FM"D+YB,_1!XQD,%V-MG=)J+!A!Z(@ )(ZH)6IG!)N:NY\ MM)*F9]Q#D.I#[A'JJKH!BR2U) DSL @+D76M5D)%E.3C":_5@@^?L<\PK0![ MM.@H 2\YL&Z>&(YCW\(%,,,(HTW?!=0+,5?_Q.8.L%-R3&9)#<-0#DW.33MP M>'MZ?,GK%L8EDD[A]"L90<> &W:>_-K&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " 7%*.A+ZR&F/NO75MS[9^S?FP"0)VKG&'V!,9<"_> M7 GM$!=;>@O80#&Z*%+7!C ,TZ!#3>]7I3H[TJHD=]XV/3Y2C]V[#M$_>]R2 M<>L#__W@N;G57!X$53F@&_Z!^<_A2,4NF*UHWX3@XGF)L") &<"3/]+B"9"-!-T-@/MF0KU M$^*H*BD9/:J_UH!D48!-)))YEHXV "P28$8&P M/0M E\ >6G3X4>!@(R*W0.2,(%+T:$&/W?3828\5/5[0$R,!-B)U"R1.@<2B M9X: 1B0*T>L,)Q!F:>:629TRJ263&S(VHG +9$Z!S*(#LU0=/B*Y?+3*RIGE1ZP\DP3>%@_BM0_0502P,$% M @ %W,.33PM#/?F! ,Q< !@ !X;"]W;W)K/OVI63% ML&>&R8UU\#_D3XK\..3BU+3?NVV,_>S'OCYT#_-MWQ_OBZ)[VL9]U7UICO&0 M_GENVGW5I\?VI>B.;:PV8]"^+K12KMA7N\-\N1C??6V7B^:UKW>'^+6==:_[ M?=7^MXIUX7V,8 D;%W[MXZJ[N9T-3'IOF^_#PV^9AK@9'L8Y/_5!$E2YO<1WK M>B@I^?AW*G1^J7,(O+Y_+_V7L?&I,8]5%]=-_<]NTV\?YF$^V\3GZK7NOS6G M7^/4(#N?3:W_/;[%.LD')ZF.IZ;NQM_9TVO7-_NIE&1E7_TX7W>'\7J:RG\/ MDP/T%* O 6 ^#, I $E <78V-O7GJJ^6B[8YS=KSUSI6PZ" >TR=^32\'/MN M_"^UMDMOWY;:+(JWH9Q)LCI+]+7D5K$6%/8B*5+]%Q-:-*''>+R.=W(\BO$X MQIOK>$\:<9;X47(8)59Y#U?UG)O"=:!+I1%D/T;T8[B?0/R<)?:J'H0T^;PB M?K@.C$43C.S'BGXL]U,2/Y;7 \J[DO3CFNM&#B=!:'UI@\]8DCD-'-1(00V!0WK'.0(1J]4KG]0IBMRNEI*5^30O-/VNJ;)T:>Z6T,&#E9+P8JP=I*T]7(4$'/NW7S[&/3_TS7$ZHBXNY^3+_P%02P,$ M% @ %W,.38I2JT:& @ : D !@ !X;"]W;W)K^+*^#S''X'Z8%E2]D;OQ BO/>JK/G*OPC1+(* 'RZDPOR%-J26;TZ4 M55C(+CL'O&$$'[6I*H,0@"2H<%'[ZZ4>V['UDEY%6=1DQSQ^K2K,_FU(2=N5 M#_V/@=?B?!%J(%@O&WPF/XGXU>R8[ 5#E&-1D9H7M/88.:W\3W"QA9$R:,7O M@K1\U/94*GM*WU3GVW'E T5$2G(0*@26CQO9DK)4D23'WSZH/\RIC./V1_0O M.GF9S!YSLJ7EG^(H+BL_\[TC.>%K*5YI^Y7T"2'?Z[/_3FZDE')%(N*K4.! M!DD@YQ\@0B=$J/W1&.*./W+Z(^V/Q_[$2**39%I2:PEX 0 :B3Q235AB)TML MLZ0&2R=!HUD0Z/X,G">$$R+D)$(V4680V9(8&2RSD@E%XJ1(;(K4$R8(W(4)V%2169F -1G,HQ3D*#.Q7-(TR6,017?6"MXIF-#F MLBHF=''%20B053H=TC3)T R7NX;"T.9")E?X<&\[)'#VZ[DK,K1+C(4W>0'YB=BYI[>RKDZ:G/N!.E@LB0X$4&N\AKS] I MR4FH9BK;K#O[NXZ@37^O"8;+U?H_4$L#!!0 ( !=S#DTM_;>BR 0 H5 M 8 >&PO=V]R:W-H965T&ULC5C;CN)&$/T5Q/N.N_KJ M'C%(@R%*I$1:;93DV0,] UH;$]LS;/X^[W1? S:G+J6JZ#KTX5_77 M9A]"._M6%L?F8;YOV]-]DC3;?2CSYJXZA6/\YKFJR[R-C_5+TISJD.]ZH[)( MI! V*?/#<;Y<]&N?Z^6B>FV+PS%\KF?-:UGF]7^K4%3GASG,WQ>^'%[V;;>0 M+!>G_"7\&=J_3I_K^)1J^MH]_+9[F(LNHU"$;=NYR./;6\A"472>8A[_CD[GEYB=X?7G=^^_].0C MF:>\"5E5_'/8M?N'>3J?[<)S_EJT7ZKSKV$D9.:SD?WOX2T4$=YE$F-LJZ+I M7V?;UZ:MRM%+3*7,OPWOAV/_?AZ^<>]FO($<#>3%(,;^R$"-!NJ[@?[00(\& M^FM@/I[S;=G!O8KNVW6+?G?Z[6,\FKKXM MG5LD;YV?$;(:(/(:DMY"UA0"%T02XU^2D%P2*TG,Y6V C"*<1SG\T,GF0R#M-6NO>WM];0^HU@/$]9#C0,(KIZ1!]: XL!*$0;U;4YP1 M4DB'_&V8N,Z!04(F=)F%AJY2WZM604!V# 6>1O37%*1H(:[?P-XR]5H,'P M_!S+S]'-K7G[E+5/:7W0)ENEM#ZI3E/4K8S"0-E4XN936-PC!F^E#84IH6TZ ML;$]R\U3;BCIE2=AG/,:=32C*&VD175:4Q1([P0JP(:!@79JHFL@^/-?4&YD M @2*07M 264,;C8.-*2-8,#(T%YW#L&:%*IY$3S8&+$ :688HK %-,Y1SK( M (T15EO,D>(D2&%-BCDRD84 IZ=(LB/T$20EZ3%)2?NHK23#A<%9 ;$>F"/% M@?!.>< Z&C$WC;,.R"G%X+Q5('&- M*,S8.'H4+A'%Q?WGQ<09#OP$!CJ"/1[!0*>AE5[$P8D94F<:'U6'D 5!]XK ^ 3NM/-NX0C7/*&*01.A6D@8S'%$ PQR]% MVB@/_=1_-%XI2*H4\,!>23JPHV['@B)C8)^T!+POU@P.XG\AB7H]ZS$R-0\CI! M4IW@L4X8,>EU3N).**SW&%R$"7PY,.$.GTB;'[J[Y<>+!*D(/\!%7XV@V^/: M6FU2A?4> [7&Q/_D!C!-SJF,.BXEFH]S&O6T5 :+]^3J'J<,]4M_J=;,MM7K ML>VDT-7JY>+N47;W0&A]!?<9,.MKN-\,UW+?W0^WA'_D]JK:MROZ. MZ+FJVA )B+N8^C[DN\M#$9[;[J.+G^OA=FYX:*O3>/.87*X_E_\#4$L#!!0 M ( !=S#DW29I*M?@4 $\; 8 >&PO=V]R:W-H965T&ULC9E;;^,V$(7_BN%WK\69X45!$F#MHFB!%EALT?99FRB)L;;E2DJR_?>E M9*W7YAP:]4-L*8?#P]NGH7C[WK1?NY>Z[F??=MM]=S=_Z?O#S7+9/;S4NZK[ MT!SJ??S/4]/NJCY>ML_+[M#6U>-8:+==4E&XY:[:[.?WM^.]3^W];?/:;S?[ M^E,[ZUYWNZK]=U5OF_>[N9E_O_%Y\_S2#S>6][>'ZKG^H^[_/'QJX]7R%.5Q MLZOWW:;9S]KZZ6[^T=RL)0P%1L5?F_J]._L]&YKRI6F^#A>_/M[-B\%1O:T? M^B%$%;_>ZG6]W0Z1HH]_IJ#S4YU#P?/?WZ/_/#8^-N9+U=7K9OOWYK%_N9N' M^>RQ?JI>M_WGYOV7>FJ0G<^FUO]6O]7;*!^FFTW_IT]O'9]LYNB1"N[ MZMOQ>[,?O]^G^-^+X0(T%:!3@5CWM0(\%> ?!61L_-'9V-2?JKZZOVV;]UE[ M'*U#-4P*<\.Q,Q^&FV/?C?^+K>WBW;=[4YC;Y=L0:-*LCAHZUYP4RQC]5 6A M*E:DBM-E!6NM\"6N@6$C>"S/%XT@'$!@ !D#R%F ,B2=<)3X4;(?)8M 0J5) M>FNMA=:(=P7V8Z$?J_R8@A-#1XT]J\S,-Z[TJ7C!96!?,AXPO0S#'JH M3$VQYH -WOK4DM9=J:;0OCG(OM2EL%E"+!!,Z8 MPB T3IM2'>U 5:4KTSF[1D+GA7W&$D:KT6SE(K6DH;DP<49Z5@L$*&T1S><& M#P/6:,*R2BJT1FQJ1^-UP?9\^5^ZP8 U&HNLUJPF[#!!O%JQ0&===GT0QBQI MS')*6=+P7%CO@TOS#22,Z_\\$[CTA#E+@(WI1"*-62K2%; &JA!*"9F4CC!I M29-6TCE$FI_Q211,.FI MY 0B'+#AD%+&K22)@ZD^;DPI=//:B",26O(#1H& M+>G$U:0)Z6H275@B'ZF>.M(Z(;*93(\PM\D"]&=R<<*4)4U9D^:!*P+TM,ZQ M#2E$D)*]GHSQR0"?E.*3-3ZY!)WT_^')&)X,X)E2<<5@=U_$!X?JGZNI M[*4=C$X&Z*04G8R 2#90IB[!/!2PQZG8+^?>\4HF*("*,HI147#,4Y)2E^7 MK8'.6%]R!J*"(2H HFKC* "B9$OE2,?*(4(P/\6#/LYDL(*A)P!ZG$)O$OF+ M!GFK(0RBJ28MSXXA=G7[/)[8=+.'YG7?#R_\S^Z>3H4^TG",D=Q?F9OU\6SG M1YCC4=/O5?N\V7>S+TW?-[OQ*..I:?HZ6BP^Q&%YJ:O'T\6V?NJ'GS[^;H]' M/,>+OCE,QU?+TQG:_7]02P,$% @ %W,.3>VL0%BT 0 T@, !@ !X M;"]W;W)KX,]:'_3H%'<>=.TS/8&>!U!2K)TM[MEB@M-RSSZSJ;,<7!2:#@; M8@>EN/EU HEC01/ZYG@2;>>"@Y5YSUOX!NY[?S;>8@M++11H*U 3 TU![Y/C M*0OQ,>"'@-&NSB14QL^9DRXI W!] M?F/_&&OWM5RXA0>4SZ)V74$/E-30\$&Z)QP_P5S/!TKFXK_ %:0/#TI\C@JE MC2NI!NM0S2Q>BN*OTRYTW,?I)DMFV#8@G0'I CC$/&Q*%)4_?4F1;J4XI?_ MTVWX?E/A/L+W?RB\VR;(-@FR2)#]M\2MF,-?2=BJIPI,&Z?)D@H''2=YY5T& M]CZ-;_(>/DW[5VY:H2VYH/,O&_O?(#KP4G8W?H0Z_\$60T+CPO'.G\TT9I/A ML)]_$%N^&PO=V]R M:W-H965T&UL?5/MCI4P$'V5I@^PY0*ZZPV0[%UC--'D9HWK M[UX8H-E^8%LNZ]L[+2RB$O^TG>F<,V>FTV(R]MGU )Z\**E=27OOAR-CKNY! M<7=C!M!XTQJKN$?3=LP-%G@304JR-$G>,L6%IE41?6=;%6;T4F@X6^)&I;C] M>0)III(>Z*OC472]#PY6%0/OX"OX;\/9HL56ED8HT$X832RT);T_'$]YB(\! M3P(FMSF34,G%F.=@?&I*F@1!(*'V@8'C=H4'D#(0H8P?"R==4P;@]OS*_B'6 MCK5,^S3=YML#V >D"2%? 7558,Q$[]W[@X8D/ MQQ1[4P=G;$6\0_$.O=?JD+TKV#40+3&G.2;=QJP1#-G7%.E>BE/Z#SS=AV>[ M"K,(S_Y0>+M/D.\2Y)$@_V^).S%Y\E<2MNFI MO%:7*D-J..D[SQK@-[G\8W M^1T^3_L7;CNA';D8CR\;^]\:XP&E)#,Z9,^-Q,1G[Z'H 3YZ4U*ZDO??#D3%7]Z"XNS$# M:+QIC574/)4OQGN(+$\* $<]1&NKB2>G3>J(4% MI2C^-.]"QWV:;[)L@>T#T@60KH#;F(?-B:+R]]SSJK!F(G;N_<##$R?'%'M3 M!V=L1;Q#\0Z]URK)DX)= ]$2WB-#E2FU''2=YXUX&]2^.;_ F?I_T+ MMYW0CER,QY>-_6^-\8!2#CNT 0 T@, !@ !X;"]W;W)K!DI^%DB!V4$N;U"!+'G";TS?'8 M-:T+#E9DO6C@![B?_-*RL$Z5#.+EZ+$R[1W M.N[C=),F,VP;P&< 7P"W,0^;$D7EGX43169P)&;J?2_"$R<'[GM3!F=L1;SS MXJWW7HHD33-V"41SS'&*X>N8)8)Y]B4%WTIQY/_ ^39\OZEP'^'[=PJOMPG2 M38(T$J3_+7$KYN9#$K;JJ0+3Q&FRI,1!QTE>>9>!O>/Q3?Z&3]/^($S3:4O. MZ/S+QO[7B Z\E-V5'Z'6?[#%D%"[&PO=V]R:W-H965T<"CKM_/\"N MZVW6O@!WW'OW[CC2 =6JM1EMG.N.C-FB 2WL#7;0^IL*C1;.FZ9F MMC,@R@C2BO'-YB/30K8T3Z/O;/(4>Z=D"V=#;*^U,+].H'#(Z):^.1YDW;C@ M8'G:B1I^@/O9G8VWV,Q22@VME=@2 U5&;[?'4Q+B8\"CA,$NSB14QLO$2>>4 ;@\O[%_B;7[6B["PAVJ)UFZ)J,' M2DJH1*_< P[W,-7S@9*I^&]P!>7#@Q*?HT!EXTJ*WCK4$XN7HL7KN,LV[L-X MP_<3;!W )P"? 8>8AXV)HO+/PHD\-3@0,_:^$^&)MT?N>U,$9VQ%O//BK?=> M\VVR3]DU$$TQIS&&+V/F".;9YQ1\+<6)_P/GZ_#=JL)=A._^4'A8)TA6"9)( MD/RWQ+683W\E88N>:C!UG"9+"NS;.,D+[SRPMSR^R7OX..W?A:EE:\D%G7_9 MV/\*T8&7LKGQ(]3X#S8;"BH7CGM_-N.8C8;#;OI!;/[&^6]02P,$% @ M%W,.3=&UL M?5/;;MP@$/T5Q <$+[M)5RO;4C95E4JMM$K5YIFUQS8*%Q?P.OW[ B:.D[IY M 6:8<^;,,.2C-D^V W#H60IE"]PYUQ\(L54'DMDKW8/R-XTVDCEOFI;8W@"K M(T@*0K/LADC&%2[SZ#N9,M>#$US!R2 [2,G,GR,(/19X@U\<#[SM7'"0,N]9 M"S_ _>Q/QEMD9JFY!&6Y5LA 4^#;S>&X"_$QX!>'T2[.*%1RUOHI&%_K F=! M$ BH7&!@?KO '0@1B+R,WXD3SRD#<'E^8?\2:_>UG)F%.RT>>>VZ N\QJJ%A M@W />KR'5,\U1JGX;W !X<.#$I^CTL+&%56#=5HF%B]%LN=IYRKN8[K9)]@Z M@"8 G0'[F(=,B:+RS\RQ,C=Z1&;J?<_"$V\.U/>F"L[8BGCGQ5OOO92;ZRPG MET"48HY3#%W&S!'$L\\IZ%J*(_T'3M?AVU6%VPC?OE'XG_R[58)=)-A]6.): MS'N59-%3"::-TV11I0<5)WGAG0?VEL8W>0V?IOT[,RU7%IVU\R\;^]]H[&UL?5/;;MP@ M$/T5Q >$7=:;1"O;4C91U4JMM$K5YIFUQQ<%& ?P.OW[ G8<)[7Z LPPY\R9 M84@'-,^V 7#D54EM,]HXUQT8LT4#2M@K[$#[FPJ-$LZ;IF:V,R#*"%*2\8J]DZV&DR&V5TJ8/T>0.&1T2]\=J)&GZ"^]6= MC+?8S%*V"K1M41,#54;OMH=C$N)CP.\6!KLXDU#)&?$Y&-_*C&Z"()!0N, @ M_':!>Y R$'D9+Q,GG5,&X/+\QOXEUNYK.0L+]RB?VM(U&;VEI(1*]-(]XO 5 MIGKVE$S%?X<+2!\>E/@_@X[3^$J5MMR1F=?]G8_PK1@9>RN?(C MU/@/-AL2*A>.-_YLQC$;#8?=](/8_(WSOU!+ P04 " 7-,8J[M&T+7.]!5Y'D)(LVVSNF.)" MTS*/OK,M,)A::@CYLCZ=]B(\!WP2,;G$FH9*+,<_!^%@7=!,$@83*!P:.VQ4> M0/1GX7M>\*>J"DAH8/TC^9\0.D>FXI M2<5_@BM(# ]*,$=EI(LKJ0;GC4HL*$7QEVD7.NYCNCDDV#H@2X!L!AQB'C8E MBLK?<<_+W)J1V*GW/0]/O#UFV)LJ.&,KXAV*=^B]EMO;NYQ= U&*.4TQV3)F MCF#(/J?(UE*&PO=V]R:W-H965T592VYRVSG4'QFS9@N+V"CO0_J9&H[CSIFF8[0SP*H*49&F2W##%A:9%%GTG M4V38.RDTG RQO5+WF\-Q%^)CP&\!@UV<2:CDC/@4C.]53I,@""24+C!POUW@#J0,1%[& MGXF3SBD#<'E^9?\::_>UG+F%.Y2/HG)M3O>45%#S7KH''+[!5,\U)5/Q/^ " MTH<')3Y'B=+&E92]=:@F%B]%\>=Q%SKNPWBSW4^P=4 Z =(9L(]YV)@H*O_" M'2\R@P,Q8^\['IYX9^P2B*:8XQB3+F/F".;9 MYQ3I6HIC^@&>KL.WJPJW$;Y]H_#S.L%NE6 7"7;_+7$EYB9YEX0M>JK -'&: M+"FQUW&2%]YY8&_3^";_PL=IO^>F$=J2,SK_LK'_-:(#+R6Y\B/4^@\V&Q)J M%XZ?_-F,8S8:#KOI!['Y&Q=_ 5!+ P04 " 7<.3,>YZ-US[X#".1% M*^,+VH70'QGS50=:^!O;@\&;QCHM IJN9;YW(.H$THKQW>Z.:2$-+?/D.[LR MMT-0TL#9$3]H+=R/$R@[%C2CKXXGV78A.EB9]Z*%SQ"^]&>'%EM8:JG!>&D- M<= 4]"$[G@XQ/@5\E3#ZU9G$2B[6/D?C0UW0710$"JH0&01N5W@$I2(1RO@^ M<](E902NSZ_L[U+M6,M%>'BTZINL0U?0>TIJ:,2@PI,=W\-[L2-S4^U[$)\Z.''M316=J1;I#\1Z]US*[RW)VC41SS&F*X>N8)8(A^Y*" M;Z4X\;_@?!N^WU2X3_#];PK_07#8)#@D@L-_2]R*V?^1A*UZJL&U:9H\J>Q@ MTB2OO,O /J1'9+_"IVG_)%PKC2<7&_!E4_\;:P.@E-T-CE"''VPQ%#0A'M_@ MV4UC-AG!]O,/8LLW+G\"4$L#!!0 ( !=S#DW[9;?@M $ -(# 9 M>&PO=V]R:W-H965T-\=&'-% UJX*]-!BS>5L5IX-&W-7&=!E!&D%>.;S9YI(5N:I]%WLGEJ>J]D M"R=+7*^UL"]'4&;(Z):^.AYDW?C@8'G:B1I^@O_5G2Q:;&8II8;62=,2"U5& M;[>'8Q+B8\!O"8-;G$FHY&S,4S"^EQG=!$&@H/"!0>!V@3M0*A"AC#\3)YU3 M!N#R_,K^-=:.M9R%@SNC'F7IFXS>4%)")7KE'\SP#:9ZKBF9BO\!%U 8'I1@ MCL(H%U=2],X;/;&@%"V>QUVV<1_&&_YY@JT#^ 3@,^ FYF%CHJC\B_ B3ZT9 MB!U[WXGPQ-L#Q]X4P1E;$>]0O$/O)=_NDY1= M$4G;.,D+ M[SRPMSR^R;_P<=KOA:UEZ\C9>'S9V/_*& \H97.%(]3@!YL-!94/QT]XMN.8 MC88WW?2#V/R-\[]02P,$% @ %W,.308*YVRT 0 T@, !D !X;"]W M;W)K&UL?5-A;]L@$/TKB!]0$I*U:61;:CI-F[1) M4:=UGXE]ME&!\P#'W;\?8-?S-FM?@#ONO7MW'-F ]L6U )Z\:F5<3EOONR-C MKFQ!"W>#'9AP4Z/5P@?3-LQU%D250%HQOMG<,BVDH466?&=;9-A[)0V<+7&] MUL+^/('"(:=;^N9XDDWKHX,562<:^ K^6W>VP6(S2R4U&"?1$ MU3A^VQ],^ MQJ> 9PF#6YQ)K.2"^!*-3U5.-U$0*"A]9!!AN\(C*!6)@HP?$R>=4T;@\OS& M_B'5'FJY" >/J+[+RK\HF8K_#%=0(3PJ"3E*5"ZM MI.R=1SVQ!"E:O(Z[-&D?QAM^/\'6 7P"\!EP2'G8F"@I?R^\*#*+ [%C[SL1 MGWA[Y*$W972F5J2[(-X%[[78WMYE[!J)IIC3&,.7,7,$"^QS"KZ6XL3_@?-U M^&Y5X2[!=W\H/*P3[%<)]HE@_]\2UV+N_TK"%CW58)LT38Z4V)LTR0OO/+ / M/+W)[_!QVK\(VTCCR 5]>-G4_QK10Y"RN0DCU(8/-AL*:A^/=^%LQS$;#8_= M](/8_(V+7U!+ P04 " 7;-9EZ9XH^B^57O]6D=EW&TYP=V;O2SN'[AXX:*.!IW M_XU?>&/@=B5&8R<:Y7ZCW5EIT8XL9BDM>Q^N=>>NU^%)D8]EN(".!70J*)U. M,@BYE7]BFFU64EPC.1Q^S^P[)O?4G,W.3KJC<,_,XI69O6S(,ETE%TLT8K8# MAMYB)D1BV"<)BB2V=%9.<7D&5YBY\NQ6/5MB@AP2Y(X@_V^+Q-LBP@1664"1 M A!DG@C"Y%AD 446@*#P1!!F@4664&0)"):>",*46*2$(B4@J#P1@"E3+%)! MD0H0^"\>80(OGJ380>F<(L]]"P%0F05T DXE@&*F@T!%0 ?:]8%00+'P=1 H MX$J"?4TR0%'Z.@A4!72P_0GP=C6+. 0*I!S!"4" O2OJZR!0Z#O (4" PXO9 MN0%0%<@:@G. )-7?MI 4"!N"(X" GQ>^8$#08'$(3@-"+#ZPH\#!*H"WQO% M>4#G5C=-DJ<#0:%_59P'=&YUFOK?&P0%OC>*\X#.K4Y3/W<@*) [%.71MGXIVXMRYGO-F=FHM'ZAKGO[!A[[T.Y/'NE/1J]"F M!7.-TD$(SO3" %5^H;9;T[VL; M0DG"B^T9GW/FXG$^:O-B.P"'7J50ML"=<_V!$%MU()F]TCTH?]-H(YGSIFF) M[0VP.I*D(#1);HAD7.$RC[Z3*7,].,$5G RR@Y3,_#V"T&.!4_SF>.)MYX*# ME'G/6O@)[E=_,MXBBTK-)2C+M4(&F@+?I8=C%O 1\)O#:%=G%"HY:_T2C&]U M@9.0$ BH7%!@?KO /0@1A'P:?V9-O(0,Q/7Y3?TQUNYK.3,+]UH\\]IU!=YC M5$/#!N&>]/@5YGJN,9J+_PX7$!X>,O$Q*BUL7%$U6*?EK.)3D>QUVKF*^SC= MW&8S;9M 9P)="/L8ATR!8N8/S+$R-WI$9NI]S\(3IP?J>U,%9VQ%O//)6^^] ME#39Y^02A&;,<<+0%29=$,2K+R'H5H@C_42GV_3=9H:[2-^MHU]GVP+9ID 6 M!;)W)7[Y4.(&)DT^!"&KGDHP;9PFBRH]J#C)*^\RL'^K.9QFPRG.[G'T26;US^ U!+ P04 M " 7P?[8! #2 P &0 'AL+W=O80_:W]1HE'#>- VS MO0%119*2C.]V-TR)3M,BB[Z3*3()8?C/N CX'<'HUV=2:CDC/@ M"IXD&;L$H1ESG#!\A?E ,*^^A.!;(8[\/SK?IJ>;&::1GJZCWUQO"^PW!?91 M8/]/B?Q3B5N8]%,0MNJI M/$:;*DQ$''25YYEX&]X_%-/N#3M#\*TW3:DC,Z M_[*Q_S6B Y_*[LJ/4.L_V&)(J%TX?O%G,XW99#CLYQ_$EF]<_ 502P,$% M @ %W,.30\&JWZL @ <@H !D !X;"]W;W)K&ULC5;1CILP$/P5Q <>)+*<5$4^LH;5Z"XNN=03WB9MR(7^HO)W<^!JY U93D5%:U&PVN'TO':W:+7'O@XPB)>"MF)T M[V@I1\9>]>#[:>WZFA$M:29U"J(N-[JG9:DS*1Y_^Z3N4%,'CN_?LW\UXI68 M(Q%TS\H_Q4GF:S=QG1,]DVLIGUG[C?:"(M?IU?^@-UHJN&:B:F2L%.;?R:Y" MLJK/HJA4Y*V[%K6YMMV3..C#X #OP[FLU1"\*M K4R\STI'EWYIE2*]3L;8-1F'HWG:C'[#H,'F'0@/!4]J$$ MADKL\"PB8@F(N:8< +9/X34X5 MG>*FQ2!+@46[8=!-L4 3Z=4X5 B:4.[#T$ MF<^RH6#8?!@PWXPJ! JFMO)&)W5%^<4T-<+)V+66^DP=UU0 M-Y"LZ3L\;V@S-_\!4$L#!!0 ( !=S#DVTF_%YHP, $$0 9 >&PO M=V]R:W-H965T!T&[.8@J;^_D4=3ZSDXV5:[T9;,/VF,C\FT?5)4!#<,XJ/*B]A>S M?NRE6#U^6?V5=^\;N8M;\6C+/\MMNHP]U/? MVXI=?BK5JSS_(4Q#W/=,]W^)=U%J>%>)YMC(LNW_>YM3JV1ELNA2JOQC.!9U M?SP/=WAFPG -0'T$J"Y;P5$)B"Z!*3AS0!F M@7 [L9P$T _PJ(;@;$)B#^ MW1X2$Y!8)07#[/:/ZRE7^6+6R+/7#"ONF'<+F]PG>D%LNL'^^??W]!-K]>C[ M@D9D%KQWB0QF.6#H"$/'F-44\Y4ET!5QQ%/K:;6 M4UR4Q#'A#-?-8-T,U)U8=2-,BDDX).$@@?485P.&VY.#:6)($T]IF#VY\82& M.UD2R)( %DMAJV3"DCE94LB2 A9;H^ET 421DR>#/!G@B7 "$F+'"4$*2\>/ M!C1ZO&$(%C\ TIA%Q%J3:\#*N*-NAU,24+'*C)6P2!+@$=ZD7ZY\ ^#,KG8 M95?5AG?$H16*;8("F^"N%%BQ%"AV4JL!C6N-7$18UQ3HFCO42K%:*5*K90U/ M!G2]"A)^:VE3+%<*E,@3FPR!;$W_#FC]"]"X8BQ\BH3O\ Z*]4R1GJVFEP@4 MNR87ZYFB%SZU>9+IMQUQO_,IUC,%>HY=W]U8SQ2]T)E=;399=S%Z&0-<1,/4 M=IC@:G-2B6;?[T5;;R-/M>J^EZ]&+_O=!]IM;JSQ);E_)F!\I??'PV[V*_VP MN?X[;_9%W7IO4NDM5;_QV4FIA*X^O--U'_1^_G)1BIWJ3A-]W@R;VN%"R:/9 ML >77PT6_P-02P,$% @ %W,.32:; Q%" @ ?@8 !D !X;"]W;W)K M&ULC57;CILP$/T5Q >LN=AF$Q&DS:5JI5:*MFK[ M[)!)0 N8VDZR_?O:AF4)N*OF(=CC<\Z<&6R3WKAXD06 \E[KJI$KOU"J72(D M\P)J)A]X"XU>.7%1,Z6GXHQD*X =+:FN4!0$%-6L;/PLM;&]R%)^4579P%YX M\E+73/Q90\5O*S_TWP+/Y;E0)H"RM&5G^ [J1[L7>H8&E6-90R-+WG@"3BO_ M*5SNJ,%;P,\2;G(T]DPE!\Y?S.3+<>4'QA!4D"NCP/3C"ANH*B.D;?SN-?TA MI2&.QV_JGVSMNI8#D[#AU:_RJ(J5_^A[1SBQ2Z6>^>TS]/40W^N+_PI7J#3< M.-$Y M>P)^)^ /":0GD D!=;7;9FZ98EDJ^,T3W79HF=EUX9+HUY6;H'T[=DWW4^KH M-8MHE**K$>HQZPX3C3'Q!+.98\(!@;2#P4;DLK&.'"GP)(4#ELS+HS$. [<=ZK1#'6V< M;A@ZSY-@.NOCSH'#B\48UQE"HT-5@SC;&TYZ.;\TRNRI472X1)\B&UL?57;CILP$/T5Q 9/M(=.?CE3UF(AC^SB\9X!/NF@EG@!0HG7XJ9SRT+;#JPLZ%60IH,# M<_BU;3'[NP-"[UO7=]\-+\VE%LK@E46/+_ #Q,_^P.3)&U%.30L=;VCG,#AO MW6=_L_=U@/;XU<"=3_:.2N5(Z:LZ?#UM7:04 8%** @LEQOL@1"%)'7\&4#= MD5,%3O?OZ)]U\C*9(^:PI^1W*-.I?L("EP6C=X>9?ZO'ZE+XFU 6LU)&73O]36;+I?56!DE<>#<%-/CL MC$\P\?%'#T^BCQ2!C6(7+,*#1X+]TB/-[0RA-8E0QX=3@5%F!XBL )$&B!ZJ MD,RJ8'Q2[=,9DCS/$$)VHMA*%%N(TEDUX@51A- J3V+E22P\V8S'YK-2]M1* MDBX!4C0CL?FLW)[,2I)9 &;W9V=\XDG%TL>*&2U+J"BV2\FM4G*+E' F)5_> MDB"-EUJ66&M:?&1_N,BB)IJ_7+2HC)^D>90E*UPK3<*W<"VZA+](/?,M[\.; MM*86V$5W<>Y4]-H)U00FUG%2/ >JMSM3*D#*1$^R&+6<>..!P%FH;2KWS+1]AP !D !X;"]W;W)K&UL MC9GK;JLX$,=?!?$ !=^X5&FD)CTMO:Q4G=7N?J:-VT0'0A9H<_;MEXN;PGB& MT ]-(/\9S]CCGPU>'(OR5[75NG9^Y]F^NG*W=7VX]+SJ=:OSM+HH#GK?_/)6 ME'E:-Y?ENU<=2IUN.J,\\[CO!UZ>[O;NRZ7B^*CSG9[_5PZU4>>I^5_ M*YT5QRN7N5\W?N[>MW5[PULN#NF[_E/7?QV>R^;*.WG9['*]KW;%WBGUVY5[ MS2Z?9-0:=(J_=_I8#;X[;2HO1?&KO;C?7+E^&Y'.]&O=NDB;CT^]UEG6>FKB M^-;[ODFV1>TDJOB^R?W:;>7KF1ZVST6_J1U3^+8Z)-0LIU M3/9/^E-GC;R-I&GCM_^<[?O/H_]+T%@S' #;@SX MR:!I>\I & /Q;2 F#:0QD-\&%V!C$ M$U(9SBX&@<*VZW M,6YAC2B$&&MN$$T8CC4_,#]RK+FU-6$,$CX;<'+>R3T6;S36/" :-98\8FY M4T]8V@H?(H&7BN@\R*&'R >ETFM4I]EW&N7W?Z#[Y@H?9@A'P4L\>(D$ST!, MO28<-!6KV(HHL64L(L-1>#C*"B<$Y;-29.*P+V/@!TIN0"('5 M39$,F.^#.9O8.L4G(@KQB$([(A7@'B+<0X3D!&*]C:S^"]54]\5X4S'2%$00 MHE$ # !+^X<1C4L;6WD0(0^D8"'L +M5JM8X 2&. M0 C6],J(1K5OK?/K3I"%(V2!O;,V MHF'O!-C<072"^Q$5$@$JCH JEH0/@BL/G&0(I D$*K+_$B$;UI^C)*0A<" P7Q 95$!-<(!/<&BM.5?*&JF M$X03V,,=:.G&B(8C*B2=%($X88-)^!SW(0DP26RO T;[4=J[F,EG44F02=ID M@N\B'HT&V1"2K1$,DS;#A$^L>9)@DYS#)B,"=0/@9$3M ^Y Q>!&?XZOY*RO M<6[4>RJ;4L(GUG-)$$5BCV56^=#O@HC6"&)(FQAV_5# H%LCF"$Q9A TD 0- M)$(#NWXB:\S9A0AA =DJ_P*^G[V;Y2LYYZO/S1N\VL]U^=X=8E7.:_&QK]M7 MMX.[IX.R:]X>#8#[*W9YRY#[=^PRZ8_!OMWWIW)_I.7[;E\Y+T5=%WEW:O!6 M%+5N@F^F@^ML=;HY763ZK6Z_ALWWLC\-ZR_JXF!.^KS3<>/R?U!+ P04 M" 72. DJX R^Z>N^/NP9Y=6//:'BCESEM5UNW\=G.@5=[>L2.MQ9,=:ZJ< MB\MF[[7'AN;;SJ@J/?#]V*ORHG87L^[><[.8L1,OBYH^-TY[JJJ\^?M 2W:9 MN\1]O_%2[ ]N+R.B)=UPZ2(7AS-=TK*4GD0TB4K?Q=;?IB[J>MLZ2X_E?R%7;Y0E5#D.BK[;_1,2P&7D0B. M#2O;[M_9G%K.*N5%A%+E;_VQJ+OCI7\2!\H,-P!E (,!":\:!,H@^&\0734( ME4%X*T.D#*);#6)E$ \&87;5(%$&R6 0=%7R^NIVK^LQY_EBUK"+T_0==\QE M8Y/[1#3$1M[LWG_W3+RQ5MP]+P(_GGEGZ4AA'GH,C# P12P11!!,,8\?>OEL M(I)L"GGZT,GJJA-/U&(H"* %@G.$N L@0(2ZJQ M! A+'. L(%RT?J#KIRF2!(B*XIUT'3 M8"PJ2I!@ IT' UE*2W!Q(I@Z97K28,R7&$*][Y\06!BEUI8BN) 11,F(+@P* M-&[?P+=W+\'5C"!R1F*+"UPVB#GLQJPMB2D<@ D'@B/7LL+E@R#ZH<_+4H&F M V/YK!%<98@I,T:+KE"0;2YQD2&8RNA? 6:?@+LE<.%AB!*0XS*82#;@@!7 M&D"4!BRA JX/@(R^,;<*-"X*Q*&U*F!9OR 2 18U WRF 5N=:!^*%6#+$[", M(^ 3#NL&1?+[VZ1O&., M4^'1OQ,>#V+O-UR4=,?E:2+.FWX#U%]P=E2;.V_882[^ 5!+ P04 " 7 MUNXD84!N!;L7P!:^:;1("4;+5JI5:*MNKVMP,#6&M[6-N$[=W77Z$4O\-SAID\GL&SNH3J>WWTOHE^%GE9K^-CTYP>DZ3>'GV1UI_"R9?M7_:A M*M*F/:P.27VJ?+KK+RKR1"X6-BG2K(PWJ_[<2[59A7.39Z5_J:+Z7!1I]<^S MS\-E'8OX_<37['!LNA/)9G5*#_Y/W_QU>JG:H^2:99<5OJRS4$:5WZ_C)_'X M['1W01_Q+?.7^N9]U'V4UQ"^=P>_[=;QHFN1S_VVZ5*D[1O>M:2ML0UYW?^.MN>Z"<68I6U*D?X<7K.R?[V,^=\OPQ?(\0)Y MO4#U%R1#H;[EOZ1-NEE5X1)50^>?TFZ,Q:-L^V;;G>R[HO];V_BZ/?NV45*M MDKKBE4OV/44L.:CE%/5\+JY8U0JHE,=8*JU8::BIVK3BN%7(MB7N0PJX5Q[6:NIZYJRJL6G%4JZGJN4K8M.*8 M1D&:6#IK;%H#TYI8UFEL6G-,:V2:6OQI;%IS3.NIZ;DOMEBTYHC64]']=RRB M$O$=FN,9!6FJ[[!GC3P3"R6-/6N.9XT\4TL_C3UKCF?]P7E:8]&:(UI_<)[6 MV+3FF$9!U+W;8-,&F2:&PAF/:(--D(6S:<$R;J>FYIQD&HS88:BTU;CFD[-:UFNM]BTY9CVDY- MSY;"IBW'- HR5!ULV@+3AEC46>)Q-^MY-S+MJ,?JV+3EF+93T[/=CTU;CFD0 M1,U'%GNV',\HR!"+9H<].^#9$,P<]NPXGAWR3-PW'.;L.)P=F*)G!MEASH[# M&011@^PP9<>AC(+,_8HYN=DX+'QUZ+=,ZV@;SF73[1/>G+UNRS[)?N/QO_!A M3_>/M#ID91V]AJ8)1;_)N ^A\6U;VKDVCHX^W5T/N?5\->ZG#01-. MXSYQ&PO=V]R M:W-H965T:F22$W"M$F;5'7: M]IDF3H(*. ,GZ?[];$,IV)>$+P&;YQ[?2^+JIF[!R&. MCY[7; ZLS)H'?F25_++C=9D).:SW7G.L6;;51F7A$81"K\SRREW,]-QSO9CQ MDRCRBCW73G,JRZS^MV0%O\Q=['Y,O.3[@U 3WF)VS/;L)Q._CL^U''D]RS8O M6=7DO')JMIN[3_@QQ9$RT(C?.;LT@W='27GE_$T-OFWG+E(>L8)MA*+(Y./, M5JPH%)/TXV]'ZO9K*L/A^P?[%RU>BGG-&K;BQ9]\*PYS-W:=+=MEIT*\\,M7 MU@FBKM.I_\[.K)!PY8E<8\.+1O\ZFU,C>-FQ2%?*[+U]YI5^7MHO%'=FL 'I M#$AO(->^9>!W!OZG07#3(.@,@MZ 1#<-:&= /PU\'=Y6NP[F.A/98E;SBU.W M^7#,5-KA1RJW:Z,F]>[H;S*>C9P]+WQ*9]Y9$76898LA TP4CR%K&X)[A"<= MZ+T@D!=+8IF3\0(K&Q$EA@]W2=*;)",W?3!8OK8/AL%"AA?+%A-I3*4Q(4E0 MC$Q!-E=@Q'T-4,6A'YI+IC8.)R2AL+( 5!;8RF@($U"0@ ($D1&:%D,'?@;$ M3Q!"1FAL'$;(@JTGTJ5WZ4;R0E!>",@SSP"$,;<*P(17'(E 1R* !MQ;C') M0#!Z\(T8VQCR0,P$G$"4WB$:28I!2?']4[6.[:/@1W9.I#8.)U>W.@'=28 ( M$Y@ ([BFH@F'H0.-TC(@U#?+V@I@LRK%5++T-ME8W)4_# S$Q[]" 5;[)TPF M)'$'&BH6F'>H+TK6;W7O7;C;/BI$JIY&VA,;_$CRL,S*]5_Z_; MR4_Z]O+P(ZOW>=4XKUS(IE2WCCO.!9/.RU1UG8.\K_2#@NV$>HWD>]TV[>U M\&-W(?'Z6]'B/U!+ P04 " 7&![\=>F>65.Y]V69\Y=V\'4]<_V6$2O82K0N M,GDYLB4KBM:3Y/%7.77/,5O#X?V;]X9G,<]:P)2_^Y&NQF[F)ZZS9)CL4 MX@<_?6$JH*B^22IF]]M>\ZJZG_DD< M*C/< )0!G UD[$L&@3((W@TN1PB507BM0:0,HFLIQYUW64BFT]K?G+J?L7MLW9ADPF5"V+53G;OOWLFWU@C9X_S((ZGWK%UI#"+ M'@,## 0PQMR;&')&>)+!F09@-!9@AHC&$98F)(CI&'-G8FBJ$44BC1$/'SMY M1)P$$9YO@)8]Z!R$PV2(KS'M,5&'J7H>?ONGT35=A18J(4HE-*GX6EWO>TPZ MH.+?^ D>)4*C1$B41(L2(5'B (\2HU%B(PHD1(O28^@@2AJE9EE-&$F&J!$; MBK*A9LZQI6@)ZB QTXDTGHO$X G(*EF:L# :XT9\4I1/BO )-3X])ADO%4/, M*;:@+!V#^'CG\I'R:D)=*I"1MR62I4<2,Q+5"ZQ 0[FF]OH2M W>$D BVX$,$4 M(B3Z.@!3B(0B^R:&B],PH19*N&+!5*RYY2C0J( $$$H(SK[I -X &D MFT' M<&$#(FP:Z4F%)MG43A97-B#*IK'%!:Y9P#2KD5T LIV'=K*XM,&4-D0VLKAD M =O2C:]8#)3H:^4*T.,'H#%CO$, TB'"6&>>%7F%O<# I6;WMSJ&- ML^*'2K0?RX/9\UGW%MJ#C3:_(),[@LS?D\E#?Y)]=]\?K+]G]3:O&N>9"WF< MZ@X]&\X%DPGX-Y+Z3I[ESX.";41[2^5]W1]H^X'@>W58]\Z_&,S_ U!+ P04 M " 7)4M@ K>&.UE&;9*#1N$9-T"(_*!#]#KG2,7C"B] M%"UZV(M GADCXL\6*!_+, JO@9?N MU"H30%4QD!-\!_5CV N]0K-*TS'H9 OXV<$H%_/ .#EP M_FH67YHRQ*8@H% KHT#T<($=4&J$=!F_)\UP3FF(R_E5_=EZUUX.1,*.TU]= MH]HRS,.@@2,Y4_7"Q\\P^5F%P63^*UR :KBI1.>H.97V&]1GJ3B;5'0IC+RY ML>OM.+J=[$KS$^*)$,^$_/^$9"(D,R%*K7E7F;7Z1!2I"L''0+B?-1!S)Z)- MH@^S-D%[=G9/NY4Z>JF2];I %R,T8;8.$R\PT8Q 6GU.$?M2;.,[>OP^P6G[TSD-R9\F$_^)*DW27HGD$8W.1QD;2&].Z@,QWF2WOCUX%*\ M2I+,7\_*6\_JWE"._0*95R#[V%!V7RA.$XSQC:&/<:X>M+B6#,3)OF 9U/S< MV^ZQB,Y-XC&VU_H?W'68;T2&ULC5?;CJ,X$/T5Q/L.%,8VM))( MG]G653-W#\:JF]YER66?UKJ0I]F?O@_Y[XEA^.IIT(%K-3=E#? ME?G[]%+;47#ULLM+536YKKQ:[>?^,SQM(&T-.L0_N;HT-^]>F\JKUC_:P>?= MW ];1JI06].ZR.SC3:U44;2>+(__!J?^-69K>/O^V_N?7?(VF=>L42M=_)OO MS''N)[ZW4_OL7)AO^O*7&A+BOC=D_T6]J<+"6R8VQE873??K;<^-T>7@Q5(I MLY_],Z^ZYZ7_1\)@1AM$@T%T-;"Q'QFPP8"]&\0/#>+!()X:@0\&W(D0]+EW MQ5QG)EO,:GWQZOY[.&7M9P=/W"[7MIWL5J?[S]:SL;-O"Y; +'AK'0V898^) M;C R&4/6&/+N)+ $KBPBBL4R0N;1., *(V3J:ADQ%-1A:+=?;QC3VJ M50^1':3J2:1,LH@[^6 A *>4*PP$ MSCC$D=MG4SUN)G@<)9F0229$DG>JE)(.T@^[=HTAL;M@*4X&[M" D);:<$)[ M$2!$Y3%F3.6.ZL/'K35@1KT%;N4V)"H64MZK#;D!/$,TH;<($*[-0\R8"BWR M@%4>=]4 >.$3CBO:)0/(S=M*;XVGSD:YP:K>^ !9XE]ZI#:S)@44;=!%AL MZ4V+ +:[EA#1'4ZT+@,69J*QL.*2&Q>!>[1S :W,@*49-QC61]M@S*Y]Z'+" M2"G"5-Q;.EI(@5)2U&/)Q V, #[IZD-W!6J\K3Y7ICU3WLQ>KUG/47MJ=^:7\+0" M8G[=7LNZ4_Z[^_Y.]S6K#WG5>*_:V+M"=Z+?:VV432#\9!?I:*^1UT&A]J9] ME?:][N]2_<#HTW!/#*Z7U<7_4$L#!!0 ( !=S#DWC^\T@/@, -T- 9 M >&PO=V]R:W-H965T1?O2G3B7 MWFM5UMW*/TG9/ 1!MSOQ*N\6HN&U>G(0;95+U6R/0=>T/-\;IZH,@) XJ/*B M]M=+T_?4KI?B+,NBYD^MUYVK*F__;7@IKBN?^F\=/XKC2>J.8+UL\B/_R>6O MYJE5K6",LB\J7G>%J+V6'U;^(WW8,J(=C,7O@E^[R;VG2WD6XD4WONY7/M$9 M\9+OI Z1J\N%;WE9ZD@JC[]#4'_4U([3^[?HGTWQJICGO.-;4?XI]O*T\E/? MV_-#?B[E#W']PH>"(M\;JO_&+[Q4YCH3I;$396?^O=VYDZ(:HJA4JORUOQ:U MN5[[)S$,;K@## XP.BCMCQS8X,#>'4)3?)^9*?53+O/ULA57K^W?5I/K24$? MF!K,G>XT8V>>J6H[U7M9LS1>!A<=:+#9]#8PL:&C1:"BCQ* 26S U=1+'%,W0 !F2:#9+-+,&G1%P)DH)CANY8ZH.1O?-5>K@FMXQ6P>C^Z8K M1>E^I'#'A!V,IH,7$O=;ICCF%.$\LZ28)96E;B4<=8JPGM&Y4FA-W8^4<-PI MPCL!1P@<4XIPFL$\V1AYU8Y%EN(T4P1G$CI"X*!2A%0[U=1*%1:.=8?B/%,; M:$@=:Q_@I )":L9FJ0Y&-RMQFH6)8U0 9Q405K-P+D7MA1(^8 AP7 '!-8H= M(7 , <$PFJ]A8&,8A6'DS!;G$! .XSF'8']TPX4#(< I!(3"V!4"IQ 0"NU1 MB:U1 08D=2RY@(,("(BN51MP$ $!T1Y8&T2R<&W]3MQKJ7>?DYZQS/*H]FVS_HWZNS2GS3>P_0'G^]Y M>RSJSGL64FW9S<;Z((3D*D>R4*_]I,Y:8Z/D!ZEO$W7?]@>.OB%%,QRF@O%$ MM_X/4$L#!!0 ( !=S#DW"'OOJOC$ )OI 4 >&POOWI5S._B=53TLDV9?-M^LX+464+L1) M6B;E@SA->CR]./ M)^_$Z=EQKV&$8Y@SCU8PUR+^(OX6/S0"=OVP<288]/>_:_S@(LZ3#!>S$.^B MTOE6X2KXPQ^\V((Q%C3.^U5T6W^ZC%:%,^+Q-L_I@Z28PY+^$4=YX^S[^X/A M_FC0@)7WR2K.Q3%\=YOE#DJNUM$*GU_&FRPOD_16'&?K390Z+RH<9^LUD-15 MF1JLHG<>P-&# GCGT]4[\6+O MI3-1/(WO7.0@-W.@1L0AHF^#6^[% MC /B*DMO]\LX7[<#V0:<_YG:\U42W22K!/'E;+S>STWTX-L>>)YO =_QEPV2 MIG=CRFS7MGR$A=U&M[&>9N?&2*XND*M%L;TIYGFRP1?K8Z,:>UULHGG\YZ] M3Q5Q_CG^ZAOAPWKC(NT=-M#581T==Z]E4)Z]Y042;7?9:A'GQ1^)NLH'9R.O M0"@!7$=BGJ6?@103@$X 0B0;%BP>]_J]?G^ VR2 P;?Q&S'IA_T^_2=ULHBV MY5V6)_^$KZ)2@"*)M=(E\@8Y$Z]O8$U*UKP1::8^3HH"R27+15:)8'<<>.X, MT[BBVBH4.=S #S?;$B8OY;1OQ#_C/",@)[4U=5I("'1<;.)YF7R.5XZ^,4G2 MC\E? I6#V2B<]F?AY+!/KPRF!^%LW ]'HT$-QT]9$X\_/AB&_ 3+'1HH(L^.ZC'"T^ETO!!BZV^8/:?P!IGA7E&S$< M3\/)D$&:_>)$=[18) @_2(A-E"SVDQ14]"8!B>&1U-OUEL7P(EXF\\2C>E*0 M#F6>K5:XMTD*YKLU*S^M,\=D?"SAF&> M^5E#9,TV5_O L#NA7O?[[C8NH3P4VD# MW6OB+9!ZS\&8C%ALO?B41EN0 ?'B9;/I/^KL-SM"\A1$PCJNYF]AD\OX!#GV7T;9X58$GEV=(551(#,(*R/!V+!]RP M(DO3V/7AHOS'F+Y%803CKS/O]'$:HW..+T6+=9*2LX]BV"_E,@>D9J 3PJI' M_NZ[HS@+.Y5R6;WA=2-.2*H"HZ_Q'2]^/R!Z@9H7\4TIP$$H5TQA7@O5O^;4 M"[&SKKB4*Q8O5C"I0Y_."^@SI!VUD?MQ5); CML2E3F.!!N>? 0F EIV(C'N MU[ T=,F,$LA.L?$0N28,.8J,#4Y./_7Z5W7=D:GI_2>^3ZUOM M0X3&@M^?VXVLKF@_6ORP+4J&GCP\^&J>P!BI=S/A1XH= +M]3A8H*A_$BRVB M)$E?=H/]78NL.)H#O4M%#KA,+A'\6'SX<-QJS4E3>0G^!GJ&R=PE7L4E=2^# M56CA<3GU)_-'3G5\%Z7H/((19R"$?'>20FV.^MGC$;R+H!)88+%K4RZV^?PN M*F+$^L8;Y7#%%PY+NB1)2?P":C+0BV#K.SRG91W@,24?O=E.URB0J_8N8->B MEVP8[EATGLWC>"$_,?1_C4@Z?V=2BH,"(!RR>0'#7=]37(M8P&F211*YH53] MQ8L\WD0/Q,LOY4::F^(+9QGK>*&^A4]?BK4; _&IIR]Q/D^8;)@_,F_XQGJQ MR?=ZAYH999AO "]C^';9^R%Q) JP>=<(:&.H%/V]F_@V25.<%[%,<>)'?1_# M[XU?7FTW&U;AH)D723$'Z;O-F6X4E0-!Z+2&/\J+;B1)*45#[6^5T1=?F#7= M9X0U\Y T4*18! RS!4+6B&.!Y+=1FOR3DT/L)6O/'9?W=ELD:5PT1:,1WQ>@ M=>?HM#3;KV?GUR=B(/[/?QP.!X,WXOSRVZ.ST_][='UZ?B:.SMZ)=R=7QY>G M%_COX/R]>/OIZO3LY.K*,B_$"S"6:(AA_XU,3-"_!F]>AD$$@*\B(&.T'?)- MQD9\"&L&WS[;L)1?1RFQ3X'6P7ZVW(<1]Z.\Q$# +3KPP);[:->!.@ 9NHSF MRK>F_8#IY]L5H%V.#62_V,[I[P$.#X2!5IJDP55\BZ'-*$U!M122[O@?^T J M)$GE"$5/7&WG=\:$&-VY I>'=Q?@"@Q\#*9O"C$' M%8V$#5\CV$"Z^2W"I<%)T@78&/E#3QQA'%7<)^6=4F44\\A(!8-5%M((<@+% MZC! 6T7H!-$T8H[K: <0RR9*#*$/ ;24UJ6SA4CZC).!T@MR[VN 9: MM_?$M0%0M"JR"BIT:6!\6D( =D0!J+._1I1$*PS<8^2G8!:62 $ZEOL'X\R! MP1$^F"X3:%7:B #-#&/B2XL05>A-?!>MEJ0A*LR$P6!0'QX=[#GY7TN"B_:4 M-F[XIKS/$#Y%RC C_W"*%F.6%#A3C#^^V* "*7H!,FZ,5O7IP%R.W!!4L**#],MLO0#I6T!O<(.&'M<(@H$",A>"L M\9=YS(]'*ICXTQ:6$RSC&-!Y"AL@8VLV%!H_9(SB)NXO,B#R,&AD'*)_\/[! MRX+M3);)7*SC!4:LT(KD20J,><-[@(@$UB@B,0=3*DJ(,H$^B)Z*N!J3V(MA M68@M^!=Y@&#>Y(C;-%H#A'^+5FOQ?HLPPM:-#X=O"/%G40D$H;GP+Z!,2I X M\A6@_PRY#-3M70+L?@]*P$ [*$\#&\P6;V'C-%<')X VHA4>+4++/&<9<3XO M,XQM8J#!PR"XP; M*X 8MVI[4Y%ZCDQ.^Z;0(G<24+90ZC\6GZ,-Q83R &6< M#?:'[1QTUL(6S7"<_;F&AJV@M9['6J9&N? +QTQ8,K$60L0@\OS[^[BUH Q0\*;2SV4R M_Q&]4DI)"\Q!V]B[CY!\DEN$=/5 WI<448L H/MKE )E/R#:!\:H2"3B^RQ? M@2%WGL+:8U)AH=@2RMV)OS^__$_BC#C*5P\R.FWR!HU(O,W?(>T$;$.1$B"A M(]-HM7=!N21HBN+_;5RNNXL64O"C_PU*G^'%G!IL3GD7880)3.^"]= ^\%\N M/B=YN041&Z?PMRS5OBH^) &-VQG?JI@PL8^2_4B+."EL=7*;(L^BLLVJP%M! MX&I,C DQ'R/^1V@S"8BZ;'M[A^L/*G-<&PY'B\\)&-N%1+_FF*L$E?,Q*PC< M$G!G0Y0,$BF9$4]B G85)Y+)1OEHFQP8BC1.0N2-40,1DFQHB;#90P!7)J+$>TX[29F9BL([K8HM0)P( M+1D"GBT?!81)(XX7R3?X\I*,Q0"KR9&OTU9 M@V1< # %[\X/=#.;*2IC(C]E"8Z M!$B0'<$V 2;$"^D\?'MT=*$\!S9'R"XB?YUFQ!=":=L052;KH );+#)*GF(L M+Y+6I)1QE6M8P"OYFN#+XTI-PYYO+1QXS"&V2@CR2B@&*O20K*6/RG8* I+& M2)K ,:2@T/HABU?"Y!T.Q<]-3&'EN6)Y?'FYA<4\@.CMB;JQ6,2! L"WF:*X MR[:K!8Z*-8MR(W_8IG.6&@G+!T==RVBLPHQW:"5-%#4%'*]20".\Z+_'GAQO M3QQK8V^^ G.8F()QH,DO6$<+"D4 ?<&8$K\21+3](XI3,%U*EZLJH^&:M(U! M_LJB]$VYP)*-&!3JG")O.=7:D3%1Q75CC!7E56@!J.2BHGQ2+2K6[66VN0Z* MSXV@>.#%+2>,6*!'JB0)IK!<;]P M#"TAB4751(^&[-(C.OH!Q+E^]E]&B^0 MM(%>YEH,\^#D*ANJR=@'$:\24 <(;$]\XLC425$F:^)DTK+V8GWC 1K1E7.(&4/!J< MH$:\IEQ :1YG2V0P-*$T?\Z)?18)VEJJ+@^)J *-U+*&K,=IC1,CC&4:KF2* M8!D ;=,=&/DK]+#@;:0U%21'PAJ;#H0!]RSA/)4C@>4X$RY_UA,QSPI_S#/27INZZT%B3 MF\)1!9@LD/E/P>&?-;!Q03;8:PJ3R( ,$G#E6FCUVQ32$49(!Y6JX?\J>UMY MI*%\5A$6-B!TZ*/8;I#$]"P\II)&E0Q_ M(^:5_:K"&P$)*FEJN&:L95?*S1W+(=L)Q)X9^4G^!=!@LT#0RMNP2S+KLG MP0:N^B.L,RD*"8&#U>P43G' M1[(Y2?S%*XUJPWR)][OU0ID"J>= M,%B+:K/(\(T'8O, E,%&4S^]D:%8'S01F_@O[L1%3HP(I-A# @$>#&>G" M4/\1"7Y:#^H6([ETHI)+PE]92X.2>,,ZN G8MD0655053XQ9!%C_E1MZ@)U M8,2>/W#"/KF>-VQ2?I;.-!@6('!SM=M*'B[0V01[)5@E2VWL4$I/2!JE$*E MQ(B)[X&$=/XO1ZE>DHF6D:&]H:@3:WE*5%+U-+_4PC*WAI8 [OT&1*J*7*/ME9*):NPJR(A ME@8H#I?F2+6[UQZ<":3KPDPL!NXF&Q9V(7FL> UN?+)"JY#A4O\2R1J%' N) M$*01<"H;2@D,OI_BMJ*9!H* EE'6/D#/$9 (JZ32E6VEXEGG,MYI0]^@2P2Z M ?,O" +P&/Y=SRJG66.X+T7FK16&4[ 205/O]L0'>"5("C*F]=XJW-5UCS\5 M&_ N+A*0-UMI]G].XGMI6\-J82\)M2B]8J1MA+8D0IA7V>EYD@.=8;4#QZK) MFH_9"F&O4:I,-C^46$-*!ME+244VP>?(/TSL1ZDYOQ1[",:N$2F2B\E((NE; MT&FW" Q@X ?I-FQI&RI#-=!<"WL,GN:&]@T+$LE]8]JD3!-&R\ JDB$'8ODZ MI,@?*!C75-W%;['$(#F@H\R:\76@U%D30H7*M&*$REP!.[6:$TS#U8/B2CU? M93%64RCS?P66;$B^&:DS>ZW2GOP<)2NJ I'Q1R-5*.3& ES2"#BM\B^:+L1T:-59)+ H>C0!K-N$.)NQ=V.&>1+(C*&4[XP5F=M:&P_ ^8 MX/J0H( ^8I%O&A@256R95XQ#:CF09B/K<:->)#,.AI!?7XL@X%!5(:P1@+G" M.J8H!\)XF\$?>L.\KQQG"^T[!BIZ<71UK((78G30WQ_ _R:AM>1MY;]'VO\[TKY=L'N:@B+>KAU?0@I_9?A]IMP,&=X C#@LY&\6:+W]-F@HA-9+.;^IIN8C0<(#C1,;J@(Q*T &4 MZZ_^=8.F(ZUL%XRC.HSLAEI:V1A.OD3Y*8I,Y7EVPUD*S)Q(_&(@@W5:33YJ M8&IBQ&!P?ZU4J*UG7<01U8XUF6Z?8+?/]!07?(I)VWF5(PK4I7Q(33EU3Y.# M6KIV05:Q4.4#*]"(,FQL>Z/U4P+@_U0IF)LDS=8)U9>R5;R1.%]G8/GCB$&\ MWJRR!_5!Y6@PPL&]E+9G!6,(BDG6U1 5A16D. 3EB%8/[++-Y4I3#;%,-)-L MW$?K)/B<@>W#/@(,X?F\)TZ^(/ULD^).2SR#':QR3+@C,VEHC9V9L/#AW=QF* M9"QNP>\!/@ 909QB L"<4T:U"23K02AD#?8UEMHT@R9C>7('^JEU^>B*N9E 0V$<;7.:)S@SA>ZPHA"O5CF O(/N?(JTK8VLE\$XM:*55Q M6^V&5H':H"%0VR-T5)F#5%\>6<^B?*4/-L+P!(=9Z]^VE!U4E64CGX)3KQ%0MD RK81AY-IB@.4 MD.YH1[31?G(-.3 <4%'(8!A.^H?A;"1/"O;#\71"1_.L(VLA>?!@L8 ]1";! M(EEM9;43*0M*71:FOD3'"XM$R"@)6L'CFI6&LYX>X*SSPURXW7(\ M"C7NWI#/Q=+X>Z-P,&Q:N#V4758;,FT2M#X$H=&&>,,F]QH&M(M&L2 M">6M*G-%&E5:NULEZ>AW@7]PDVU+F5=C1[F:CJR]1E_)W@5.M>S::)2RZ+G# M._OZ>95IBDU2I@UCH>#79P'1,.&/ZH869G2+1HE"P!%=SC).1?JVB M7G1\4C\A1D"G?\XQG*U>% \;.,-6^UG9_ZP1DD(ZVRKM9N $_5P>UK-^S1JT M.22.UHE*5J1TH@1!C]-YW8XR5<9X0O+$?/6TBDD4A;+)(@HL\TLZ3XL!>UQ8 M@D8K4O$-'Q8AP5JI!(J$W"= !#>Q#NW)4K_8"-Q0U#-1,>5YE%*25\4\B(=3 M-MGUCT'U_KU*X$;RZ@&)GWIPP2_,W47K-:KUF!2LUA;0VBS4<"!.(P-/_MGA M<; NBH0BZ6B<%?:KF$_@(%A]X5R95CB+,SHY\5=LFD(%5B! M0:M. ("IU$37(W&T!> 3I;I:RAK>.MUG9D252-1:&564"A-A40):@8V3RH@K M8H'"?2(*M'&)@_%Y>G.S;^2A>;JB"Y9ZOES:!^G%D9D]M3PHR5)5(#-;+O?E M@ $-:)GUZ,_,XUHY5YZE&7I>//PI5H9]Y@(8L!L.PL8X9%"+0UJ'*]X?7;W5 M(49YBN3HZA.,W:-A]]$BL<[\FP8G8;_)LZ17 ,#W\4VN M2F85@#"?,4^@Y^D/0_$!O,J-P MU$@?CCHZ_N[3Z=4IGH6Z^G4*G^695"DB6[UR/^RV.6Q5?7CLUU/(4:G4>PCL"E0+K2A\$X$7R$HO^9I-Q.!P= MZ)/C-;^,] )=X&.$I8%H]R;A;##J24=3Z@!$SZ3_=9/&,TZE!VHZJ:S S%$1 M_1 @2UYZR[YEB150;&*<=6]2KV8]N PQDQ9%RR"@I#9EL]F#LV/0!=FN5(:+ M.[W7[PTF" G\931AOFM&S)3O5J*W8"FPEDB,9U\;M*(4:-!8N'UMY6MK&ZY3 MQC=9]J,=+==D&_.-@_]!99?U\FV4+Y'B9@PGPN:T1*"O&0HYJ6RGL 18- M9O\7L 1$ X8S?)7I54$"KE>OTBB.[%R>+H]%\9E7JJ]/C83Z=.*A HMNY6C$ M"T&-%PAT\_R/O_R=SC#A(JCN""L/525#2,$A950B \R3#9JH^ *8<"4*%J." MXL#O\K6XOUK.;XDCU,9M6/Z<-X,Q MAXDVJVWAAIF<>ZPXF]3*5IY2[")F$U'5L,)@JY624"+/'J(5.0]&F @PBHHP MNHT;6#G 8W5^# D;0^HP 19%A01J+$]6EV(X^5H6?6'Y'F=(,C'LX<]%=9*+ MID(Y4V!= NG]8(V'\+HEZ65^KUJH(1P6N N)HB>5=6)ZE,VTEW8%B[WL82(_6/&3#%2SJV#010RU3)%]JN!) MB>R%X>A;YV:4(41A#:QY<,I<%$%@6%;&$[&HT0 M5X"2M@O,@NH",Y/1M5%&WKZ:I%9]Q#2C$Z+HEH=V78UR S7V/$4^->G,"- A MX@@M.&-29F(-46*GT?F61EF9T'B(1QKR>P?,UH$_MFQ>"E(3N(-^I3LNK7<%2,1%);&Y344@G+8D#8Z6?-A'+,4W2X@>"WPL/:;JIJR^BL[@VZ1 MI%'W&)AUCV]DN-%;[M@3[[:Y(H5&61_44CU*":KB=1]>2,8[1O3! :D$;<[( M),[TX,#\V4[F (PF&E4]JYON#=K2O7R&T89G.!E7J:3!PT6IT;HO)2+J+AVVJT4^0YW&20:*Q+C[)ZKG&>7IF;0ZNYI+ MJ ;]K^6I7;JA&'XYD+!@<#:HYRME9HN5W*+#$J3I].1=)G-I;RI7Z[F82)U2 MH!PK4_:0<]"^M]GA&80'TUDX/G3=[T!:V-=W9A*TD &7*L#%"D7&P5)UUXTL M6B6C$)_M'0X.F:DLRZ6>D>6XL9'0S70LV=^*_C:;BD9P=3'VBF1D4%.NM"Y\RYG.G4NH.@1M1@9N5T30SY M/NF61!K2<74YN@,JM0N;:DU?-#$88PV..7U_$(RO0* FK!N4B\\RR<@-*JI7W,,G#/L6 U)3U:@7ER2.UU&N[[*4T4 +]6V!B"HBAC":<,D#RG9L M20<60!++&:B0'D\DE/+@,E)9KR8L9%F)7<-C.%;H*G=B/^*L2E,0EOS>9F'Q\;:DM%?JS=4-56*3(I^Y7LQWX2V@+EBR\JMK" M=^@%JU_*+RBX+<22U!X8%CC);5=PN]'.FFR>3H+=,4GI+;9$2^E FWERO"%% M\51+ILA65!\W& S"R?2PA=X:(N$@%3 2/NB-IF9EE%6X)*-1\FI&9)&]PW!\ M,.!8S;O6;?> .QR&@^EA>'C8 5R[(\GU2%V M.MUSH8RTS\V[E^&+C(]#ZI--15RSW$S3*JD$R]/]DT;[\& ,]#?M()&,6!Y; M,+[54M4K2^W J"/TPH+Y10>>T3#L'S:1OXY@Q,9%JY$JNI5Y0=M&Q24"(8 ? M-1ZT+%+>YXGN]P3>99<,#)4%G57XG"54\5U=U%0I$'L%?!B2YW=B:F2&7ZIH+600-M5B$=8^&%/)J^ M7/'AC.I^.;!SRZJ^NOGN6M :@=3<8Q7VH!%N*XFV*9)=6F, M^$LF#XA_?"?T55OFQ3"&,<#;N3>82"UU3?<,\7@Z#P]?]'NCT=?U(K3$,BMJ M>:4I&6H.D!WC+';]M7O1%B'\W'^O\COK?F#K\),ZD4*W-\B6>7SD25RHZ$-C M1,#?;XO"!%,=)KBZ/C_^FSB_X/*1)XK?6RH477B+%@:]<==L==W'N:%*,[DE M=.>R%(Q!4Y7"6%8I3($@U87CY!SA91U?]FD]6FA3?/K+)J$EW\3@%<=I%FA"[72(>07#-B;#:W@3F MWKCA$T<]@D=,1QIC*M#%?UJ5(M+>G/5-6YC3KH1:>:LL C9$!4K&<"UE7/KL MM[I#=J BB56VUXF.5N-N4N_GWN@'CG5)R[4H/F6<5(/'-3$FC_L7P?6/Y0%;,# 7ID= >Q^ MH 9O8GK4(]@1N45^H8V#J3_#4#_5#Q6#ZS]YX2@\'H[Z6@OK/'@@(>CCN MBP,YG/ISV)L,^.&D;SABQM_0Y<87ACM?..C+GHY"#SX]H$>C4?7;1#XZF/&C M7<..)Q42Y&$X\%V&//!DXB)CJ+X\@%D5(>H_U7JGT^K'?3%6/\\,Q.'/A]-@ M$H[E]./P4#YR&O@T](\@Z^106R??'UU>'IU=/\(P:8]&J .,%N]A >A,IV#; M97']6*$A8@.C4GW(X0X6NFA)U+_K('=&'&C"W=D9WU31#K_4=43V03CB*LU: M\,,,B$SMNE;R2SV7X50ZP[AV(? Y?(\3[=Z=&H1C(.C1M#%,;$OB3F@>])7: MG) 1$U3Y( W#(P6\MT2 :5(-:9EAT[ _,0[OAD/)M6V+-"3Q(VA+6KF!L>X: M?;F=Y)K.Q'=_S.O9 MF YM0P4^6ZC-0!HA.F^P+Y"WB5C0VBT#JJ(%_Q1&:&[JU,=Y:Y!]62:G9/8* M;U]>VR%/N@TQIT,"=N4M';S&U&=D5'=$EFL8&JSILPA!5^UR0&W7)C!=&^P< M;$O?*MKD\87&$VT-4\D$94E1-//Q2Z/&DZ*C,[^RD?%DH^V#NAB8-[RT&EC^ MZ@7=R%VJJ+M+.)E*MP-?Z;:ZP[,IYAHRC587[?/IYT+? K^O3^EYLZ1W2;RL MCET""$O8*+Y6WO#K$6,>R@F:_./"2S:61]P'J5HSM16,4CS=/' AT"+>H 8$ M!\LD:O%"&B+JJ(@U3AS1,1MU>^#+1ZE6S4GVA#N8:(=9I Y2*D9V9:\>/_"- M[SA M5+[:\LO_5E>7&!7?3S1B_NE\F/3ZO:*P0$60ZELA?<&BUJVH"$]IK8A M<+>A)]YV2VFYY>Y:PE.3(75E5D/\1ENDC?FWP6"X*__6N=K2U!@BNW?C1X/* MP)>G$'30L;(6ZJ6>UT;D_!W@AVC)-'/4.7#S)1BV]HJO[67CM1&/>OD1U9Y@ M[BDCZ_C\X\?3:ZQAO@JPI/GXG%HTG)Q1?X8C%?'C:F95K%-=4ZA(Z\3A<)+- MNK$J&<4#%-&*C)YYE OSMB&K\6#(UZ2!0['-\;EY;D@%P@)]S1.J6GF7 M0G4Z==I4"))RG115IP9.=6I_/&(ZZ41V\F#6@[X5CQ @K\HD*E09&+1?JK*G MO\"SSV"W!+8\H'L.9#0,GP!3@HU8/M2_=UN <]^<2W4SX,X7GI0S&%3]^*Y. MOJ42^,N3B_-+I)V@X:*KX6%?V7>RD#T@HJCN?T!+B@LX??J[NC!!-@8?A=(IIK6%@M0]6_;1AK.K=/?GV='H0F!7K'8&2?VL%;#@9A=/!2&"M^GC0 MMZ;!^>7C/?V"TW2X%9@7@\.!>$E_&1_ .L;B92LX+P;A(3#'$(3-2S$]Z(>S M@XD[)8YW& X&_7 TX^$/0"0/9@,8FPO'J:1_04<7NFYA%VSA<8-1.#F<"#YA M,)B, SYS'2]TT;HY-VVG^F;/^(I/I;2"AFB8TI^3?CMU@G& \9.;$UJ[T@59Q0E=&[WQAI_(85JS_ MZ>W5R7>?D/M/_HXJ1!BC@>[SY'8JWEB*IQHP;1'#R7@<3EK*;YK<@G%O:-88FW]X$)+ ^9R->WLO'I)F+CN-6!GVD+U.^W(]) VQUM;[=% MZXVHNSQUJV59 M 6TUP<07@*/XPE^W:<;3>X&)%^IO+YVK+'S-O3J]]-P![+D#V','L%^P YA[ M&+:Q(=@C7OU]] X+].!1I]YA=0346XGM>O[<:JS6:LS;J-[H/+;K^>^^,YF; M'',:E75XY;F7V7,OLW_;7F8N?[2U-GO^Z(]]T5[[HO&\O!WT!>MKN!VM$E[Y.N_DZYJ@=E53?QR7=7JV.K0 M9.T)G_S2?=F"Y[YLSWW91/D[ZLO&%MEOUII[:?&\[]R@WG/,5X3A>X+N_\=CWJ')WB-)G;_<:_6U,[YXAR M';Q_:5.[@$_E_(9-[>RCI[])4SO?S:V_7E.[H*I?_,V:V@7>8?_U3>T>5W_< MI*6>>]S%SSWN_AUZW 5&ZZ'?;X\[QR[UMKSK]M;_KL9X3CEL0Y^\KN]UZ*<7 M&/WTQ&_53R]0_?24O/OU^^D%D?).N_?3JV]#>WN]Q[W]\YKQN:Y?>V^^Q[[_ MW,OON9??7GW6;&U G"E.W%OIJ?A7O9/'/2;8A;3/M>DFO^^6FG@^,/A\8/#YP.#_E .#W8_^O(O!T5N! M'X/6+6KUER!B/EV]$R_V'#%Q6B\H<>KHS7Q+2Z+%#4I50<^+*NAY1F<\_HMO MLG5.,EZT1PX=9\ ($:O;RAK'M@&R.ZXT??/6*@!4_\(*$EW/I[\5_RT^@BI> M;]>-PWUJ*$BDPJK2+K*K?SOE KZ?"V'TI17"T3\B7V\6^>\'CW/#JGO[U#3]'9U MS5[SMHUGOFTSFE2T:"#OCOL^A94]@=4:3KD\2JL=[6X8ZI$FWG,CWBZ8CP+F M0G7 H=2N;D.Y\+38/#6:.]:S[:[F,UH\NKODVR2"W<=)JA>D&Q6NFA#NAHB& MM_M>F>4#'(]\Y$=^:??!VV2K5:YP:/]1&_?7*.WIN);_88-M9#YT;*.+6D6& M[FRCFVEYLCU-S<7:B=.V^I63=ONW*A-9!TDP="] MS#H-#/+FFEHW<=U:HZ:52ZQ=.*J.'G;%#7Y3Z_G2I)P?-42;@FZ3H[#ZOW/+ MG9]EQ/PL +HH$-6OQ6@(\XE:H5@*T>W;TC@@]6)Q@XVR4>!37.-&XMY?$8 M*7WBW+%C6WZK[#[..6/_V$^WFTW3IUHD>VY$]Y-3_?[3=A2T(TKE9NSF%NWO MTE7R'(A5G-[B5S^V<4VSK%'SZPMFNRT<*.=$-R5I-L#;.Y T>0P&+A8>ZTE& M+X(__ ';RG2&]QQ/+UXE7_8II((EJ>A^=2/Y%J^C$R::1W,Y\K&C[8LGY1HU M&[N&U=8PK/;$*ZF/_,KSW'5'^=I+/QN9 '1X_9+T_WD:-[M3S?G/^OU>5='C M?XMJ6:Y1KC%B#>8S!KQW*&>J"VY6!2KFD@^0:=0M\%]JP+V"=T MT\BNH0[54&W[>9:TD*+M6S>Z#%D@%9\ M&;> -GX440%Y=AIMT%?##?QHTWF:1QDHZ@[&W6:YOI.Q'W5*J,H%S[E3 M0N/[I_J*CC\VFRGO93. '6-W=4+DO718%.P-5>%M]\U!C+9S#(\+7NJ;.3%4 MUV:D=[Q+7?S&=ZF+77>I.S9> M!5F"<<$E&.=5644CZ:A2#"56.GSC7K'\.)6D+X3]H*\-VXUIW1+6[&N=EGCE M+M]5 .AH\T%#U:1R9V#*O%&WZ3;=SL&V;H/Y$T31RKAW>$?,Q9D8[YON])(S M^ZNB*+_Y_U!+ P04 " 76QE MU%7*U?. MUWV"3.@DD8S@-.J,!I+%I^RW6#,MD*G>#I "&??R-S M2/#C^HYY8ZZ#W8]#Z="*E?;5_#?93]]+[#QK$#*V"!P@CV0QC71 M&I2X-8Z;[,#O0JBW%^O:*"P564>3&1X3W&"*+*7*00UE(KR!TIA!8>4H6E9V MU+(.;%!KR8V14U)*09R&349O&-H,&'NP%_MSL_ MF%\6C XLF,9D4P=54M$GPV>O2F8 4!BM0&F:;2-?%:D7T.G-=>J*0S5/3E#S MO][G$@0HPK9%F[M_S+O\GQ5/W_R]9/=7V1=\7+OZW!)M)ST!D;-3$#D_?I'3 MJV?6&/2-<:O[[O3> 47+EC)-1:^VHGD.7H]]_"3XSKZ[V$X''%NPH==D:5ZL M._PF-X>"M$S?VR6Z8()'^Z,5'LV'68N!(L&C_0ERVO(K5W!\%J?? %!+ P04 M " 7YKGOEQ#H_P7VX+!*TOK&A7PT*UR MWSI0E5\#A*;.Y6!PE#=*F^S\;#?6S.7G9W'GNX9G__=\/!2J#/H)[M5BD@TR M;)!'79CL4MLU$=^OK:I(5N!]4P#Y/VNM%#9EPIQHON.NJB.!\D)?65& \ M5 +WO*UUA1R5^*IJ94H0":0D(.5'0@X3R"$!.?P0R'G$P:X)Y"$!>?B1D*,$ M8%F#GL[#,(N$Q&NC1T2MA." M[827;0J+E*084*D\X&6)CR:\I#2D(Y@E,0^V?!"WW0+T*13EA()9"C^4<[CB M>CQ4_!?,^7\73V*6SE2PZHJF.VBMBW@I&)7W!7O@+SP\;B+;U1/L33PJXPOFD"=-5(Q3 M3"KY"^;H[X6(.,"JO ;_*:6CLK]@#O]7T^XM0DDI03(K@7S-LD@Q*5=(9E>\Q4DJ1S$K9 MUBGO$5(^D=P^Z M."4:R2R:?Q=B'76*21E',AN'K,;$0?I3@]+.D%L[K\38FYPI)J6=(? M/)XO55W.G(B;[>?/X2@6+ $ $44 : >&PO M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/%V,UN@D 4AN%;,5R PSGC;Z.NW+AM M>P,3'('(7V:FJ=Y]*9MBHG.Z,)\;"(&<\R[($\+FW58FE&WCB[+SDTM=-7Z; M%"%T;TKYK+"U\=.VLTU_Y]2ZVH3^TN6J,]G9Y%9QFBZ4&\](=IOQS,GAN$W< MX4C)Y-.XW(9MHBZ5^F[=V1?6!J^&$TW[!?TCU\[^9WU[.I69W;?95VV;<*?B M;T&B[@=Q/(CA03H>I.%!LWC0#!XTCP?-X4&+>- "'K2,!RWA0:MXT H>M(X' MK>%!E HRIO@D"6N\UB1P37BO20";\&*30#;AS28!;<*K30+;A'>;!+@)+S<) M=!/>;A+P)KS>+.C->+U9T)M?\*TM?6SC]69!;\;KS8+>C->;!;T9KS<+>C-> M;Q;T9KS>+.C->+U9T)OQ>FM!;XW76PMZ:[S>6M!;O^!?R4AO7QAGCQ_!E4WN MGUUR,_QAS0AN'ZZ5?7[&,/7A_I'2H=]BU7!\^ILR3/V-4#=_#7<_4$L#!!0 M ( !=S#DWH]2X:D $ .84 3 6T-O;G1E;G1?5'EP97-=+GAM;,V8 MWV["(!2'7\7T=K$(W=R?J#?;;C>3[058>VJ)+1! IV\_6G7)EBYQ49/?32D< M..>#DN^BD_>M)3_8-+7VTZ0*P3XPYO.*&NE38TG'2&E<(T/LN@6S,E_*!3$Q M&HU9;G0@'8:AS9',)D]4RE4=!H^[\3;U-)'6UBJ701G-UKKXE72X3Y@ZJKLY MOE+67\4)R>!Y$[/X.#9-8M0G[(@*OQ>V_;CN=4W.J8+^A6;*4N54F'S5Q"6I MMXYDX2NBT-2IKZ2CXBTXI1=[WKETX44V,3';U.S'A/1R'&%;4S] %SEGY1"O M!?65Z@*[)S^IX.$VY,;1T+H8=4'U;"\BS6/4LW;B.;=([=4IJ#BJ>$Q]N0_[ M:=RR>^\[\.^@9UUSVJF?CT. <&0@'-<@'#<@'&,0CEL0CCL0CGL0#CY" 4$Q M*D=1*D=Q*D>1*D>Q*D?1*D?Q*D<1*T[P M "L" 1 " 9D! !D;V-0&UL4$L! A0#% @ %W,.3:TMX;9E @ %@@ !@ M ( !^ @ 'AL+W=O&PO=V]R:W-H965T&UL M4$L! A0#% @ %W,.32W]MZ+(! "A4 !@ ( !:Q, M 'AL+W=O&PO=V]R:W-H M965T&UL4$L! A0#% @ %W,.32Q(U(FT 0 T@, !D M ( !Q24 'AL+W=O[(! #2 P &0 @ &P)P >&PO M=V]R:W-H965T&UL4$L! A0#% @ %W,.39%[QAJT 0 T@, !D ( ! MA"L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ %W,.3?MEM^"T 0 T@, !D ( !1S$ 'AL+W=O&UL4$L! A0#% @ %W,.37'Y:_BX M 0 T@, !D ( !#C@ 'AL+W=OP?[8! #2 P &0 M@ '].0 >&PO=V]R:W-H965TH[ !X;"]W;W)K&UL4$L! A0#% @ %W,.3;2;\7FC P 01 !D M ( !S3X 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ %W,.32N1O]0^!0 >AP !D ( !KD< M 'AL+W=O&PO=V]R:W-H965T 9 M " :10 !X;"]W;W)K&UL4$L! A0#% @ M%W,.3:2=:2,A P (0T !D ( !=U4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %W,.3<=-)3-[ P MN X !D ( !T%X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ %W,.3:R+7YOA @ ^!0 M \ ( !49H 'AL+W=O $ $44 : " 5^= !X;"]?7!E&UL4$L%!@ I - "D $0L -"@ $! end XML 45 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 46 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 129 206 1 false 52 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://marimedadvisors.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://marimedadvisors.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://marimedadvisors.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://marimedadvisors.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://marimedadvisors.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Organization and Description of Business Sheet http://marimedadvisors.com/role/OrganizationAndDescriptionOfBusiness Organization and Description of Business Notes 6 false false R7.htm 00000007 - Disclosure - Summary of Significant Accounting Policies Sheet http://marimedadvisors.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Acquisition Sheet http://marimedadvisors.com/role/Acquisition Acquisition Notes 8 false false R9.htm 00000009 - Disclosure - Property and Equipment Sheet http://marimedadvisors.com/role/PropertyAndEquipment Property and Equipment Notes 9 false false R10.htm 00000010 - Disclosure - Debt Sheet http://marimedadvisors.com/role/Debt Debt Notes 10 false false R11.htm 00000011 - Disclosure - Equity Sheet http://marimedadvisors.com/role/Equity Equity Notes 11 false false R12.htm 00000012 - Disclosure - Stock Options Sheet http://marimedadvisors.com/role/StockOptions Stock Options Notes 12 false false R13.htm 00000013 - Disclosure - Warrants Sheet http://marimedadvisors.com/role/Warrants Warrants Notes 13 false false R14.htm 00000014 - Disclosure - Related Party Transactions Sheet http://marimedadvisors.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 00000015 - Disclosure - Commitments and Contingencies Sheet http://marimedadvisors.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Segment Reporting Sheet http://marimedadvisors.com/role/SegmentReporting Segment Reporting Notes 16 false false R17.htm 00000017 - Disclosure - Subsequent Events Sheet http://marimedadvisors.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 00000018 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://marimedadvisors.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://marimedadvisors.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Stock Options (Tables) Sheet http://marimedadvisors.com/role/StockOptionsTables Stock Options (Tables) Tables http://marimedadvisors.com/role/StockOptions 19 false false R20.htm 00000020 - Disclosure - Segment Reporting (Tables) Sheet http://marimedadvisors.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://marimedadvisors.com/role/SegmentReporting 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://marimedadvisors.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://marimedadvisors.com/role/SummaryOfSignificantAccountingPoliciesPolicies 21 false false R22.htm 00000022 - Disclosure - Acquisition (Details Narrative) Sheet http://marimedadvisors.com/role/AcquisitionDetailsNarrative Acquisition (Details Narrative) Details http://marimedadvisors.com/role/Acquisition 22 false false R23.htm 00000023 - Disclosure - Property and Equipment (Details Narrative) Sheet http://marimedadvisors.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://marimedadvisors.com/role/PropertyAndEquipment 23 false false R24.htm 00000024 - Disclosure - Debt (Details Narrative) Sheet http://marimedadvisors.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://marimedadvisors.com/role/Debt 24 false false R25.htm 00000025 - Disclosure - Equity (Details Narrative) Sheet http://marimedadvisors.com/role/EquityDetailsNarrative Equity (Details Narrative) Details http://marimedadvisors.com/role/Equity 25 false false R26.htm 00000026 - Disclosure - Stock Options (Details Narrative) Sheet http://marimedadvisors.com/role/StockOptionsDetailsNarrative Stock Options (Details Narrative) Details http://marimedadvisors.com/role/StockOptionsTables 26 false false R27.htm 00000027 - Disclosure - Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details) Sheet http://marimedadvisors.com/role/StockOptions-ScheduleOfStockOptionsOutstandingAndExercisableDetails Stock Options - Schedule of Stock Options Outstanding and Exercisable (Details) Details 27 false false R28.htm 00000028 - Disclosure - Warrants (Details Narrative) Sheet http://marimedadvisors.com/role/WarrantsDetailsNarrative Warrants (Details Narrative) Details http://marimedadvisors.com/role/Warrants 28 false false R29.htm 00000029 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://marimedadvisors.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://marimedadvisors.com/role/RelatedPartyTransactions 29 false false R30.htm 00000030 - Disclosure - Commitments and Contingencies (Details Narrative) Sheet http://marimedadvisors.com/role/CommitmentsAndContingenciesDetailsNarrative Commitments and Contingencies (Details Narrative) Details http://marimedadvisors.com/role/CommitmentsAndContingencies 30 false false R31.htm 00000031 - Disclosure - Segment Reporting - Schedule of Operating Segments (Details) Sheet http://marimedadvisors.com/role/SegmentReporting-ScheduleOfOperatingSegmentsDetails Segment Reporting - Schedule of Operating Segments (Details) Details 31 false false R32.htm 00000032 - Disclosure - Subsequent Events (Details Narrative) Sheet http://marimedadvisors.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://marimedadvisors.com/role/SubsequentEvents 32 false false All Reports Book All Reports mrmd-20180630.xml mrmd-20180630.xsd mrmd-20180630_cal.xml mrmd-20180630_def.xml mrmd-20180630_lab.xml mrmd-20180630_pre.xml http://fasb.org/us-gaap/2018-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 50 0001493152-18-011724-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-18-011724-xbrl.zip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